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ABSTRACT 
Breast cancer is one of the most common causes of cancer-related death in women world-wide. 
Despite many advances in medical research, incidence and mortality rates still remain high. In 
the last decade, evidence has emerged that links components of the immune system, including 
various signalling mediators and cell subsets, with regulation and promotion of breast cancer. 
Among others, the chemokine superfamily has been heavily implicated in the pathobiology of 
breast cancer due to their ability to induce cellular migration, proliferation and recruitment of 
supporting cells to the tumour microenvironment upon binding of cognate chemokine receptors. 
However, the underlying mechanisms and specific details governing the function of chemokines 
and their receptors in regulating breast cancer development and progression are largely 
unknown. This study systematically examined the roles of two chemokine receptors, CCR7 and 
CCR6, in breast cancer initiation and progression. These receptors had previously been shown to 
induce cellular proliferation and migration of breast cancer cell lines upon stimulation with 
chemokine ligands and had been implicated in regulation of other malignancies, but in vivo 
evidence for their roles had not been shown to date.  
Using the MMTV-PyMT transgenic mouse model for breast cancer, it was found that deletion of 
CCR7 significantly delayed mammary tumour onset and reduced both the number of primary 
tumours and extent of distal metastasis to the lungs. It was further found that CCR7 exerted its 
tumour-promoting function by maintaining populations of stem-like cancer cells. Stimulation of 
CCR7 in stem cell-enriched cultures induced self-renewal and the loss of this receptor resulted in 
a significant decrease in tumour-propagating ability of the cells. Furthermore, pharmacological 
blockade of CCR7 reduced proportions and activity of stem cell-like pools, indicating that this 
receptor can potentially be targeted therapeutically to eliminate quiescent cancer stem cells. 
Deletion of CCR6 in the MMTV-PyMT model also significantly delayed tumour onset, reduced 
the extent of epithelial hyperplasia, and resulted in a decreased incidence of mammary tumours. 
However, no evidence was found of a role for CCR6 in mammary epithelium, or in maintenance 
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of the cell lineage hierarchy. Upon further investigation, it was discovered that CCR6 was 
involved in the recruitment of tumour-promoting macrophages to the mammary tumour 
microenvironment. CCR6 was highly expressed on tumour-associated macrophages, and the loss 
of CCR6 significantly reduced the numbers of macrophages present in PyMT-driven mammary 
tumours.  
Taken together, cumulative data generated throughout the course of this project conclusively 
demonstrate that CCR7 and CCR6 both have important roles in the development and progression 
of breast cancer and may therefore have therapeutic utility in targeting both the transformed 
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1.1. Breast cancer  
Breast cancer is the most diagnosed cancer in women world-wide. Of cancer cases in women, it 
is also the biggest killer [1]. Overwhelmingly, the primary lesion is not responsible for death due 
to cancer, rather it is the progression to metastasis that is fatal. Once the cancer has spread to 
surrounding tissues, such as the lymph nodes, the lungs, the brain and the bone, there is no 
reliable or effective form of treatment [2]. Despite significant advances in medical research, the 
morbidity related to breast cancer is still high, and new therapeutical targets are needed to inhibit 
the progression of breast cancer in the early stages, before multiple mutations have occurred and 
the disease becomes invasive.  
1.1.1. Normal mammary homeostasis and how it may contribute to the 
development of breast cancer 
As with any neoplasm, it is necessary to understand the normal homeostatic processes in order to 
comprehend how cancer develops. Rudimentary mammary epithelium is formed embryonically 
in both mice and humans, and foetal mammary stem cells have been shown to possess a similar 
genetic signature to specific breast cancers, including the aggressive basal-like and Her2-
enriched subtypes (discussed in more detail below) [3]. Furthermore, in a recent study, tumour 
cells from breast cancer patients that had been treated with various chemotherapy regimens were 
compared with normal and foetal mammary stem cells, and it was found that gene expression 
signatures of normal mammary stem cells could predict the response of tumour cells to 
chemotherapy [4]. As such, there is value in examining breast cancer from the perspective of 
developmental biology.  
The mammary gland is an unusual organ – the majority of its development occurs post-natally. 
During puberty, hormonal changes trigger the rapid expansion of breast epithelial cells and 
subsequent branching morphogenesis. An epithelial “tree” then grows out from the nipple to 
form the adult ductal structure [5]. This process is largely driven by fibroblast growth factor 
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(FGF), epidermal growth factor (EGF), transforming growth factor (TGF)-β, and Jak-Stat 
signalling pathways, among others [6-9]. 
The ends of each duct are termed terminal ductal lobular units (human), or terminal end buds 
(mouse). These structures split as the epithelium grows, to form a dense network of ducts [10]. 
The ducts are lined internally by luminal cells, and externally by basal cells, the two major cell 
lineages within the mammary gland [11]. A complex stroma surrounds the ductal network, which 
is comprised mostly of adipose and connective tissue but also includes tissue-resident immune 
cells and fibroblasts [12]. The extracellular matrix and surrounding stroma, which is vital to 
proper development of the mammary gland, can also promote breast cancer due to intrinsic and 
extrinsic factors [13]. 
The first menstrual cycle in humans, known as menarche, typically occurs at around 8.5 to 13 
years old, and with each cycle the mammary epithelial cell population expands and contracts. 
During pregnancy, the mammary gland is significantly remodelled, with the expansion of 
alveolar lobules capable of lactation. When lactation stops, the mammary gland undergoes 
involution over the course of three months, with apoptosis of alveolar cells and atrophy of 
lobules. This is the general homeostatic process until the event of menopause, the cessation of 
menstrual cycling, at the approximate age of 51 [5, 14-16]. Whilst the risk of contracting breast 
cancer increases significantly based on family history, consumption of alcohol, radiation 
exposure, use of hormone therapy or oral contraceptives, and a sedentary lifestyle, each of these 
normal stages in a woman’s lifetime – menstruation, pregnancy, and menopause – can alone 
contain risk factors for breast cancer including early menarche age, late first birth age, and late 
menopause age [17]. 
As such, normal mammary development and the development of breast cancer are closely linked. 
Many signalling pathways involved in normal tissue homeostasis and maintenance within the 
breast are also involved in tumour formation [18], and signalling components that control other 
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normal processes – in particular those that limit growth and regulate cell death – can be damaged 
through mutations, which eventually can lead to onset of cancer [19, 20]. 
1.1.2. A brief overview of breast cancer development and progression 
Malignancies in the breast often begin from uncontrolled proliferation due to mutations in key 
signalling and regulatory pathways, including (but not limited to) Wnt [21], hedgehog [22], 
Notch [23], phosphoinositide3-kinase (PI3K) [24], Jak/Stat [25] and NF-κB together with RANK 
and RANKL pathways [26]. If the lesion is detected early, the patient’s chance of survival is 
relatively high. However, if left untreated, the small lesion may rapidly proliferate to form a 
primary tumour mass. As the primary tumour progresses, it hijacks the body’s homeostatic 
functions. It forms its own blood vessels and corrupts the normal processes of cellular 
proliferation and DNA repair. Furthermore, cancer cells are capable of evading the host’s 
immune defences, and even using them to their advantage [27].  
There are five main subtypes of breast cancer, clearly defined by a distinct genetic and 
morphological profile: luminal A, luminal B, basal, human EGF receptor 2 (Her2)-enriched, and 
claudin-low. Luminal cancers (luminal A and B) are the most heterogenous, and express high 
levels of luminal-associated genes such as Esr1, Gata3, Foxa1, Xbp1 and Myb. These cancers 
are typically oestrogen receptor (ER)-positive and Her2-negative, and present with mutations in 
the MAP-kinase and PI3K pathways. Luminal A tumours, due to the low proliferation rate, 
generally have the best prognosis for breast cancer patients [19].  
The basal-like subtype is the most aggressive subtype and is predominantly negative for ER, 
progesterone receptor (PR), and Her2, collectively known as triple-negative breast cancer. These 
cancers are characterised by a high mutation rate in the TP53 and PI3K pathways, and a loss of 
Rb1 and Brca1/2 [19].  
Her2 amplification in breast cancer results in a shorter overall survival and time to relapse in 
patients compared to those without Her2 overexpression. Upon receptor activation, the EGF-
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mediated signalling cascade results in expression of genes that promote tumour growth and cell 
survival. Treatment of patients with trastuzumab (also known as Herceptin) specifically targets 
the Her2 receptor, and this therapeutic has been used relatively successfully as an adjuvant for 
Her2-positive cancers over the last couple of decades [28].  
Claudin-low tumours have been classified as the most “stem-like” of breast cancers. They 
typically express high levels of markers associated with an epithelial-to-mesenchymal transition 
(EMT) and have low expression of proliferation genes and markers. As such, cells of these 
tumours are slow-cycling, a characteristic of stemness, and the low expression of adherence 
genes (claudins) suggests that these cancer cells are better adapted to non-adherent survival. 
Furthermore, the expression of stem cell-related surface markers (discussed in more detail 
below) and genes is higher in these tumour cells compared to cells from other tumour subtypes. 
A claudin-low diagnosis has a worse prognosis than luminal A, but has similar survival 
prognoses to luminal B, Her2-enriched and basal-like cancers. [29]. 
Even from an early stage, some cells that are capable of metastasis are believed to exist within 
the tumour [30]. Cells that have metastatic characteristics are able to extravasate into the 
surrounding vascular network and circulate throughout the body until they home to a suitable 
secondary site. Primary breast cancer cells typically metastasise to sites such as the lymph nodes, 
lungs, bone marrow, brain and liver [31], and the metastases formed are molecularly distinct 
from the primary tumours, possessing a genetic “metastatic signature” [32]. Very few drugs to 
target breast cancer metastatic disease exist [33], and it is a difficult area to research due to the 
lack of suitable in vivo models that accurately mimic human disease [34]. Thus, treating breast 
cancer at the early stages is preferable and has a greater chance of a positive clinical outcome. 
1.1.3.  New concepts in research 
Recently, the focus of research in the field of breast cancer has somewhat shifted. As the bulk 
tumour mass can often be resected quite successfully, more attention has been given to 
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discovering other factors that are involved in tumour promotion and are necessary for cancer 
recurrence and spread. Based on these new concepts in research, there are now a variety of new 
possible therapeutic targets that have been proposed to treat breast cancer at various stages in its 
progression (outlined in Figure 1.1), although no clinical results are available as yet [33]. 
The tumour is not a lone entity; whether it is the primary site or a secondary metastasis, it 
requires a number of other supporting untransformed cells and signalling factors if it is to 
survive. This includes resident cells such as fibroblasts, and certain immune cells that are 
recruited to the tumour microenvironment.  
Cancer-associated fibroblasts (CAFs) (including myofibroblasts, mesenchymal stem cells, tissue 
fibroblasts and adipocytes) can be involved in many aspects of tumour progression including 
proliferation, angiogenesis, metastasis, and resistance to cell death. CAFs can secrete a range of 
factors, including growth factors, cytokines and chemokines that can drive cellular growth and 
induction of EMT, pro-inflammatory mediators that can activate and recruit various immune 
cells, and angiogenic factors. Mesenchymal stem cells are able to differentiate into 
myofibroblasts or adipocytes, aiding tumour growth. Most importantly, CAF numbers within the 
tumour correlate with poor prognosis for multiple malignancies, including breast cancer [35]. 
Interestingly, some findings suggest that CAFs in the tumour microenvironment may also be 
important for maintenance of breast cancer stem cells (discussed in detail below). Breast cancer 
cells co-cultured with CAFs that secrete chemokines CXCL12 and/or CCL2 had greater stem-
like characteristics and higher proportions of putative cancer stem cells [36, 37]. Through 
remodelling of the extracellular matrix, CAFs can also enhance cancer cell survival and their 
ability to invade [38] through a collective invasion mechanism [39], generating circulating 
tumour cells. 
New techniques have allowed the study of these disseminated circulating tumour cells (CTCs), 
which have recently been equated to cancer stem cells [40]. High numbers of CTCs in patient 
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blood samples correlate with increased metastasis, aggressive disease, and shorter relapse-free 
survival times. It has been proposed therefore that CTC levels should be used as an additional 
biomarker to standard biopsy procedures, due to the non-invasive nature of blood tests. 
However, CTCs are rare, and due to their propensity to circulate in clusters they are often 
trapped within small capillaries. Hence, their detection at present remains difficult, despite the 
clear clinical benefits of early intervention to impede metastasis [33, 41]. 
As with the primary site, the pre-metastatic niche is prepared for seeding of circulating tumour 
cells by a number of factors. Tumour-secreted factors from the primary site - including various 
growth factors, chemokines, tumour necrosis factor-α, hypoxia-inducible factors and granulocyte 
colony-stimulating factor - recruit bone marrow-derived cells and immunosuppressive cells to 
secondary organs, and remodel the site to promote cancer cell adhesion and invasion, hence 
creating microenvironments suitable for colonisation by metastatic tumour cells. Whilst it is 
possible that the formation of pre-metastatic niches is not essential for metastatic colonisation, it 
is thought to greatly enhance the chance of secondary disease occurring [42, 43]. Therefore, 
disruption of the metastatic niche is a potential therapeutic avenue. So-called cancer stem cells, 
discussed below, are the likely candidates for the preparation of the metastatic site, due to their 
increased expression of surface receptors involved in migration and their ability to propagate 
tumours in secondary sites [44].   
The concept of a “cancer stem cell” (CSC) was first proposed by John Dick and colleagues, who 
found that in acute myeloid leukaemia there was a small subset of stem-like cells that possessed 
the capacity to differentiate and proliferate, and had the potential for self-renewal that was 
expected of a leukaemic stem cell [45]. This theory has been investigated in great detail in the 
last decade, in many different types of cancers. It states that a small subpopulation of cells exist 
within the tumour that is responsible for its maintenance and growth, termed “stem cells” for 
their stem-like characteristics [46]. The tumour microenvironment is believed to be responsible 
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for maintenance of not only the bulk tumour mass but also the CSCs [47], and so specifically 
targeting both the stem cells and the supporting niche simultaneously is a potentially new 
therapeutic approach to prevent breast cancer relapse. Despite this, the underlying biochemical 
pathways and cellular interactions within this biological system are currently largely unknown.   
1.2.  Adult stem cells and cancer stem cells in the breast 
1.2.1.  Properties of adult stem cells 
Somatic adult stem cells reside in all tissues, and are formed from embryonic precursors during 
foetal development. However, unlike pluripotent embryonic stem cells that are capable of 
forming any cell in the body, adult tissue stem cells are generally only multipotent – they are 
only able to form any cell in that specific tissue. This stem cell property of differentiation is 
usually only employed in cases of tissue damage and repair, and stem cells are mostly quiescent 
in solid tissues [48]. Tissue-resident stem cells are capable of asymmetric division, similar to 
embryonic stem cells. Whilst terminally differentiated cells can produce two identical daughter 
cells, stem cells can give rise to one transit-amplifying cell (as required) and can also self-renew 
to form another stem cell, to maintain the pool within the tissue [49].  
These stem-like properties – self-renewal, quiescence and the ability to differentiate into multiple 
lineages – are also the hallmarks of so-called cancer stem cells, hence the name.  
1.2.2. The cancer cell-of-origin 
As mentioned above, cancer stem cells are believed to be responsible for initiation, growth, 
maintenance and metastasis of the tumour [46, 50]. Currently however, it is unknown whether 
CSCs are a separate, fixed population of cells, or whether this pool of cells is in fact plastic, and 
any cell within a tumour can acquire stem-like characteristics depending on the circumstances 
[51]. Stem cells that are identified in various assays may not include those with latent 
regenerative capacity [52]. This is important to keep in mind when designing therapeutics that 
target CSCs, if new cells can easily take the place of destroyed CSCs. It is also important to note 
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that not all cancers may follow the stem cell model, and in breast cancer, various mutations may 
give rise to tumours that vary in the extent to which they follow this model [53]. 
Kordon and Smith first proposed a stem cell model in the mammary gland in 1998, following a 
series of transplantation experiments [54]. It is now understood that normal adult stem cells or 
bipotent progenitors that reside within epithelial ducts [55] differentiate into two cell lineages, 
the luminal population and the basal/myoepithelial cell population [11]. Within this hierarchy, it 
is still not clear from where cancer stem-like cells arise. The current consensus is that CSCs may 
result from mutations in normal adult stem cells and/or that more differentiated cells may be able 
to acquire stem-like characteristics upon mutation, and upon transplantation only these certain 
cells are able to form secondary tumours [46] (Figure 1.2).  
Therefore, the “cell-of-origin” within a cancer may not be an adult stem cell, but a more 
committed progenitor or potentially even a terminally differentiated cell, depending on where 
mutations arise if the mutations are able to confer a stem-like phenotype [56]. The cell-of-origin 
has been putatively identified in a small number of cancers, including acute myeloid leukaemia, 
which originates in common myeloid progenitors [57], and prostate cancer, which originates in 
basal cells [58].  
In breast cancer, the cell-of-origin for various subtypes of breast neoplasms (outlined above) 
potentially arises from different cells within the hierarchy (Figure 1.2), where basal-like tumours 
with Brca1 mutations originate from luminal progenitors [59], claudin-low are the most stem 
cell-like in terms of gene signatures, and luminal A and B subtypes present gene signatures 
overlapping with differentiated luminal cells. Her2-enriched tumours have no putative cell-of-
origin defined as yet, but may arise from the luminal lineage also, as these cancers contain a high 
proportion of luminal progenitor cells [60]. Identification of cells-of-origin is difficult, as it is not 
currently possible to purify CSCs from solid tumours to near homogeneity, unlike the more 
defined populations in haematopoietic cancers [61]. 
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1.2.3. Characterisation and identification of cancer stem cells 
Despite being unable to completely purify CSCs, a number of methods allow for the 
identification and enrichment of putative CSCs within heterogeneous bulk cell populations [62]. 
In vitro and ex vivo, this includes flow cytometry and specific cell culture techniques. Different 
tumour types have different putative surface markers for CSCs, the combination of which selects 
for a population that has the stem-like properties of self-renewal and differentiation. Notably, 
positive expression of the markers CD133 and/or CD44 has been shown to enrich for the 
putative stem cell population in a number of solid tumours [63].  
Just over a decade ago, Al Hajj et al. proposed a CD44+CD24-/lo surface marker profile to detect 
human breast CSCs, as sorted cells with this profile had an enhanced ability to form tumours 
upon xenotransplantation compared to alternative phenotypes. They also noted that this 
population does not express a number of markers that are associated with leukocytes, endothelial 
cells, mesothelial cells and fibroblasts, and so the stem-like population can be further elucidated 
based on “lineage-negative” (Lin-) gating or sorting [64].  
Shortly after, Shackleton et al. characterised the mouse breast stem cell population and found it 
to be enriched in the CD24+CD29hi subset [65]. Other groups such as Stingl and colleagues 
report that sorting cells based on CD49f and EpCAM expression can enrich for the stem cell 
population [66]. Generally these marker profiles are thought to overlap, and a certain amount of 
personal preference exists in terms of ability to separate out populations during flow cytometry 
or fluorescence-activated cell sorting (FACS). As illustrated in Figure 1.2, these marker profiles 
select the basal subset of cells, which is believed to contain the CSCs, putative myoepithelial 
progenitors, and terminally differentiated basal cells [60]. Within this basal population, most 
cells are myoepithelial non-dividing cells, which have repopulating capacity and the ability to 
clonally expand. Progeny of these cells function as long-lived lineage-restricted stem cells in 
normal mammary glands and during pregnancy [67]. Mouse mammary epithelial cells can be 
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further sorted into the luminal subset based on CD24+CD29lo [68], which can be delineated 
further into luminal progenitor cells (CD61+ [69, 70]) and terminally differentiated (Sca-1+) cells 
[60] (Figure 1.2).  
In 2010, Di Fiore’s group proposed a new set of markers to elucidate human mammary stem 
cells, in which Notch ligands delta-like ligand 1 (DLL1) and delta and Notch-like EGF receptor 
(DNER) were used in conjunction with CD49f (CD49f+DLL1+DNER+) to enrich 530-fold for the 
stem-like population compared with an 85-fold enrichment when gating on CD24+CD49f+ [71]. 
However, since publication of this article no further evidence has been reported for the use of 
this marker profile in stem cell isolation, and it has not been tested in the mouse mammary gland. 
Putative breast CSCs may also be identified by the “side population” technique, which involves 
isolating a cell subset capable of Hoechst dye exclusion [72], or the ALDEFLUOR assay, based 
on enzymatic activity of aldehyde dehydrogenase 1 (ALDH1) [73].  
Specific cell culture techniques can also be used to enrich for stem-like cells. One of the most 
widely used approaches is the “sphere assay”, a non-adherent culture system designed to select 
for cells with clonogenic and self-renewing potential, in which cells that are unable to survive 
without attachment undergo apoptosis [74]. This assay is based on another proposed property of 
stem cells – resistance to anoikis [75]. First developed to study stemness in nerve cells, the 
neurosphere assay [76] has been adapted for many solid malignancies, including brain, colon, 
prostate, lung and breast cancer [46].  
Dontu et al. first characterised the potential of mammospheres to enrich for mammary stem cells 
and found colonies generated by this type of culture were clonogenic (i.e. not the product of 
aggregation) and capable of passage [75]. Since then, this assay has been used extensively to 
study normal mammary and breast cancer stem cells in vitro and ex vivo. Whilst the primary 
heterogeneous mammosphere culture is thought to contain a greater proportion of luminal cells 
and select only for cells with clonogenic potential, passage of sphere cultures selects for bona 
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fide self-renewing cells by enriching for the stem cell-containing basal population [46, 77]. Other 
cell cultures have also been used to study CSCs, including the colony-forming assay pioneered 
by Stingl’s group [78], and the Matrigel assay, which also allows for identification of 
differentiation capacity in a semi-solid media [79]. 
Approaches to study mammary stem cells in vivo are continuously evolving. The limiting 
dilution assay, first developed to study breast CSCs by Clarke and colleagues, involves injection 
of decreasing numbers of mammary epithelial cells into the mammary fat pad, designed to 
determine the repopulating capacity of cells from a given population, genotype and/or treatment 
[64]. This assay was the foundation for two landmark papers in 2006 by Visvader’s and Eave’s 
groups, which were able to generate entirely new functional mammary glands in mice from a 
single cell [65, 80].  
Recently, study of the cell hierarchy within the mammary gland and other tissues has 
significantly expanded, with the advent of cell fate-mapping by label-retention and lineage-
tracing techniques [81]. However, limitations still exist in the mouse models used, and thus the 
conclusions drawn are not without controversy. Blanpain and colleagues, based on lineage-
tracing experiments, have proposed that both basal and luminal lineages are maintained in adult 
life from unipotent lineage-restricted precursors. They postulated that a multipotent stem cell 
does not exist in normal physiological conditions and may only appear during stress conditions 
such as transplantation [82]. Visvader’s group then counteracted these findings shortly after, as 
their own cell fate-mapping study suggested a bipotent precursor did indeed exist at the top of 
the hierarchy giving rise to both luminal and basal cell types [83]. The issue is still awaiting 
resolution. 
Although this is the closest the field has come to identifying stem cells at the single cell level, the 
final picture of the mammary gland hierarchy has yet to be definitively established. This may be 
achieved by a combination of cell fate-mapping and prospective isolation of refined populations 
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of stem and progenitor cells. Despite this, the question of plasticity in the stem cell population 
still remains contentious as demonstrated by Van Rheenen and colleagues, using elegant 
intravital imaging combined with lineage-tracing experiments to show that even when a CSC 
disappears following asymmetric division, the loss is compensated for by clonal expansion of a 
neighbouring stem-like cell [84].   
1.2.4. Clinical implications of cancer stem cells 
As with normal adult stem cells, CSCs are believed to be mostly quiescent. This means that 
conventional therapeutics designed to kill rapidly-dividing bulk tumour cells may be somewhat 
ineffective at targeting this slow-growing and potentially plastic population, leading to relapse 
[52]. Furthermore, CSCs potentially up-regulate expression of ATP-binding cassette (ABC) drug 
transporters, and so any drugs that may happen to enter the cell are quickly eliminated [85]. 
Drugs designed to target cancer-specific cell surface molecules may also be useless against 
CSCs, which could have completely different surface marker expression. These drugs, including 
immunotherapies (discussed in more detail below), may also select for a more aggressive CSC, 
as those that do not express the target are able to survive and multiply, differentiating into bulk 
tumour cells that the drug is unable to recognise [86]. Furthermore, finding a drug that 
selectively targets cancer stem cells over normal stem cells is a significant challenge [46], 
although large screening experiments may make this approach viable [87, 88].  
As outlined in Figure 1.1, finding unique, functional CSC markers is one potential way to 
specifically target this small subpopulation of cells in conjunction with standard chemo- and 
radio-therapy. Candidate therapeutic targets may include receptors and their oncogenic forms, 
adhesion molecules, signalling pathway members and metabolic components [52]. Another 
option is to force CSCs to differentiate [53], into cells that can be readily eradicated by 
conventional methods. An additional avenue to explore to eliminate CSCs is to disrupt the 
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supporting niche, so that CSCs do not receive the survival maintenance they receive from 
stromal cells and the immune system [46].  
1.3. The immune system and breast cancer  
The immune system plays a key role in breast cancer progression. Infiltrating immune cells, 
which are recruited and present in many solid tumours [89], and are able to be readily identified 
[90], may influence many aspects of cancer, including proliferation, evasion of growth 
suppressors and apoptosis, avoidance of immune destruction, and induction of invasion, 
angiogenesis, and metastasis [38, 91]. However, the information available to date lacks 
consistency, and the roles of various cell subsets appear to vary depending on the tumour type 
and circumstance. 
1.3.1. The adaptive immune system in breast cancer  
Numerous reports have demonstrated that infiltration of cytotoxic T cells (Tc), helper T cells 
(Th), regulatory T cells (Treg) and the dendritic cells that prime them results in increased anti-
tumour immunity, and infiltration of these cells into primary breast tumours has been associated 
with good survival prognosis in breast cancer patients [92-96]. Importantly, harnessing the 
actions of these immune cell subsets to create breast cancer vaccines is of particular clinical 
interest [97].  
It is important to note however, that the role of these immune subsets in breast cancer is 
somewhat contradictory. For example, it has been reported that Th cells can promote early 
mammary tumour development via cytokine secretion [98], Tc cell infiltration has been 
associated with progression to metastasis [99], and dendritic cells can also have an 
immunosuppressive effect in breast cancer [100]. In addition, the actions of cancer-associated 
fibroblasts, macrophages and mast cells can block anti-tumour responses of Tc cells [38]. Treg 
cells in particular have been shown to play a tumour-promoting role in breast cancer, in which 
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the down-regulation of immune responses by Treg cells leads to evasion of the immune system 
by cancer cells and an increase in cancer cell invasiveness [101].  
Similarly, B cells have been shown to have an anti-tumour role and can even form ectopic 
germinal centres within the primary tumour to activate T cell-mediated anti-cancer immunity 
[102, 103] but, conversely, their infiltration has also been associated with a higher tumour grade 
[104] and they have been found to play a pro-metastatic role through conversion of resting T 
cells into Treg cells [105]. To summarise, there is currently no definitive answer as to the role of 
active immune cell subsets in the promotion or inhibition of breast cancer, and their level of 
infiltration and involvement is likely to be determined by cancer subtype, stage of disease, 
tumour microenvironment and specific subset interplay.  
1.3.2. Tumour-associated macrophages  
Although thought to have a role in anti-cancer immunity under certain conditions [106], tumour-
associated macrophages (TAMs) are prolific in human breast cancer  [107] and in MMTV-PyMT 
mouse mammary tumours [90] and are consistently found to play a significant part in tumour 
promotion and poor patient survival [35]. Tissue-resident macrophages exist in all tissues to aid 
in immunity against site-specific pathogens, removal of apoptotic cells, and secretion of certain 
growth factors [108]. In the mammary gland they are also involved in development of the 
mammary epithelium and in tissue remodelling during pregnancy, lactation and involution [109-
111]. These macrophages are defined as classically-activated, or of an “M1” phenotype.  
However, during cancer progression, both newly recruited and resident macrophages within the 
cancerous tissue can be alternatively activated and switch to an “M2” phenotype [112]. This 
switch, induced by particular microenvironment cues, results in a decrease in pro-inflammatory 
chemokine and cytokine production, a decrease in antigen presentation, suppression of the T cell 
anti-tumour immune response, and promotion of angiogenesis, cell proliferation and tissue 
remodelling [113]. Furthermore, TAMs promote cancer cell survival and resistance to 
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chemotherapy, and together with mast cells can remodel ECM components to allow for cellular 
invasion [38].  
M1 macrophages are induced in vitro by interferon-γ, sometimes in combination with microbial-
derived stimuli (such as lipopolysaccharide) or cytokines. M2 macrophages can be generated by 
interleukin (IL)-4 and IL-13 [113]. The M1 and M2 phenotypes are identified using a number of 
methods. In vitro, different conditions can induce a change in the inducible nitric oxide synthase 
(iNOS) to arginase 1 (Arg1) ratio within macrophages. iNOS is involved in pro-immunogenic 
functions, whereas Arg1 expression has immuno-suppressive effects, which can exacerbate 
tumour growth. Hence, M1 macrophages can be identified based on high iNOS and low Arg1, 
and M2 macrophages have low expression of iNOS and elevated levels of Arg1 [113, 114]. M2 
macrophages can also be identified based on positive expression of IL-4 receptor (IL-4R), 
mannose receptor (CD206), and IL-10 [113].  
1.3.3. Immune selection and tolerance of breast cancer stem cells 
The following contains excerpts from Appendix A.  
In addition to their role in breast cancer progression, there is some recent evidence that points to 
a role for various immune cells in the regulation of breast CSCs (Appendix A [115]). As recently 
proposed [115] and outlined in Figure 1.3, the “immuniche” (the components of the immune 
system within the tumour niche that support cancer stem cells) may be a determining factor in 
stem cell survival, maintenance, and subsequent tumour growth. A high infiltration of CD4- and 
CD8-positive immune cells has been previously correlated with increased breast cancer stem cell 
phenotype [116], and the presence of macrophages in mammary tumours was also found to 
maintain the breast CSC niche through secretion of specific cytokines, such as IL-6 and CXCL8 
(also know as IL-8), enhancing the stem cell-like state and activity [117]. Cells within the 
immuniche may not only directly support CSCs (as in the case of TAMs and secreted factors by 
other stromal cells such as CAFs and mesenchymal stem cells [47]) but may potentially select 
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for more aggressive or evasive CSCs through the processes of immune selection (Figure 1.3), 
which could also play a part in resistance to immune-mediated therapy by cancer stem cells.  
Bulk cancer cells can develop resistance to conventional cytotoxic drugs due to up-regulation of 
drug transporters [27], and it is thought that CSCs may have more robust mechanisms of drug 
efflux. The same may be true for immunotherapies, where CSCs avoid killing by cytotoxic cells. 
For example, it was found that treatment with trastuzumab depleted Her2-expressing breast 
cancer cells through a natural killer cell-mediated mechanism. However, cells that survived this 
natural killer cell immune selection had increased stem-like CD44hiCD24lo surface marker 
expression and were able to grow more robustly as mammospheres compared with naïve cells. 
After six cycles of treatment, the CD44hiCD24lo cell content was significantly increased, 
indicating that proportions of breast CSCs increased over time through immune selection [118].  
Tumour cells are also able to avoid recognition by primed immune cells through immuno-
editing, a process in which tumour cells lose or modify tumour antigens. Findings by Knutson et 
al. showed that immuno-editing may occur through the process of EMT, a route that may also 
result in the acquisition of a breast CSC phenotype. The authors have suggested that immuno-
editing is not an incremental loss of tumour antigens but rather an active process in which cells 
use EMT to de-differentiate into cells of a stem-like state [119].  
Immune selection and immuno-editing may result in tumour cells that would otherwise be 
attacked by the immune system being recognised as self, thus leading to tolerance and immune 
evasion. Exact mechanisms underlying these phenomena are not yet known, however 
glycoprotein CD200 has been previously reported to have a role in breast CSC immune evasion 
[120]. CD200 is commonly expressed in myeloid cell populations and has been studied as a 
therapeutic target due to its role in immunoregulation and immune tolerance, as deletion of 
CD200 in animal models can lead to development of autoimmune disorders [121]. In 
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tumourigenic and invasive breast cancer cells, it was found that a high percentage of CD200+ 
cells were of a CD44+CD24− phenotype [120].  
It is plausible that the infiltration of immune cells into mammary tumours may stimulate more 
mature breast cancer cells to de-differentiate into stem-like cells through EMT, coinciding with 
the activation of molecules that promote tolerance of CSCs by the immune system. This in turn 
may enhance CSC immune evasion and the development of more aggressive tumours.  
1.3.4. Chemokine receptors in cancer 
The recruitment of immune cells to the tumour site is mediated by the actions of chemokines and 
their cognate ligands, which have also been widely linked to cancer progression and metastasis.  
Chemokine receptors are G-protein coupled receptors (GPCRs), consisting of seven 
transmembrane domains, which bind low molecular-weight chemotactic-cytokines 
(chemokines). Upon binding of chemokine ligands, the receptor undergoes a conformational 
change leading to activation of intracellular G-proteins. This results in a signalling cascade that, 
depending on the context, can stimulate cellular growth, migration, pseudopodia formation, 
adhesion, and angiogenesis, as well as angiostasis [122]. When expressed on immune cells, the 
action of chemokine receptors leads to homing of an immune cell to a specific site via a 
chemotactic gradient. Because of the involvement of chemokine receptors in migration of cells, 
they have been widely implicated in metastasis of cancer cells throughout the body [123]. Table 
1.1 summarises the involvement of chemokine receptors in cancer pathogenesis. In breast cancer, 
the chemokine receptors CXCR4, CCR7, CCR6 and CXCR3 and the ligand CCL2 have been 
associated with metastasis [124-127].  
The receptor CXCR4 is the most studied of all chemokine receptors in cancer, and its many 
documented roles in breast cancer encompass cell survival, proliferation, motility, invasion, 
angiogenesis, recruitment and activation of a number of different cell types, and metastasis 
[128]. CCR7 is often up-regulated together with CXCR4 in cancer [125, 129] and previously the 
Chapter 1: Introduction 
	  
	   	   	   	   	    
19	  
McColl group reported that CXCR4 together with CCR7 regulates breast cancer cell metastasis 
through inhibition of anoikis [130]. In addition, these two receptors form a heterodimer on 
metastatic breast cancer cells, which activates alternative signalling pathways and promotes a 
metastatic phenotype (Kochetkova; unpublished). However, CCR7 has not been as well 
characterised as CXCR4 in the literature. 
Chemokine receptors are further involved in regulation of cancer progression through 
recruitment of immune cell subsets. For example, macrophages can be recruited to the tumour 
microenvironment through the CX3CR1/CX3CL1 and CCR2/CCL2 axes [131], the expression of 
CCR5 has both anti-tumour activity when expressed on infiltrating Tc cells and pro-tumour 
activity when expressed on Treg cells [132], dendritic cells can migrate to the tumour 
microenvironment via CXCR4, CCR6 and CCR7, and CXCL9 and CXCL10 are strong 
chemoattractants for CXCR3-expressing T lymphocytes [133].  
Importantly, there is a paucity of information from in vivo experimental systems regarding the 
specific function of individual chemokine receptors in cancer progression, and very little data 
exists regarding their role in primary tumour formation. 
1.3.5. Chemokine receptors and cancer stem cells 
The following contains excerpts from Appendix A. 
Recently, a small body of evidence has also implicated chemokine receptors in maintenance of 
stem cells, as summarised in Table 1.2. Whilst most of the available data refers to mesenchymal 
stem cells, some chemokines and their receptors have been suggested to play a role in 
maintenance of cancer stem cells [134].  
Seminal work on the involvement of chemokine receptors in breast CSCs has come from Max 
Wicha’s group, which have studied the role of CXCR1. CXCR1 is closely related to CXCR2, 
with which it shares multiple ligands including CXCL8. Both receptors have been heavily 
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implicated in the elimination of pathogens but also shown to contribute significantly to disease-
associated processes, including tissue injury, fibrosis, angiogenesis and tumourigenesis [135]. It 
was found that CXCR1-positive cells were present in the CD44+CD24− population in breast 
cancer cell lines, and were also almost exclusively contained in the ALDEFLUOR-positive 
population. Stimulation of CXCR1 with CXCL8 increased primary and secondary 
mammosphere-forming efficiency (MFE). In addition, CXCR1+ALDEFLUOR+ cells were able 
to form heterogenous tumours upon transplantation [136, 137], providing functional support for 
the role of CXCR1 in breast CSC regulation.  
Treatment of breast cancer cell lines with a CXCR1 inhibitor or an anti-CXCR1 antibody 
resulted in a five-fold reduction in ALDEFLUOR+ cell numbers and inhibition of the CXCR1 
interaction with its ligands in sphere culture caused a massive decrease in primary and secondary 
MFE. Interestingly, when normal human mammary epithelial cells were cultured as 
mammospheres, addition of CXCL8 again increased the primary and secondary MFE, further 
implicating CXCR1 as a regulator of stemness in both cancer and normal breast development 
[137].  
The CXCR2 chemokine receptor was previously shown to mediate breast cancer 
chemoresistance [138], an implied property of breast CSCs. Co-expression of CXCR1 and 
CXCR2 by cancer cells is reported to promote cancer growth [139], and as mentioned above, 
both are receptors for CXCL8 which is expressed by breast CSCs [140]. As well as CXCL8, 
CXCR2 interacts with chemokines CXCL3, CXCL5, and CXCL7. Wicha and colleagues also 
examined the result of neutralising CXCR2 but did not observe a difference in the breast CSC 
population [137].  
Contrary to this, other reports showed that siRNA targeting of CXCR2 and CXCL3 decreased 
the viability of CD44+CD24− basal-like breast cancer cell lines through a decrease in Stat3 
activity [141], and sequestering CXCL7 blocked expression of other immune modulators from 
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putative breast CSCs [142]. In addition, CXCL5 stimulation of breast cancer cell lines increased 
the ALDEFLUOR+ cell population [142]. As CXCR2 antagonists are already in the clinic for 
other conditions such as pulmonary disease [143], inhibiting this receptor may prove a promising 
breast CSC-targeting therapy, however the role of CXCR2 in breast CSCs still remains to be 
validated in cancer models in vivo.  
Recently, CXCR4 was reported to contribute to the maintenance of the breast CSC population 
through transactivation of the aryl hydrocarbon receptor [144] and was also expressed in 
CD44+CD24− breast cancer cell lines, which correlated with their invasiveness [145]. 
Furthermore, CXCR4 was detected on the surface of mammosphere cells, and CXCR4 
antagonists decreased MFE and the proportion of CD44+CD24− breast cancer stem-like cells 
[36]. Interestingly, CXCR4 expression has been putatively linked to the functionality of the 
CD24 surface marker (a breast CSC marker) in metastatic spread, but this finding requires 
further validation in vivo [146].  
The CXCR4 antagonist plerixafor (AMD3100) has shown some promise in preclinical trials 
[147, 148] and could also provide an option for targeting stem cells. For example, in tamoxifen-
resistant breast cancer cells, Dubrovska et al. showed that AMD3100 inhibited the breast CSC-
enriched side population [144]. This study highlights the potential use of chemokine receptor 
pathway antagonists as adjuvants to conventional cytotoxic drugs, which alone cannot eradicate 
the quiescent cancer stem cell populations.  
It has also been shown that anoikis-resistant cells (which have enhanced stem-like phenotype) 
up-regulate CXCR4 preferentially in breast cancer over normal mammary epithelium [149]. As 
the McColl group previously found that activation of CXCR4 and CCR7 inhibits anoikis [130], 
this suggests that both receptors have a role in promoting the breast CSC phenotype.  
In a study reported in 2011, Asiedu et al. comprehensively characterised the chemokine and 
chemokine receptor profiles in breast cancer cell lines with high CD44+CD24− cell content, with 
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the view to identifying potential breast CSC regulators among this class of immune modulators. 
They reported increased expression of CCR7, but unexpectedly down-regulation of CXCR4. In 
addition, CD44+CD24− breast cancer cells had increased expression of CXCR7, CCL13, CCL11, 
CCL12, CCL2, CCL5, CCL6, CCL7 and CCL8, and down-regulated CCR3, CXCL1 and CCL20 
[150]. Notably, CXCR7 also binds the ligand for CXCR4, CXCL12, and scavenges CXCL12 to 
promote cancer cell metastasis [151]. Increased expression of CXCR7 in the CSC population and 
its impact upon CXCR4 activity remains to be functionally assessed. Of the chemokines up-
regulated, only CCL2 and CCL5 have been conclusively shown to have a role in breast cancer 
[152, 153]. 
Whilst CCL5 has not been examined in the context of breast cancer stem cells, CCL2 has been 
proposed to affect properties of stemness in breast cancer cells. In addition to secretion from 
mammary CSCs, treating mammosphere culture with exogenous CCL2 increased stem cell 
function via induction of Notch-1 signalling and resulted in more spheres with a higher number 
of slow-cycling stem cells, as was measured by retention of PKH67 dye [37]. Whilst there are 
clear indications of a potential function for CCL2, more specific in vivo evidence is needed to 
confirm its role in breast CSC regulation. Of note, CCL2 is also involved in recruitment of 
monocytes, memory T cells, regulatory T cells and dendritic cells to inflammatory sites [154], 
and to breast tumours [155] through its major receptor CCR2, which may aid breast CSCs in 
controlling the immune system.  
The involvement of chemokine receptors appears to encompass a diverse range of roles in terms 
of primary cancer growth, immune infiltration, regulation of the microenvironment, metastasis, 
and maintenance of stem cells. However, the underlying molecular mechanisms are largely 
unknown, and may explain the shortage of chemokine receptor-targeting drugs in breast cancer 
clinical trials.  
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1.4.  The research project 
1.4.1. Project rationale 
CCR7 is one of the major factors in regulation of T cell migration to secondary lymphoid organs 
[156], induction of tolerance through interactions with dendritic cells [157], and control of 
immune responses via Treg cells [158]. Cell migration mediated by CCR7 follows the gradients 
of its two chemokine ligands, CCL19 (EBV-induced molecule 1 ligand, ELC) and CCL21 
(secondary lymphoid tissue ligand, SLC) [159]. In addition to its well-documented homeostatic 
role in immunity, CCR7 has also been shown to be involved in various malignancies (see Table 
1.1). 
However, whilst the chemokine receptor CXCR4 has been widely investigated for its oncogenic 
properties, CCR7, which is up-regulated together with CXCR4 in breast cancer [125, 160], has 
not been as well-characterised. It was shown in archived human breast cancer tissue that high 
levels of CCR7 correlated with decreased patient survival and metastasis to the lungs and lymph 
nodes [125, 161]. Using in vitro cell line culture, CCR7 was found to promote breast cancer cell 
motility and invasiveness [161, 162], and intratumoural CCL21 can contribute to suppression of 
anti-tumour immunity [38]. Whilst these data circumstantially implicate CCR7 in breast cancer 
development and progression, there has been no definitive in vivo evidence for the role of CCR7 
in the primary tumour reported so far.  
CCR6 has been previously associated with higher grades of breast cancer and reported as a 
possible prognostic marker together with CCR7 [124, 163]. As with the CCR7 receptor, CCR6 is 
expressed on a variety of immune cells, and induction of CCR6-mediated pathways is stimulated 
upon binding to its ligand CCL20 (macrophage inflammatory protein (MIP)-3α) [164]. In 
particular, CCR6 is involved in dendritic cell localisation and homeostasis [165], and Treg cell 
migration [166]. However, a function for CCR6 in malignancies has not been previously shown, 
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despite being expressed in a number of cancers (see Table 1.1), with no direct causal link 
between the expression of CCR6 and cancer progression reported to date.  
It was previously found that higher CCR6 expression levels were linked with breast tumour stage 
and grade [163], and breast cancer metastasis to the pleura [124]. Expression of ligand CCL20 is 
also reported to be up-regulated in human triple-negative breast cancer cell lines [167], and 
stimulation of ex vivo peritumoural mammary cells with CCL20 increased cell proliferation, 
migration and invasiveness [168]. However, CCR6 has not been investigated in primary breast 
cancer in vivo and hence no functional role for CCR6 in breast cancer has been documented.  
Thus, potential roles for the receptors CCR7 and CCR6 in breast cancer development and 
progression are implied, however the underlying mechanisms and functional relevance of their 
expression have not yet been established. 
 
1.4.2. Hypothesis and Aims 
1.4.2.1. Hypothesis 
The hypothesis for this project was as follows: 
The chemokine receptors CCR7 and CCR6 are important regulators of breast cancer 
development and progression. 
1.4.2.2. Aims 
Aim 1: To investigate the role of CCR7 in mammary tumourigenesis. 
Aim 2: To investigate the role of CCR6 in mammary tumourigenesis.  
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1.4.3. Summary of findings 
As CCR7 and CCR6 have been associated with breast cancer metastasis from analysis of 
archived tissue, and their stimulation induces proliferation of cancer cells in vitro, it was 
hypothesised that these receptors played a significant role in breast cancer development and 
progression in vivo via distinct molecular and cellular mechanisms.  
Using a well-characterised mouse model for breast cancer, in which the polyoma middle-T 
transgene is activated under control of the mouse mammary tumour virus promoter (MMTV-
PyMT) [169, 170], the contributions of CCR7 and CCR6 to primary breast cancer were 
examined in vivo and ex vivo.  
When it was found that both CCR7 and CCR6 were highly expressed within the breast cancer 
cell population, the MMTV-PyMT transgenic mouse was crossed with both CCR7- and CCR6-
null mice. Deletion of either receptor in these bigenic mouse models resulted in a decrease in 
mammary tumourigenesis, indicating that both receptors play a role in breast oncogenesis.  
However, it was then discovered that the function of each receptor in the promotion of breast 
cancer pathogenesis is unique. CCR7 promoted breast cancer via amplification of cancer stem-
like cells, as was found by analysing cell surface marker expression and self-renewal in sphere 
culture, and performing multiple transplantation approaches. Furthermore, the use of a CCR7 
antagonist in vivo significantly depleted stem-like cell pools, making CCR7 a plausible candidate 
for CSC-targeting therapies (Appendix B [171]).  
CCR6, however, did not play any role in the epithelial compartment of the mammary gland, as 
its deletion did not impact upon cell proliferation, maintenance of the cellular hierarchy, or 
tumour propagation upon transplantation. Upon further examination, it was found that the role of 
CCR6 in the promotion of breast cancer is via recruitment and maintenance of pro-tumourigenic 
macrophages in the tumour microenvironment. The deletion of CCR6 resulted in significantly 
reduced pools of both total TAMs and of M2 macrophages. The negative effect of CCR6 
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deletion on tumourigenesis could be restored by supplementation of tumour-associated 
macrophages (Appendix C [172]).  
Results from this study imply that simultaneous assault of both the CSC pool and the tumour 
microenvironment by targeting specific chemokine receptors is a viable option for breast cancer 
therapeutic application.   
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Figure 1.1: New concepts in breast cancer research and avenues of possible therapeutic 
targeting. 
The field of breast cancer research has expanded significantly in the last decade, with 
investigation into a number of new concepts, including study of the tumour microenvironment, 
disseminated and circulating tumour cells, formation of metastatic niches, and cancer stem cells. 
Along with the study of these areas of breast cancer pathobiology comes new possible avenues 
for therapeutic application.    
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Figure 1.2: The Cancer Stem Cell Model, mammary cell hierarchy and proposed breast 
tumour cells-of-origin. 
Mammary cells are believed to exist within a hierarchy, with a self-renewing stem cell giving 
rise to lineage progenitors and terminally differentiated cells of the luminal and basal lineages, 
which can be putatively identified based on the expression of various surface markers as 
indicated. Within this hierarchy, it is not clear from where cancer stem cells arise, however the 
cell with the most stem-like characteristics is capable of propagating secondary tumours upon 
serial transplantation (right). It is thought that different subtypes of breast cancer may have 
different cells-of-origin within this hierarchy (left), when those cells acquire stem-like 
characteristics.  
Image adapted from [60] and [173].  
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Figure 1.3: Maintenance of breast cancer stem cells by immune cells and immune modulators 
within the “immuniche”. 
Breast cancer stem cells express a variety of immune modulatory receptors on their surface. 
Chemokine and cytokine receptors are activated by immune modulators secreted by 
mesenchymal stem cells and cancer-associated fibroblasts, promoting properties of stemness. 
Tumour-associated macrophages promote breast cancer stem cell survival both indirectly and 
directly, and infiltrating T cell subsets in the immuniche provide a catalyst for immune selection.  
Adapted from [115].  
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Table 1.1: Chemokine receptors in cancer. 
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Table 1.1 (Continued): Chemokine receptors in cancer. 
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Table 1.1 (Continued): Chemokine receptors in cancer. 
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 Table 1.2: Chemokine receptors in stem cell biology. 
 
Chapter 1: Introduction 
	  
	   	   	   	   	    
34	  







CHAPTER 2: Materials and Methods 
 
  
Chapter 2: Materials and Methods 
 
	  
	   	   	   	   	    
36	  
2.1. Models and materials 
2.1.1.  Mice 
Mice were maintained in pathogen-free conditions in the University of Adelaide’s Laboratory 
Animal Services facility and the University of Adelaide institutional animal ethics committee 
approved all experimentation.  
MMTV-PyMT mice on the FVB strain background were backcrossed for 15 generations to the 
C57Bl/6 background, and C57Bl/6 background was confirmed by microsatellite analysis. PyMT-
carrying males were then crossed with Ccr7-/- and Ccr6-/- female mice on the C57Bl/6 strain 
background, and the offspring were interbred to produce MMTV-PyMT Ccr6/7WT and MMTV-
PyMT Ccr6/7-/- knockout mice. See Figure 2.1 for a schematic of the breeding strategy.  
For the assessment of chemokine receptor expression, stimulation experiments, and antagonist 
function, both C57Bl/6 and FVB backgrounds were tested to eliminate any strain bias. For 
experiments involving knockout mice, only C57Bl/6 mice were tested.  
2.1.2. Human mammary tissue 
Human breast tumour samples were obtained from the Royal Adelaide Hospital (Adelaide, South 
Australia) and normal breast tissue samples were obtained from the Queen Elizabeth Hospital 
(Woodville, South Australia). All patients gave written, informed consent prior to surgery. 
2.1.3. Basic solutions 
• MQ H2O: Milli-Q water was obtained from the Central Services Unit (CSU) in the 
School of Biological Sciences.   
• PBS: 20x phosphate buffered saline (from CSU) was diluted in MQ H2O to 1x. 
• HBSS: 10x Hank’s balanced salt solution (Gibco) was diluted in MQ H2O to 1x. 
• PBS/BSA: Bovine serum albumin (Sigma-Aldrich) was added at the desired 
concentration to 1x PBS then dissolved at 4°C before filter-sterilisation. 
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2.1.4. Carmine alum 
Carmine alum was either obtained commercially (Stem Cell Technologies) or made by boiling 
1g carmine and 2.5g aluminium potassium sulphate in 500ml distilled H2O for 20 minutes, 
followed by filtration and addition of thymol. Carmine was stored at 4°C and used undiluted. 
2.1.5. Formaldehyde 
Formaldehyde at 37% w/v (Sigma-Aldrich) was diluted in PBS to either 3.7% or 1% for fixation 
of cells. Methanol-free formaldehyde at 16% w/v (Thermo Fisher Scientific) was diluted to 4% 
in PBS for fixation of tissues before paraffin embedding.  
2.1.6. Mouse mammary tissue digestion medium 
Digestion medium for mouse tissue consisted of Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco) supplemented with collagenase, hyaluronidase, 2% foetal calf serum (FCS), and 1% 
penicillin-streptomycin.  
Enzymes from Stem Cell Technologies: The supplied mix of collagenase (3000U/ml) and 
hyaluronidase (1000U/ml) in DMEM was used at 10% of the stock concentration in digestion 
medium.  
Enzymes from Worthington: Collagenase type III was reconstituted in in HBSS/Ca2+/Mg2+ and 
used at a final concentration of 1mg/ml. Hyaluronidase was reconstituted in MQ H2O and used at 
a final concentration of 100U/ml. 
2.1.7. Human mammary tissue digestion medium 
Digestion medium for human tissue consisted of DMEM supplemented with 20mM HEPES, 
collagenase and hyaluronidase (see above), 12U/ml deoxyribonuclease (DNase)I (Merck) and 
1% penicillin-streptomycin. 
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2.1.8. Mouse red cell removal buffer (MRCRB) 
MRCRB consisted of 90% 155mM NH4Cl and 10% 170mM Tris-HCl. The pH was adjusted to 
7.2 and the solution was filter-sterilised before use. 
2.1.9. Complete sphere medium 
Mammosphere medium consisted of 1:1 volumes of DMEM and Ham’s F12 nutrient mix 
(Gibco) supplemented with 1xB27 (Invitrogen), 10ng/ml epidermal growth factor (EGF, R&D 
Systems), 20ng/ml basic fibroblast growth factor (bFGF, R&D Systems), 4ng/ml heparin 
(Sigma-Aldrich), 1% penicillin-streptomycin and 0.5% fungazone. 
2.2. Ex vivo methods 
2.2.1. Extraction of mammary cells 
Mouse mammary glands/tumours were dissected, with removal of the lymph node if possible. 
Tissue was manually dissociated and then digested in mouse mammary tissue digestion medium 
for 3-4 hours at 37°C with gentle tilting on a HulaMixer (Invitrogen). Resultant organoids were 
digested for a further 15 minutes with dispase (5mg/ml from Stem Cell Technologies or 6U/ml 
from Gibco) and DNase I (12U/ml) at 37°C before washing in HBSS with 2% FCS and lysis of 
red blood cells for 2 minutes at room temperature in MRCRB. Cells were then filtered through a 
70µm nylon mesh to then obtain a single cell suspension. All centrifuge washes were performed 
at 350xg for 3 minutes.  
Surgical human specimens were minced and digested in human mammary tissue digestion 
medium. Organoids were then extensively washed with DMEM and red blood cells were lysed in 
MRCRB. Single cell suspensions were obtained by digesting organoids with 0.25% trypsin for 
10 minutes at room temperature, with subsequent filtration through a 70µm nylon mesh. 
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2.2.2. Haematopoietic lineage depletion by magnetic separation 
When required, freshly isolated mammary cells were pelleted and resuspended in 1ml depletion 
buffer (PBS/0.1% BSA and 2mM EDTA at pH 7.4) containing a cocktail of biotinylated anti-
mouse antibodies against haematopoietic lineage markers CD3, TER-119, CD11b, Ly-6C/G and 
CD45R (panel from BioLegend). Cells were incubated for 10 minutes at 4°C with gentle tilting 
then resuspended in 1ml buffer and transferred to a 1.5ml centrifuge tube, together with 50µl 
washed biotin binder Dynabeads (Invitrogen). Samples were incubated for 30 minutes at 4°C 
with gentle tilting, then a further 500µl depletion buffer was added to limit trapping of unbound 
cells. Tubes were placed in a DynaMag-Spin magnet (Invitrogen) for 3 minutes and the lineage-
negative supernatant transferred to a fresh tube for subsequent experiments.  
2.2.3. Flow cytometry and fluorescence-activated cell sorting (FACS) 
Experiments were performed either in FACS tubes (centrifugation at 350xg for 3 minutes) or 96-
well round-bottomed trays (centrifugation at 400xg for 1 minute). Cells were pelleted and 
blocked for non-specific antibody binding by incubating for 15 minutes at room temperature in 
mouse gamma (γ) globulin in PBS/0.5% BSA. Cells were then immunostained for 30-45 minutes 
on ice in PBS/0.5%BSA. If intracellular staining was required, cells were permeabilised 
following surface antigen staining using the FoxP3 Staining Kit (eBioscience). A complete list of 
antibodies, manufacturer details and concentrations used is in Table 2.  
Samples containing biotinylated antibodies were resuspended with conjugated streptavidin in 
PBS/0.5% BSA for 30 minutes on ice. Fluorescence-minus-one (FMO) samples or conjugated 
isotypes were used as negative controls. For flow cytometry, cells were fixed in 1% 
formaldehyde and acquisition carried out using FACS Canto or LSR II equipment (BD 
Biosciences). For sorting, live cells in PBS/0.5% BSA were sorted using a FACS Aria (BD 
Biosciences) into DMEM, with the assistance of Mr Cameron Bastow and Ms Carly Gregor of 
the University of Adelaide.  
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2.2.4. Mammosphere assay 
Cells were added at a concentration of 4x104 cells/ml in complete sphere medium to polyhema-
coated ultra-low attachment trays (Corning Inc.). Where indicated, CCL21, CCL19 and CCL19(8-
83) were added at concentrations of 10ng/ml, 200ng/ml and 100ng/ml respectively. CCL20 (a gift 
from the late Professor Ian Clark-Lewis) was added at various concentrations as specified in 
Chapter 4. Spheres were cultured at 37°C and media replenished every second day. After 7-10 
days, mammospheres were counted and passaged. Samples were collected, centrifuged at 200xg 
for 5 minutes and supernatant aspirated. Warm trypsin/EDTA in PBS (from CSU) was added and 
samples were triturated through a 19G needle to break up colonies. After 2 minutes in trypsin, 
tubes were topped up with PBS/2% FCS to neutralise trypsin, and centrifuged for 3 minutes at 
350xg. Cells were filtered through 70µm filters and washed again in PBS to remove FCS, before 
reseeding into clean ultra-low attachment plates for secondary culture in complete sphere 
medium. 
2.2.5. Histology 
For formalin-fixed paraffin-embedded (FFPE) sections, tissue was extracted and fixed overnight 
in 4% formaldehyde at room temperature. Tissue was then put into cassettes and stored in 70% 
ethanol at 4°C, until embedding in paraffin and sectioning at 5µm (Adelaide Histology). To 
stain, slides were first deparaffinised by immersing in D-Limonene for 10 minutes, then 
rehydrated through graduated ethanol.  
For frozen sections, lungs of mice were perfused and dissected, then cryoembedded in OCT and 
serially sectioned at 9µm. Sections were fixed in 60/40% acetone/methanol before staining.  
For haematoxylin and eosin (H&E) staining, sections were rinsed through 3 changes of 1x PBS 
for 1 minute each before immersing in Gill’s haematoxylin for 1-5 minutes. Slides were rinsed in 
distilled H2O then differentiated for 3 seconds in 1% acid-alcohol (20% distilled H2O, 10% 
concentrated hydrochloric acid, 70% ethanol). Slides were immersed in Scott’s tapwater 
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substitute (2g sodium bicarbonate, 20g magnesium sulphate per 1L distilled H2O) for 2 minutes 
before rinsing again in distilled H2O. Slides were immersed in eosin for 0.5-2 minutes and rinsed 
in distilled H2O briefly before completely dehydrating through graduated ethanol followed by D-
Limonene. Slides were mounted with Depex (Thermo Fisher Scientific) and scanned using the 
NanoZoomer Digital Pathology (NDP) System (Hamamatsu Photonics). Lung sections were 
manually quantitated using the NDP Virtual Slide Viewer software for number of metastases and 
area at the largest point.  
2.2.6. Immunofluorescent staining 
Antigen retrieval of FFPE mouse mammary sections was performed by boiling slides in 0.1M 
sodium citrate buffer (pH 6.0). Slides were immuno-stained with rabbit anti-CCR7 (Epitomics) 
overnight at 4°C, and primary antibody was detected with Alexa Fluor 488-conjugated goat anti-
rabbit (Invitrogen) for 30 minutes. All staining was performed in humid chambers. Slides were 
counterstained with DAPI, mounted, and analysed using the Leica TCS SP5 Confocal 
Microscope System.  
For these experiments, Sarah Boyle extracted and fixed the mammary tissue, and analysed the 
results. Adelaide Histology embedded and sectioned the tissue as above. Ms Valentina Poltavets 
(formally) of the University of Adelaide performed the staining. 
2.2.7. Immunohistochemical staining 
For α-smooth muscle actin (α-SMA) staining following antigen retrieval (as for IF staining), 
slides were immersed in 3% hydrogen peroxide in PBS for 20 minutes with gentle agitation to 
inhibit endogenous peroxidase activity and blocked for 30 minutes in 10% normal rabbit serum 
in PBS to prevent non-specific antibody binding. For Ki67 staining, slides were blocked before 
antigen retrieval. 
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All slides were then incubated overnight at 4°C with mouse anti-α-SMA (Dako) or mouse anti-
Ki67 (Vector Labs). Specific antibody binding was detected using the EnVision Dual Link 
System (Vector Labs) followed by incubation with diaminobenzidine (DAB) substrate (Dako). 
All staining was performed in humid chambers. Sections were counterstained with haematoxylin, 
dehydrated and mounted. Slides were scanned for analysis as specified above in Histology. 
For these experiments, Sarah Boyle extracted and fixed the mammary tissue, and analysed the 
results. Adelaide Histology embedded and sectioned the tissue as above. Ms Natasha Pyne and 
Doctor Michael Samuel of the Centre for Cancer Biology, University of South Australia, 
performed the staining.  
2.2.8. Mammary gland whole mounting, image-stitching and quantification 
Intact mammary glands were extracted and spread onto glass slides before fixing in Carnoy’s 
fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) for 3-4 hours at room 
temperature. Slides were then transferred to 70% ethanol for at least 10 minutes before gradually 
changing to distilled H2O. Whole mounts were then immersed in carmine alum overnight, then 
fully dehydrated through graduated ethanol followed by D-Limonene, and mounted with 
Permount (Thermo Fisher Scientific). Mounts were photographed using a Nikon SMZ1000 
dissecting microscope connected to an Olympus DP70 camera, and the images stitched together 
using the Mosaic plug-in in Image J. Quantification of epithelial growth and area of hyperplasia 
was performed using Image J.  
2.2.9. Enzyme-linked immunosorbent assay (ELISA) 
Wells of a high-binding 96-well tray were coated with CCL19, CCL21, and CCL20 capture 
antibody (all from R&D Systems) overnight at 4°C. Non-specific binding was then blocked for 1 
hour at 37°C with PBS/3% BSA. Mammary fat pad samples were weighed and then 
homogenised in ceramic bead tubes with 500µl ELISA buffer (10% glycerol, 1x protease 
inhibitor in PBS), and samples and chemokine standards in ELISA buffer were added at 
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100µl/well. Samples were incubated at 37°C for 90 minutes, then incubated with biotinylated 
detection antibody (all from R&D Systems) in PBS/1% BSA for 1 hour at 37°C. Streptavidin 
conjugated to horseradish peroxidase (HRP) in PBS/1% BSA was then added to samples and 
incubated at room temperature for 30 minutes, followed by development for up to 30 minutes in 
the dark with 75µl/well tetramethylbenzidine (TMB) substrate. The reaction was stopped by 
adding 50µl/well 1M orthophosphoric acid, and absorbance read at 490nm on a Biotrak plate 
reader. Between each incubation wells were washed with PBS/0.05% tween. 
2.2.10. Calcium signalling analysis  
The intracellular calcium mobilisation assay was performed as described [130] on cells isolated 
from tumours dissected from C57Bl/6 MMTV-PyMT mice at 20 weeks of age. Ligands added 
were CCL21 (100ng/ml) and lysophosphatidic acid (LPA) (50ng/ml).  
For these experiments, Sarah Boyle extracted the mammary cells and analysed the results. 
Doctor Marina Kochetkova of the University of Adelaide performed the assay.  
2.2.11. XTT proliferation assay 
Isolated mouse mammary cells were plated in adherent culture (1:1 mixture of DMEM and 
Ham’s F12 nutrient mix, 10% FCS, 20ng/ml EGF, 5µg/ml insulin, 0.5µg/ml hydrocortisone, 1% 
penicillin-streptomycin, and 0.25µg/ml fungazone) in 96-well plates and the following day were 
starved. The cell proliferation assay was carried out 24 hours later using the XTT Cell 
Proliferation Kit (ATCC) according to manufacturer’s instructions, using 100ng/ml CCL19, 
CCL21 or CCL20. FCS (0.5%) and EGF (20ng/ml) were used as positive controls.  
For these experiments, Sarah Boyle extracted the mammary cells and analysed the results. 
Doctor Marina Kochetkova of the University of Adelaide performed the assay.  
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2.3.  In vivo methods 
2.3.1.  Tumourigenesis studies 
Mice were monitored for onset of mammary tumours by manual palpation. For long-term 
tumourigenesis, mice were allowed to develop tumours for up to 24 weeks, unless the 
cumulative burden reached 2mm2 before this point. Upon sacrifice, tumours were counted, 
extracted, photographed, and weighed.  
2.3.2.  Tissue transplants 
Procedures were performed on mice under isofluorane anaesthetic. Mammary gland fragments of 
1mm3 size from donor MMTV-PyMT mice were transplanted into the fourth inguinal mammary 
fat pads of congenic non-PyMT recipient mice. After surgery, wounds were closed using surgical 
staples and either Temgesic or Rimadyl analgesic was administered subcutaneously. Mice were 
monitored for adverse reactions to surgery and subsequent tumour growth. Glands were either 
whole-mounted after a number of weeks or allowed to develop tumours. See Figure 2.2 for a 
schematic diagram of the procedure. 
2.3.3.  Limiting dilution assay 
Mammosphere colonies derived from 8 week-old pre-neoplastic MMTV-PyMT mice were 
dissociated as above and filtration was performed using endotoxin-free PBS (SA Pathology). 
Cells were injected in 20% Matrigel (BD Biosciences) in DMEM using a Hamilton syringe fitted 
to a 26G needle into the fourth inguinal mammary glands of anaesthetised recipient mice at 
decreasing concentrations to determine the limiting dilution as previously described [71]. Mice 
were sacrificed after 6 weeks and glands whole-mounted. See Figure 2.3 for a diagram of the 
procedure.  
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2.3.4.  Macrophage reconstitution assay 
Mammary tumour cell suspensions were prepared from MMTV-PyMT Ccr6WT at 15 weeks old 
and injected into the fourth inguinal mammary fat pads of anaesthetised 5 week-old Ccr6WT and 
Ccr6-/- recipients in 20% Matrigel in DMEM, at 100,000 cells/gland.  
Two days later, tumour-associated macrophages were sorted from MMTV-PyMT Ccr6WT 
excised and dissociated mammary tumours based on CD45+F4/80+ expression. 50,000 TAMs per 
gland were injected in DMEM orthotopically into the inguinal glands of Ccr6-/- tumour cell 
recipients. Control groups of Ccr6-/- and Ccr6WT tumour cell recipients were sham-injected with 
vehicle only. Tumour development was monitored for 6 weeks, then mice were sacrificed and 
tumours extracted for analysis. See Figure 2.4 for a diagram of the procedure.  
2.3.5. Antagonist studies 
CCL19(8-83) truncated ligand was used at a concentration of 1µg/50µl in vivo. The antagonist was 
diluted in saline and mice were injected under anaesthetic into inguinal mammary fat pads using 
an insulin syringe. Control mice were sham-injected with vehicle alone as previously reported 
[174, 175]. Glands were then allowed to develop tumours over a number of weeks. See Figure 
2.5 for a diagram of the procedure. 
2.4. Statistics and graphing 
All quantitation results were graphed using GraphPad Prism. Unless otherwise indicated, data is 
shown as mean ± standard error of the mean (SEM). Tumour-free survival curves for long-term 
tumourigenesis were graphed using the Kaplan-Meier method and distributions were compared 
by the log-rank statistic (Mantel-Cox test). Tumour-free survival for the reconstitution assay was 
compared using 2-way analysis-of-variance (ANOVA) with Tukey’s multiple comparison test. 
Flow cytometry experiments were acquired using FACS Diva software (BD Biosciences) and 
compensated, gated and analysed using FlowJo (Tree Star Inc.). Data was analysed on Prism for 
statistically significant differences using the student’s t test, ANOVA, or Chi-square (χ2) 
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analysis. Results from the limiting dilution assay were analysed for tumour-initiating cell (TIC) 
frequency and statistically significant differences using L-Calc software (Stem Cell 
Technologies). P-values were used to denote statistical significance. Levels of significance were 
*p≤0.05, **p≤0.01, and ***p≤0.001.  
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Figure 2.1: Murine breeding strategy for this study. 
CKR = Chemokine receptor.
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Table 2: Antibodies used in this study. 
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Figure 2.3: Procedure of the limiting dilution assay. 
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Figure 2.4: Procedure of the macrophage reconstitution assay. 
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3.1. Introduction 
Despite concerted efforts and significant advances, breast cancer-related mortality is still a 
leading cause of death in women world-wide [1]. Clearly novel therapies are urgently needed. 
The “cancer stem cell” theory specifies that a small subset of cells in a heterogeneous tumour 
(termed “cancer stem cells” (CSCs)) possess stem cell-like properties of self-renewal and 
differentiation. CSCs are suggested to sustain and propagate tumours, and are inherently therapy-
resistant [173, 176].  
CSCs may originate from adult stem cells, but can also arise from more committed lineage 
progenitor cells if they acquire stem cell-like features due to genetic or epigenetic changes [60]. 
Multiple intrinsic and extrinsic factors are reported to have a role in CSC maintenance, 
regulation and support of stem-like characteristics. Most prominent are the Notch [177], 
Hedgehog [178], Wnt [179] and TGFβ [180] signalling systems. Several cytokines and 
chemokines have also been recently suggested as maintaining and promoting the CSC phenotype 
in a number of solid malignancies, including mammary tumours [181]; however, definitive in 
vivo data has been sparse.  
Chemokine receptors and their cognate chemokine ligands have become widely accepted as 
important mediators of cancer growth and progression in many human neoplasms, being 
involved in tissue transformation, invasion, angiogenesis, and resistance to chemotherapy [89]. 
Among these, the chemokine receptor CCR7 has been implicated in metastatic spread of 
multiple malignancies [161]. In breast carcinogenesis, it has been attributed a number of 
potential functions, including promotion of cell motility, migration and adhesion, regulation of 
matrix metalloproteinases leading to basement membrane degradation [182], and cell survival 
through inhibition of anoikis [130]. Data obtained using cell lines has implicated CCR7 in breast 
cancer spread to the lymph nodes [162], and in human breast cancer its role was inferred from 
retrospective studies on archived tumour tissues [124]. High expression levels of CCR7 were 
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also correlated with higher grade and occurrence of secondary tumours, and poor prognosis [125, 
163].  
Whereas all these studies point to a role for CCR7 in malignancy, a direct function for CCR7 in 
cancer has not yet been established. Furthermore, its role in breast cancer in particular is unclear. 
In this study a novel bigenic mouse model was developed combining deletion of CCR7 with the 
polyoma middle-T transgene, which is under control of the mouse mammary tumour virus 
promoter (MMTV-PyMT), to study tumour development in vivo. Using this model it was shown 
that CCR7 deletion has a striking preventative effect on PyMT-driven mammary tumours, 
supporting the notion that CCR7 has a major determining role in breast oncogenesis. Moreover, 
the data reveal that the tumour-promoting effect of CCR7 is mediated through stem-like cells in 
both primary mouse and human breast tumours. These results provide new insights into the role 
of CCR7 in breast cancer stem-like cells and have important implications for the development of 
future therapeutics in breast cancer.  
3.2. Results 
3.2.1. CCR7 deletion arrests mammary tumourigenesis in the PyMT 
transgenic breast cancer mouse model 
The MMTV-PyMT transgenic breast cancer mouse model has been extensively used in recent 
years to study various aspects of mammary neoplasia. Expression of the PyMT protein promotes 
the rapid epithelial transformation of mammary cells, via the corruption of various pathways 
including those of Src, ras, and PI3 kinase. This model also results in spontaneous metastasis 
and has been found to closely mimic the development of human breast cancer [169, 170, 183]. 
Representative images are shown in Figure 3.1, in which α-smooth muscle actin is used to stain 
myoepithelial cells.  
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To directly assess the role of CCR7 in the multistage process of mammary tumourigenesis in 
vivo, bigenic MMTV-PyMT Ccr7-/- knockout mice were generated and the development of 
mammary tumours was traced relative to MMTV-PyMT Ccr7WT mice.  
Deletion of CCR7 significantly delayed PyMT-driven primary mammary tumourigenesis 
(representative pictures Figure 3.2a). Tumour-free survival was significantly extended (Figure 
3.2b) and total tumour burden was markedly reduced in MMTV-PyMT Ccr7-/- mice (Figure 
3.2c) when compared with the Ccr7WT animals. The lungs of MMTV-PyMT Ccr7WT and Ccr7-/- 
females were also examined for metastatic lesions at the time of killing. MMTV-PyMT Ccr7-/- 
mice developed significantly fewer and smaller metastases than MMTV-PyMT Ccr7WT mice 
(Figure 3.3), although the number of metastases varied largely between mice of the same 
genotype.  
As these experiments indicated a role for CCR7 in mammary gland function, normal, pre-
cancerous and cancer-bearing mouse mammary glands were next examined for CCR7 expression 
and signalling. CCR7 was shown to be expressed on all mouse mammary epithelial cells tested, 
regardless of the tumour stage (Figure 3.4, see also Figure 3.1), and the removal of CCR7 did 
not affect the expression levels of its ligands CCL19 and CCL21 within the mouse mammary fat 
pad (Figure 3.5). CCR7 was also found to be functional in PyMT-driven mammary tumours, as 
tumour cells mobilised intracellular calcium, a hallmark of chemokine receptor activity, in 
response to stimulation with CCL21 (Figure 3.6). These data showed that CCR7 was expressed 
and was functional within normal and transformed mammary epithelium.  
Interestingly, despite the large impact of CCR7 on overall mammary tumourigenesis, initial 
PyMT-driven hyperplastic growth in 8 or 11 week-old MMTV-PyMT Ccr7WT and Ccr7-/- mice 
was not affected (Figure 3.7a-b), with similar tissue architecture in glands from both genotypes 
(Figure 3.7c). This indicated that the MMTV-PyMT Ccr7-/- mammary glands underwent the 
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initial oncogenic transformation leading to epithelial proliferation, but further tumourigenic 
transition was largely blocked by CCR7 deletion. 
3.2.2. CCR7 promotes tumourigenesis by amplifying breast cancer stem-like 
cells 
To investigate the underlying mechanisms responsible for the tumourigenic effects seen, the role 
of CCR7 in mammary gland development and on stem-like cells was then examined. It was 
found that in non-PyMT wild-type (Ccr7WT) pubertal mice, the epithelial tree was longer with a 
better developed ductal structure than that in Ccr7-/- mice (Figure 3.8), indicating that ablation of 
CCR7 had a mild inhibitory effect on pubertal growth of the mammary gland epithelium. CCR7 
was robustly expressed in normal mammary epithelium (Figure 3.9), making this receptor also 
potentially relevant to normal mammary development. However, development of mammary 
epithelium in the Ccr7-/- mice caught up with that of the Ccr7WT mice by the age of 8 weeks, and 
at 12 weeks mammary glands from the two genotypes were indistinguishable (Figure 3.10), 
demonstrating that CCR7 deletion mainly delays early mammary gland development.  
Because normal development and breast cancer are believed to be linked by common regulatory 
mechanisms, it was hypothesised that the observed promotion of PyMT-driven tumourigenesis 
and mammary development was due to CCR7 regulating stem/progenitor cell pools in mammary 
epithelium. Thus, the stem-like cell content in mice was assayed using the lineage-negative   
(Lin-) CD24+CD29hi cell surface marker profile [60], which was previously functionally 
characterised in the MMTV-PyMT model [184, 185]. CCR7 was expressed in all cell lineages in 
both the normal and PyMT-expressing mammary glands regardless of CD24 and CD29 status. 
Notably, however, higher levels of CCR7 (>90%) were observed in Lin-CD24+CD29hi normal 
and cancer mouse mammary stem cell-enriched populations (Figure 3.11). Importantly, CCR7 
was also expressed on human CD44+CD24- putative mammary stem cells [64] from both normal 
and breast tumour tissue (Figure 3.12).  
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Further analysis demonstrated a significantly lower content of Lin-CD24+CD29hi cells in non-
PyMT Ccr7-/- mice relative to Ccr7WT (Figure 3.13a). In PyMT-expressing mice at the stage of 
early neoplasia, when no morphological differences were found in MMTV-PyMT Ccr7WT and 
Ccr7-/- glands (Figure 3.7) and the stem/progenitor cell populations may, therefore, best reflect 
the tumour-initiating cell content, the difference in the stem cell-enriched population between 
MMTV-PyMT Ccr7WT and Ccr7-/- mice was even more pronounced with the deletion of CCR7 
leading to a two-fold reduction in stem-like cells (Figure 3.13b).  
Recently Pece et al. have suggested a new and potentially more efficient set of markers, in which 
the Notch ligands delta-like ligand 1 (DLL1) and delta and notch-like epidermal growth factor-
related receptor (DNER) are used in combination with CD49f (Lin-CD49f+DLL1+DNER+) to 
delineate putative stem cells in human mammary tumours [71]. It was found that the stem-like 
cells from both human and mouse mammary glands defined by this profile also expressed high 
levels of CCR7 (Figure 3.14). Moreover, the Lin-CD49f+DLL1+DNER+ cell pools were 
significantly smaller in both normal and PyMT-expressing Ccr7-/- murine mammary glands 
(Figure 3.15) providing further support for the findings described above.  
It is generally accepted that non-adherent passaged mammosphere cultures are enriched in cells 
with stem-like characteristics, and secondary/tertiary mammosphere-forming efficiency (MFE) is 
representative of cells’ potential to exhibit stem cell traits [75, 149, 186]. Stem-like activity, as 
measured by MFE, was then analysed in the mammary epithelium in the presence or absence of 
CCR7. Primary and secondary sphere formation from normal (Figure 3.16a) or PyMT-
expressing (Figure 3.16b) mammary cells was substantially reduced after CCR7 ablation and, 
importantly, stimulation of non-PyMT Ccr7WT and MMTV-PyMT Ccr7WT cells with CCR7 
ligands CCL19 and CCL21 significantly potentiated mammosphere growth (Figure 3.16).  
This CCR7 stimulatory function was seen exclusively on mammosphere growth, as stimulation 
with CCL19 and CCL21 had no detectable effect on the proliferation of bulk mammary tumour 
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cells in adherent culture, a condition that supports a more differentiated phenotype (Figure 
3.17). The addition of CCR7 ligands to sphere cultures derived from MMTV-PyMT Ccr7-/- 
mammary cells also had no effect on MFE (Figure 3.18), demonstrating a CCR7 receptor-
mediated mechanism. The specificity of CCR7 was further shown by testing a panel of ligands 
for other tumour-associated chemokine receptors CCR6 [163], CXCR3 [126] and CXCR5 [187]. 
No effects were observed on MFE (Figure 3.19).  
To extend these findings to human breast cancer, the activity of CCR7 in human primary tumour 
cells from resected breast cancer tissue was examined. The addition of CCL19 and CCL21 
resulted in an increase in primary and secondary MFE of human breast cancer cells by two- to 
three-fold (Figure 3.20), consistent with results obtained in the mouse model.  
To specifically link the deletion of CCR7 to depleted tumour-initiating cells, a limiting dilution 
transplantation approach was used [71] to estimate tumour-initiating cell (TIC) frequency. 
Secondary mammosphere-derived cells from MMTV-PyMT Ccr7WT and Ccr7-/- mice with early 
neoplasia were used in this assay to address the potential of cells in mammosphere cultures to 
exhibit stem cell traits of self-renewal and tumour initiation in vivo, in the context of CCR7-
dependency. Cells were injected into contralateral inguinal fat pads of non-PyMT Ccr7WT 
recipients. Analysis of grafted fat pads after 6 weeks showed that MMTV-PyMT Ccr7WT sphere 
cells produced much more robust growth at all dilutions (Figure 3.21). Most importantly, the 
frequency of stem-like cells capable of tumour initiation within MMTV-PyMT Ccr7WT sphere 
culture (1/189) was over three-fold higher than in MMTV-PyMT Ccr7-/- (1/913) (Table 3), 
providing strong evidence for the critical role of CCR7 in the regulation and maintenance of 
stem-like cells and tumour-initiating cells in the mammary gland. 
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3.2.3. CCR7 is required for the propagation of mammary tumours 
To obtain in vivo evidence for the role of CCR7 in tumour propagation, the PyMT mouse model 
was taken advantage of, as it allows tumour formation upon transplantation [183]. Expression of 
the PyMT oncogene results in multifocal tumours and hence can generate diverse CSC pools 
owing to various underlying mutations within the same gland at the late stages of 
tumourigenesis. Therefore, it was reasoned that if taken at the early stage of pre-neoplastic 
tumour development, the population of CSCs should be more homogeneous. Consequently, 
small 1mm3 fragments of pre-neoplastic mammary tissue from 8-week-old PyMT transgenic 
MMTV-PyMT Ccr7WT and Ccr7-/- mice were simultaneously transplanted into contralateral 
inguinal mammary fat pads of non-PyMT Ccr7WT recipients. Representative histological sections 
from both MMTV-PyMT Ccr7WT and Ccr7-/- 8 week-old mice, corresponding to donor tissue, 
are shown in Figure 3.22, confirming that the glands used for transplantation were at the 
equivalent stage of tumourigenesis.  
Analysis of tumourigenic outgrowth from transplanted tissue showed that the deletion of CCR7 
almost completely blocked secondary tumour development. Only one out of six transplants from 
the MMTV-PyMT Ccr7-/- donors was able to give rise to a neoplastic lesion, whereas five out of 
six fragments from the MMTV-PyMT Ccr7WT donors produced secondary outgrowths in Ccr7WT 
recipients (Figure 3.23), demonstrating a key role of CCR7 in tumour propagation. 
3.2.4. Physical antagonism of CCR7 in vivo depletes the stem-like cell 
population and inhibits mammary tumourigenesis 
A CCR7 antagonist, CCL19(8-83) [188], was then used to explore the potential of targeting CCR7 
for CSC-directed therapeutic intervention. Initially, the ability of CCL19(8-83) to block the 
stimulatory activity of CCR7 ligands on mammosphere-forming capacity was tested ex vivo and 
found to specifically abrogate the effect of CCL21 (Figure 3.24) and CCL19 on mammosphere 
growth, providing a rationale for in vivo studies.  
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The effect of CCR7 blockade by CCL19(8-83) on tumour initiation was then examined in the 
context of the PyMT transgenic mouse model. CCL19(8-83) was injected for 8 consecutive weeks 
into inguinal mammary glands of animals from the age of 4 weeks old. Glands were then excised 
and examined for the extent of tumourigenesis and stem-like cell content and function. 
Macroscopic analysis demonstrated that CCL19(8-83)-injected glands had smaller lesions than 
their control counterparts (representative image Figure 3.25a). The total weight of fat pads was 
not statistically different; however, the cellularity (total cell count and cells per mg of tissue) was 
significantly reduced by the antagonist (Figure 3.25b-d).  
Treatment with CCL19(8-83) also resulted in a significant decrease in the proportion of stem-like 
cells (Lin-CD24+CD29hi and Lin-CD49f+DLL1+DNER+, Figure 3.26a-b) and the function of 
stem and early progenitor cells (Figure 3.26c), without affecting the level of CCR7 receptor 
expression (Figure 3.27). PyMT transgenic mice on both FVB and C57Bl/6 backgrounds were 
tested, with similar results.  
To determine whether treatment with CCL19(8-83) has an inhibitory effect on established and/or 
advanced later stage tumours, 1mm3 size fragments of MMTV-PyMT Ccr7WT tumours from 16 
week-old mice, corresponding to the invasive ductal carcinoma stage of human breast cancer 
(Figure 3.1), were transplanted into inguinal glands of Ccr7WT recipients followed by 8 weekly 
injections of CCL19(8-83) or vehicle control (Figure 3.28a). Although no significant differences 
were seen between CCL19(8-83)- or vehicle-treated tumours in size or cellularity (Figure 3.28b) 
as was observed in primary tumours, the proportions of stem-like cells determined by both 
conventional (Lin-CD24+CD29hi) or novel (Lin-CD49f+DLL1+DNER+) marker sets (Figure 
3.29a-b), as well as mammosphere growth (Figure 3.29c), were significantly reduced in 
antagonist-treated glands, demonstrating that the CCR7 axis can be blocked in vivo to target 
stem-like cells in mammary tumours.  
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3.3. Summary 
The chemokine receptor CCR7 is widely implicated in breast cancer pathobiology. Although 
recent reports correlated high CCR7 levels with more advanced tumour grade and poor 
prognosis, limited in vivo data are available regarding its specific function in mammary gland 
neoplasia and the underlying mechanisms involved.  
To address these questions a bigenic mouse model of breast cancer combined with CCR7 
deletion was generated, which revealed that CCR7 ablation results in a considerable delay in 
tumour onset as well as significantly reduced tumour burden. Importantly, CCR7 was found to 
exert its function by regulating mammary cancer stem-like cells in both murine and human 
tumours. In vivo experiments showed that loss of CCR7 activity either through deletion or 
pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse 
primary mammary tumours, providing a mechanistic explanation for the tumour-promoting role 
of this chemokine receptor.  
In conclusion, these data characterise the oncogenic properties of CCR7 in mammary epithelial 
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Figure 3.1: Tumour progression in the MMTV-PyMT breast cancer mouse model. 
Serial sections of mouse mammary tissue from normal mice and at different tumourigenic stages 
stained with haematoxylin and eosin (H&E) and forα-smooth muscle actin (α-SMA) as 
indicated.   
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Figure 3.2: CCR7 ablation delays tumour onset and reduces tumour burden in the MMTV-
PyMT-driven mouse model of breast cancer. 
(A) Representative images of MMTV-PyMT Ccr7WT and MMTV-PyMT Ccr7-/- mice at 22 
weeks old, showing grossly visible tumours (demarcated by red arrows and dotted lines). (B) 
Kaplan-Meier analysis of tumour-free survival for MMTV-PyMT Ccr7WT (n=18) and MMTV-
PyMT Ccr7-/- (n=17) mice. (C) Number of tumours in MMTV-PyMT Ccr7WT and MMTV-
PyMT Ccr7-/- mice at the time of killing.  
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Figure 3.3: CCR7-null MMTV-PyMT mice develop less lung metastasis. 
(A) Total cumulative area of lung metastatic lesions in MMTV-PyMT Ccr7WT (n=8) and 
MMTV-PyMT Ccr7-/- (n=8) mice. (B) Distribution data of lung metastases in MMTV-PyMT 
Ccr7WT and Ccr7-/- mice. (C) Representative images of H&E-stained lung sections from MMTV-
PyMT Ccr7WT (left) and MMTV-PyMT Ccr7-/- (right) mice with metastatic lesions (black 
arrowheads). Red arrowhead indicates inset magnified image.  
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Figure 3.4: CCR7 is expressed throughout mammary gland development and cancer. 
Mammary cells were gated to exclude debris, dead cells and doublets and proportions of CCR7-
positive cells in mammary epithelial cell preparations were analysed by flow cytometry. Shaded 
histograms=FMO negative controls. wo=weeks old.  
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Figure 3.5: The expression of ligands CCL19 and CCL21 is not affected by CCR7 deletion. 
Expression of CCR7 ligands (CCL21 and CCL19) in Ccr7WT and Ccr7-/- mammary fat pads with 
excised inguinal lymph nodes was assessed by ELISA. n=6 glands per genotype.  
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Figure 3.6: CCR7 is active in MMTV-PyMT tumour cells. 
Calcium mobilisation analysis of MMTV-PyMT Ccr7WT mouse mammary cells in response to 
lysophosphatidic acid (LPA) and the CCR7 ligand, CCL21. Arrowheads indicate a point of 
stimulus addition.  
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Figure 3.7: Ablation of CCR7 has no effect on early mammary hyperplasia in MMTV-PyMT 
mice. 
(A) Representative images of inguinal mammary glands of MMTV-PyMT Ccr7WT (left) and 
MMTV-PyMT Ccr7-/- (right) mice harvested at 8 and 11 weeks of age as indicated. Arrowheads 
indicate areas of epithelial hyperplasia. LN=lymph node. (B) Quantitation of area of hyperplasia 
in MMTV-PyMT Ccr7WT and Ccr7-/- mice at 8 weeks old. n=6 glands per genotype. (C) Serial 
sections of mouse mammary tissue from MMTV-PyMT Ccr7WT and Ccr7-/- mice at 8 weeks old 
stained with H&E and forα-smooth muscle actin (α-SMA) as indicated.   
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Figure 3.8: CCR7 deletion has an inhibitory effect on growth of pubertal mammary glands.  
Development of the mammary ductal tree was evaluated in Ccr7WT and Ccr7-/- C57Bl/6 mice at 6 
weeks of age. (A) Representative whole mount images of mammary glands, with apparent 
reduction in the size of ductal trees in Ccr7-/- mice (n=6) compared with Ccr7WT mice (n=7). 
LN=lymph node. (B-D) Quantitation of the length of main epithelial duct (B), total number of 
mammary epithelial terminal structures (C), and branching within mammary epithelium as 
determined by quantifying branch points per mm along three individual ducts (D).  
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Figure 3.9: CCR7 is robustly expressed in normal mammary epithelium. 
Formalin-fixed paraffin-embedded sections of normal pubertal mouse mammary glands were 
stained for CCR7 expression (magenta). Shown are two individual terminal end buds. Nuclei are 
counterstained with DAPI (grey).   
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Figure 3.10: The effect of CCR7 on normal mammary development is not present in the adult 
mammary gland. 
Representative whole mount images of mammary glands taken from adult Ccr7WT (n=6) and 
Ccr7-/- (n=6) mice at 12 weeks of age with no apparent differences in the size and architecture of 
the mammary tree. LN=lymph node.   
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Figure 3.11: CCR7 expression in mammary cell lineages as defined by CD24 and CD29.  
All cells were pre-gated to exclude debris, dead cells and doublets. Shown is the proportion of 
cells positive for CCR7 in lineage-negative (Lin-) cell populations in normal mouse mammary 
epithelium (A) and PyMT-expressing glands (B), as denoted by CD24 and CD29 surface marker 
expression. Shaded histograms=FMO negative controls. Results are representative of at least 
three independent experiments, n=6-10 mice per experiment.   
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Figure 3.12: CCR7 expression in normal and cancerous human breast cells as defined by 
CD44 and CD24. 
All cells were pre-gated to exclude debris, dead cells and doublets. Shown is the proportion of 
cells positive for CCR7 in different cell populations in normal human mammary epithelium and 
breast cancer as indicated, denoted by surface marker expression of CD44 and CD24. Shaded 
histograms=FMO negative controls. Results are representative of two normal and four 
independent tumour samples.   
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Figure 3.13: CCR7 deletion decreases the mammary stem cell-enriched pool as defined by 
CD24+CD29hi expression. 
Cells from normal mammary glands (A) and PyMT-driven mammary tumours (B) were analysed 
by flow cytometry for stem-like cell content based on the Lin-CD24+CD29hi marker profile. 
Results are representative of at least three independent experiments, n=6-10 mice per group per 
experiment.   
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Figure 3.14: CCR7 expression in the CD49f+DLL1+DNER+ cancer stem cell-enriched 
population. 
Flow cytometry gating strategy for delineating the mouse (A) and human (B) stem cell-enriched 
populations based on alternative CD49f+DLL1+DNER+ surface marker expression, together with 
representative plots demonstrating proportions of CCR7 positive cells within these populations. 
Shaded histograms=FMO negative controls. Results in (A) are representative of at least three 
independent experiments, n=6 MMTV-PyMT mice per experiment. Results in (B) are 
representative of four independent human tumour samples.  
Chapter 3: The Chemokine Receptor CCR7 Promotes Mammary Tumourigenesis Through Amplification 
of Stem-Like Cells 
 
	  





Figure 3.15: CCR7 deletion decreases the mammary stem cell-enriched pool as defined by 
CD49f+DLL1+DNER+. 
Cells from normal mammary glands (A) and PyMT-driven mammary tumours (B) were analysed 
by flow cytometry for stem-like cell content based on the putative marker profile of Lin-
CD49f+DLL1+DNER+. Data are representative of at least three independent experiments, n=6 
mice per genotype per experiment.    
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Figure 3.16: Self-renewal in normal and PyMT-expressing mouse mammary cells is regulated 
by CCR7. 
The effect of CCR7 deletion/activation in primary and passaged secondary mammosphere 
culture was assessed. Shown are mammosphere-forming efficiencies of cells derived from 
normal mouse mammary glands (A) and PyMT-expressing mouse mammary glands (B). Cells 
were stimulated with CCL21 and CCL19 as indicated. Results are representative of at least three 
independent experiments, n=6 mice per genotype per experiment.   
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Figure 3.17: The effect of CCR7 in culture is specific to non-adherent conditions. 
Results of XTT proliferation assay on MMTV-PyMT Ccr7WT (n=3) mouse mammary cells in 
adherent culture with and without addition of CCR7 ligands, showing no effect on proliferation. 
Foetal calf serum (FCS) was used as a positive control.   
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Figure 3.18: The potentiation of mammosphere formation is mediated by CCR7. 
Primary mammosphere cultures derived from MMTV-PyMT Ccr7-/- (n=4) mouse mammary 
cells were stimulated with CCR7 cognate chemokines CCL19 and CCL21. No differences were 
seen in mammosphere-forming efficiency.    
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Figure 3.19: The effect on mammosphere formation by stimulation with various chemokines. 
Primary mammosphere cultures derived from MMTV-PyMT Ccr7WT (n=6) mouse mammary 
cells were stimulated with chemokine ligands for receptors CCR6, CXCR3, CXCR4 and CXCR5 
respectively.   
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Figure 3.20: Self-renewal in human breast cancer cells is regulated by CCR7. 
The effect of CCR7 activation in primary and secondary mammosphere culture was assessed. 
Shown are mammosphere-forming efficiencies of primary cells from human patient-derived 
breast tumours, where cells were stimulated with CCL21 or CCL19. Results are representative of 
four tumour samples.   
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Figure 3.21: The loss of CCR7 reduces the size of secondary lesions upon transplantation, 
regardless of cell concentration. 
(A) Representative image of intact and respective whole-mounted contralateral mammary glands 
engrafted with 2500 MMTV-PyMT Ccr7WT or Ccr7-/- mammosphere-derived cells. Black 
arrowheads indicate areas of outgrowth from engrafted cells. LN=lymph node. (B) 
Representative images of Ccr7WT recipient glands engrafted with MMTV-PyMT Ccr7WT or 
Ccr7-/- sphere-derived cells as indicated. Shown are contralateral glands in which both MMTV-
PyMT Ccr7WT and Ccr7-/- cells produced outgrowths (black arrowheads), to demonstrate 
differences in size between lesions. At the lowest dilution, only MMTV-PyMT Ccr7WT cells 
produced any secondary outgrowth. LN=lymph node.    
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Table 3: The presence of CCR7 in MMTV-PyMT mammosphere cells maintains the frequency 
of tumour-initiating cells. 
Results of limiting dilution assay indicating frequency of tumour-initiating cells (TIC) in 
MMTV-PyMT Ccr7WT and Ccr7-/- mammosphere cultures. Fractions indicate the number of fat 
pads with lesion(s) per total number of recipient fat pads. SE=standard error.  
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Figure 3.22: Representative H&E-stained sections from mice of transplant donor age. 
Representative H&E-stained sections of pre-neoplastic mouse mammary glands at the MMTV-
PyMT Ccr7WT and Ccr7-/- donor age of 8 weeks old. Bottom: magnified images of boxed area.   
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Figure 3.23: CCR7 is required for the propagation of mammary tumours. 
(A) Representative whole-mount images of Ccr7WT recipient glands after transplantation of pre-
neoplastic mammary tissue from MMTV-PyMT Ccr7WT (top) and Ccr7-/- (bottom) donor mice at 
8 weeks of age. Black arrowheads indicate areas of outgrowth from donor tissue. Fractions 
indicate the number of fat pads with lesion(s) per total number of recipient fat pads. LN=lymph 
node. (B) Cumulative area of transplant outgrowth in recipient mammary glands. n=6 glands per 
group.    
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Figure 3.24: Addition of a CCR7 antagonist inhibits CCR7-mediated mammosphere 
formation. 
Mammosphere-forming efficiency of Lin- mammary cells from MMTV-PyMT Ccr7WT mice 
(n=9), untreated or treated with CCL21 and/or the CCR7 antagonist CCL19(8-83).  
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Figure 3.25: Administration of a CCR7 antagonist reduces tumourigenesis in the MMTV-
PyMT mouse model. 
(A) Representative image of intact MMTV-PyMT mammary glands treated with vehicle or 
CCL19(8-83) as indicated, at the time of sacrifice. (B-C) Total mammary epithelial cell count (B) 
and weight of mammary glands (C) in MMTV-PyMT mice following injection with vehicle or 
CCL19(8-83) antagonist for 8 weeks in contralateral inguinal mammary fat pads. (D) Cellularity of 
contralateral vehicle- or CCL19(8-83)-treated glands. Data are representative of two independent 
experiments, n=4-6 mice per experiment.   
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Figure 3.26: Administration of a CCR7 antagonist to PyMT-expressing mammary glands 
decreases the proportions and activity of stem-like cells. 
(A-B) Proportions of putative stem cells as identified by Lin-CD24+CD29hi (A) or Lin-
CD49f+DLL1+DNER+ (B) in mammary cells from vehicle- or CCL19(8-83)-treated MMTV-PyMT 
glands. (C) Mammosphere-forming efficiency of cells from vehicle- or CCL19(8-83)-treated 
mammary glands.    
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Figure 3.27: Blocking CCR7 function in PyMT-expressing mammary glands with a peptide 
antagonist does not affect expression of the receptor. 
CCR7 expression levels in the Lin-CD24+CD29hi population as assessed by flow cytometry, 
following treatment of MMTV-PyMT mammary glands with vehicle control (left) or CCL19(8-83) 
(right). Shaded histograms=FMO negative controls.    
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Figure 3.28: The results of CCR7 antagonism in a mammary tumour transplant model. 
A transplant model was used to examine the effects of treating advanced mammary tumours with 
the CCR7 antagonist CCL19(8-83). (A) Experimental strategy. (B) Cellularity of transplant 
recipient glands, showing no effect following treatment with CCL19(8-83). n=6 recipient glands 
per group.    
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Figure 3.29: Administration of a CCR7 antagonist decreases the mammary stem cell-enriched 
pool and self-renewal in a transplant model. 
(A-B) Proportions of putative stem cells as identified by Lin-CD24+CD29hi (A) or Lin-
CD49f+DLL1+DNER+ (B) in mammary cells from vehicle- or CCL19(8-83)-treated transplant 
recipient glands. (C) Mammosphere-forming efficiency of cells from vehicle- or CCL19(8-83)-
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4.1. Introduction 
Breast cancer is one of the leading causes of cancer-related death in women world-wide. Evasion 
of the immune system is a hallmark of cancer, and aids tumour cells to survive, intravasate, and 
potentially form distal metastases [27]. As such, the tumour microenvironment has a profound 
effect on the development and progression of malignancies, and it has been suggested that levels 
of infiltrating immune cells correlate with stage and aggressiveness of human breast cancer 
[189]. In particular, tumour-associated macrophages (TAMs) have been found to play an 
important part in facilitating breast tumour development [190] through polarisation from a 
classically-activated “M1” anti-tumour resident cell within adult mammary tissue to an 
alternatively-activated “M2” pro-tumour phenotype [112]. This “switch” results in shifts in cell 
metabolism, a decrease in pro-inflammatory chemokine/cytokine production, poor antigen-
presentation ability, and suppression of T cell responses. In addition, M2 TAMs promote 
angiogenesis, cell proliferation and tissue remodelling [113].  
Chemokines and their cognate receptors are involved in the development, migration and 
activation of many different types of immune cells, both adaptive and innate. Low molecular-
weight proteins, chemokines bind to their cognate seven-transmembrane domain G-protein 
coupled receptors (GPCRs), activating a multitude of signalling pathways, which mediate many 
different homeostatic and inflammatory functions. Importantly, a large body of literature in the 
last decade has linked the action of chemokines and chemokine receptors to cancer progression 
and metastasis [89].  
The CC-chemokine receptor CCR6 is expressed on dendritic cells [191, 192], regulatory T cells 
and various T helper lymphocyte subsets [166, 193], and mediates their migration and function 
via stimulation with its ligand CCL20 (also known as macrophage inflammatory protein (MIP)-
3α [164]). CCR6 is also expressed on natural killer cells, B lymphocytes, neutrophils [194] and 
macrophages [193, 195]. Despite the significant role of TAMs in breast cancer, the expression 
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and function of CCR6 within the macrophage population has not been shown within the 
mammary gland.  
Interestingly, together with CCL20, CCR6 expression has been correlated with stage and 
prognosis in a variety of cancers including hepatocellular carcinoma [196, 197], colorectal 
carcinoma [198-200], glioma [201], and non-small cell lung cancer [202], and a function for 
CCR6 in regulation of cancer progression has been putatively demonstrated using cell lines and 
xenograft models [198, 199, 203, 204]. In breast cancer, higher CCR6 expression levels were 
linked with tumour stage and grade [163], and incidence of metastasis to the pleura [124]. 
Stimulation of ex vivo mammary peritumoural cells with CCL20 was found to increase their 
proliferation rate, invasiveness and migration [168]. CCL20 is also up-regulated in human triple 
negative breast cancer cell lines [167]. Moreover, it was recently proposed that the presence of 
CCR6 may act as a prognostic factor for breast cancer patient survival [163]. However, no 
causative or functional link between the CCR6-CCL20 axis and progression of breast cancer has 
been documented to date.  
In this study, a well-characterised transgenic model for breast cancer was utilised, in which the 
polyoma middle-T oncogene is activated under control of the mouse mammary tumour virus 
promoter (MMTV-PyMT) [169]. This transgenic model has been shown to closely mimic the 
stages of human breast disease from initial hyperplasia, through to ductal carcinoma in situ and 
invasive ductal carcinoma [170]. Crossing this transgenic mouse with a CCR6-null mouse to 
generate a bigenic MMTV-PyMT Ccr6-/- animal model has allowed direct assessment of the role 
of CCR6 in mammary tumourigenesis in vivo. The results demonstrated that CCR6 promotes 
breast cancer initiation and progression through maintenance of pro-tumourigenic TAMs within 
tumour-bearing mammary glands, warranting further investigation of CCR6 as a possible 
therapeutic target.  
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4.2. Results 
4.2.1. CCR6 expression increases throughout cancer development and results 
in a higher number of mammary tumours 
To first determine whether CCR6 may play a role in the regulation of mammary neoplasia, 
expression of the receptor was investigated in CD45-negative normal mouse mammary cells, and 
cells from various tumour stages (representative H&E pictures in Figure 4.1). CCR6 was 
expressed on a low proportion of normal mammary cells, but this proportion was greatly 
amplified in accordance with increasingly higher grades of MMTV-PyMT cancer including 
initial hyperplasia, early carcinoma and late carcinoma as indicated (Figure 4.1). This is 
consistent with human breast cancer [163] and other mouse models of cancer [200]. 
Additionally, in both non-PyMT Ccr6WT and MMTV-PyMT Ccr6WT mammary tissues, the 
ligand for CCR6, CCL20, was highly expressed at concentrations over 50ng/mg tissue (Figure 
4.2). These data raised the possibility of a role for CCR6 in breast cancer development.  
To next establish the role of CCR6 deletion on mammary tumourigenesis, the rate and total 
extent of PyMT-driven neoplasia between MMTV-PyMT Ccr6WT and Ccr6-/- mice was 
compared. Tumour onset was significantly delayed in MMTV-PyMT Ccr6-/- mice (Figure 4.3a), 
with some mice not developing palpable tumours until 150 days old (21 weeks) compared to a 
maximum onset age of 130 days old (18 weeks) for MMTV-PyMT Ccr6WT counterparts (Figure 
4.3b).  
In order to assess the impact of CCR6 on the later stages of cancerogenesis, MMTV-PyMT 
Ccr6WT and Ccr6-/- mice were sacrificed at 22-24 weeks of age and the total number of 
mammary tumours per mouse was determined. It was found that MMTV-PyMT Ccr6-/- mice had 
significantly decreased tumour incidence compared to MMTV-PyMT Ccr6WT animals (Figure 
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4.3c). Together, these results implicated CCR6 as being an important player in breast 
oncogenesis.  
4.2.2. CCR6 deletion significantly delays tumour initiation in vivo 
It was then examined as to whether CCR6 influenced early hyperplasia of mammary glands 
during tumour initiation as well as late stage tumourigenesis. Glands from 8 week-old MMTV-
PyMT Ccr6-/- and Ccr6WT mice were extracted and whole-mounted for quantification of 
hyperplastic/early-neoplastic lesion area (representative images from both genotypes shown in 
Figure 4.4a). It was found that the deletion of CCR6 significantly reduced the initial 
hyperplastic outgrowth within the gland (Figure 4.4b), a common indicator of future breast 
cancer development. As the total area of PyMT-driven hyperplastic outgrowth per gland was 
reduced by three-fold in CCR6-null animals, it was concluded that the effect of CCR6 on 
mammary tumourigenesis is manifested very early on in cancer development.  
The difference seen in early tumour initiation between MMTV-PyMT Ccr6WT and Ccr6-/- mice 
can potentially result from a difference in normal mammary development, which may then have 
translated into decreased hyperplasia. Therefore, pubertal mammary glands were extracted from 
non-PyMT 6 week-old Ccr6WT and Ccr6-/- mice. Representative glands are shown in Figure 
4.5a. When ductal epithelial growth was quantitated, no statistically significant difference was 
observed in ductal length, number of terminal end structures or branching between Ccr6WT and 
Ccr6-/- mice (Figure 4.5b-d), and hence the overall effect of CCR6 deletion on normal mammary 
gland biology appeared to be minimal and was unlikely to account for differences in PyMT-
driven tumour development between the two genotypes. Furthermore, the levels of CCL20 were 
not statistically different between non-PyMT Ccr6WT and MMTV-PyMT Ccr6WT mammary 
tissues (Figure 4.2), demonstrating that the expression of CCL20 was not affected by the process 
of tumourigenesis. Taken together, these data showed that early stage tumourigenesis is 
mediated by a CCR6-dependent mechanism, without affecting normal mammary morphogenesis.  
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4.2.3. CCR6 promotes mammary gland neoplasia independently of cancer 
epithelial cells or stem-like cells 
To investigate the mechanism underlying CCR6-driven mammary tumourigenesis, the epithelial 
cell population was studied to determine if CCR6 was having a direct effect on cell proliferation. 
Cells at the stage of early neoplasia from MMTV-PyMT Ccr6WT mammary glands were assayed 
for proliferation upon stimulation with CCL20. No differences in cell proliferation were 
observed (Figure 4.6). Furthermore, Ki67 staining of sectioned hyperplastic mammary glands 
from MMTV-PyMT Ccr6WT and Ccr6-/- mice showed that epithelial cells in knockout mice were 
still able to adequately proliferate and staining of Ki67 was equal to that in the Ccr6WT (Figure 
4.7). This suggested that the role of CCR6 in breast cancer is independent of epithelial cells.  
It was then determined whether CCR6 may exert its effect by skewing distinct cell populations 
within the bulk epithelium, as reported previously for the chemokine receptor CCR7 [171]. The 
current prevailing paradigm has mammary epithelial and breast cancer cells hierarchically 
organised with a self-renewing, quiescent, multipotent progenitor (or stem-like cell) population 
giving rise to basal and luminal progenitors which in turn differentiate into specific lineages 
making up the mammary gland and heterogenous breast tumours [205]. Recently, a number of 
immune mediators including chemokine receptors have been implicated in maintenance of the 
cancer stem-like cells within mammary tumours [115]. Therefore, the potential link between the 
tumour-promoting function of CCR6 and breast cancer stem-like cell pools was tested.  
Freshly isolated MMTV-PyMT Ccr6WT and Ccr6-/- mammary cells from pre-neoplastic mice at 
8-9 weeks old were assayed by flow cytometry for expression of cell surface markers CD24 and 
CD29 [60] (representative plots shown in Figure 4.8a), which were previously used to define 
stem cells in the MMTV-PyMT [184, 185] and other breast cancer mouse models [65, 206]. It 
was found that the deletion of CCR6 did not alter the proportions of the stem cell-enriched basal 
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population (CD24+CD29hi, Figure 4.8b) nor the luminal population (CD24+CD29lo, Figure 4.8c) 
in hyperplastic mammary glands.  
The effect of CCR6 ablation on functional stem-like mammary cancer cell pools was also 
investigated using the mammosphere assay, which is used to select for colonies of early stem-
like progenitors [75]. Pre-neoplastic MMTV-PyMT Ccr6WT and Ccr6-/- mammary cells were 
seeded into non-adherent mammosphere culture and allowed to grow for 7 days. The deletion of 
CCR6 did not alter mammosphere-forming efficiency (Figure 4.9a), and when sphere cultures 
were stimulated with varying concentrations of CCL20, no change in their ability to form 
mammospheres (Figure 4.9b) was observed, supporting results obtained using flow cytometric 
analysis.  
Having found no difference in the proportion or function of stem cell-like pools within early 
tumourigenic lesions, a bona fide property of cancer stem cells was then tested – their ability to 
propagate tumours upon transplantation. MMTV-PyMT Ccr6WT and Ccr6-/- donor mammary 
tissue was transferred into recipient fat pads of syngeneic non-PyMT Ccr6WT mice. Using this 
approach, no significant difference was found between MMTV-PyMT Ccr6WT and Ccr6-/- tissue 
in the ability to form outgrowths when transplanted into Ccr6WT recipients (Figure 4.10), 
indicating that the deletion of CCR6 did not reduce the tumour-propagating capability of 
mammary epithelium.  
Altogether, these results demonstrated that the role of CCR6 in breast cancer is independent of 
breast epithelial and progenitor cells, raising the possibility that its mechanism of action involves 
the tumour microenvironment.  
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4.2.4. CCR6 mediates the recruitment of pro-tumourigenic macrophages to 
the mammary tumour microenvironment 
To test whether the reduced mammary tumourigenesis caused by the deletion of CCR6 was due 
to an effect of the CCR6-CCL20 axis on the tumour microenvironment, flow cytometry was used 
to investigate the levels and identity of tumour-infiltrating leukocytes in mammary tumours at 
the stage of early carcinoma (see Figure 4.1). Tumour-associated macrophages have been 
extensively implicated in tumour promotion both in the mammary gland and elsewhere, due to 
their role in angiogenesis, cell proliferation and tissue remodelling [113]. To initially examine 
the polarisation of TAMs in the MMTV-PyMT mice, macrophages were assessed for expression 
of prototypic markers interleukin-4 receptor (IL-4R) and mannose receptor (CD206) (gating 
strategy shown in Figure 4.11), which have been used previously in flow cytometric analysis to 
distinguish alternatively-activated M2 macrophages from classically-activated M1 [107, 207-
210]. It was estimated using these markers that a high proportion of TAMs were of an M2-like 
phenotype (Figure 4.11), as has been suggested previously for MMTV-PyMT mammary 
tumours [211]. Interestingly, CCR6 was found to be highly expressed within the TAM 
population as it was detected on greater than 60% of total macrophages (Figure 4.12a). Most 
importantly, CCR6 was expressed at higher levels and on a significantly higher proportion of 
putative M2 macrophages (up to 90%) than M1 (Figure 4.12a-b), using both IL-4R and CD206 
to delineate the populations. This strong correlation potentially implicates CCR6 in the 
regulation of pro-tumourigenic macrophages within the mammary gland microenvironment.  
The levels of macrophages were then assessed in mammary tumours from MMTV-PyMT 
Ccr6WT and Ccr6-/- mice, and it was found that the proportion and overall numbers of TAMs 
were significantly reduced in MMTV-PyMT Ccr6-/- mammary tumours relative to Ccr6WT 
(Figure 4.13). Furthermore, the deletion of CCR6 resulted in a shift towards an M1 macrophage 
phenotype, defined by both IL-4R and CD206 prototypic markers (Figure 4.14).  
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The deletion of CCR6 also resulted in reduced trafficking of dendritic cells to the tumour site, 
consistent with previous studies, which demonstrated a reduced overall migratory ability of 
dendritic cells in CCR6-null mice [165, 212]. Although, overall numbers of tumour-infiltrating 
dendritic cells were much lower than the corresponding macrophage population. Notably, the 
majority of tumour-infiltrating dendritic cells were CCR6-positive, consistent with previous 
findings [194] (Figure 4.15). CCR6 expression was also assessed on B cells and specific T cell 
subsets (helper T cells (Th), cytotoxic T cells (Tc), and regulatory T cells (Treg)) within 
mammary tumours. In agreement with earlier reports for various biological settings [194, 213], 
all tested infiltrating leukocyte subsets expressed CCR6 at varying levels. When CCR6 was 
ablated, only the Tc cell subset showed a slight increase in the MMTV-PyMT Ccr6-/- as a 
proportion of CD45+ tumour-infiltrating cells, however no significant differences were found in 
total cell numbers between the two genotypes (Figures 4.16-4.20).  
These findings thus suggest that CCR6 promotes mammary tumourigenesis through an 
epithelium-independent mechanism involving tumour-infiltrating macrophages.   
4.2.5. CCR6-mediated pro-tumourigenic macrophages promote breast 
cancer in vivo  
To provide definitive evidence for the macrophage-mediating function of CCR6 in mammary 
tumour promotion, an in vivo macrophage reconstitution assay was used. Reconstitution assays, 
sometimes referred to as “add-back” assays, are frequently used to underscore a role for various 
cellular subsets in multiple pathological settings, and macrophage reconstitution has been used 
previously in mammary gland studies [214]. A schematic of the experimental setup is shown in 
Figure 4.21a. MMTV-PyMT mammary tumour cells from Ccr6WT donor mice were purified and 
transplanted into the inguinal mammary fat pads of non-PyMT Ccr6WT and Ccr6-/- recipients at 5 
weeks of age. Two days post-transplantation, TAMs (CD45+F4/80+) were sorted from excised 
and dissociated MMTV-PyMT Ccr6WT tumours (Figure 4.21b) and orthotopically injected into a 
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group of Ccr6-/- recipients as specified in Figure 4.21a. All other recipients received sham 
injections with vehicle only, followed by assessment of mammary tumour growth 6 weeks later.  
In agreement with the results from spontaneous tumourigenesis studies, it was found that 
tumours grew significantly slower in the Ccr6-/- hosts compared to Ccr6WT, indicating that CCR6 
was required in the mammary stroma for robust tumour development. However, when the 
reduced macrophage phenotype was restored in Ccr6-/- mice through orthotopical injections, the 
tumour latency was significantly shortened, approaching that of the Ccr6WT mice (Figure 4.22).  
It was further found that the supplementation of Ccr6-/- mice with TAMs restored the efficiency 
of tumour growth (measured by weight of tumour-bearing mammary glands) within these mice 
to that seen in the Ccr6WT, whilst Ccr6-/- mice that received sham injections displayed reduced 
tumourigenesis (Figure 4.23) as seen in the spontaneous model (see Figure 4.3).  
Enumeration of macrophages within grafted tumours in Ccr6WT and Ccr6-/- mice (Figure 4.24) 
paralleled the results seen in spontaneous mammary tumours (see Figure 4.13). Whilst there was 
an upward trend towards increased TAMs in the Ccr6-/- mice that received TAM injections, the 
difference was not statistically significant (Figure 4.24). This, combined with the decreased 
tumour growth in the CCR6-null mice, indicated that the support of macrophages is essential at 
the early stages of tumour growth.  
Thus, these data established an essential role for CCR6 in the tumour microenvironment, 
providing a causative link between this receptor, infiltrating macrophages and mammary tumour 
development. Hence, therapeutic opportunities may be explored to control breast cancer 
progression, via manipulation of the CCR6-CCL20 axis to control tumour-promoting 
macrophages.  
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4.3. Summary 
The expression of the chemokine receptor CCR6 has been previously correlated with higher 
grades and stages of breast cancer and decreased relapse-free survival. Also, its cognate 
chemokine ligand CCL20 has been reported to induce proliferation of cultured breast epithelial 
cells. This study investigated whether CCR6 plays a functional role in mammary tumourigenesis, 
using a bigenic MMTV-PyMT CCR6-null mouse to assess mammary tumour development. 
Levels of tumour-infiltrating immune cells within tumour-bearing mammary glands from 
MMTV-PyMT Ccr6WT and Ccr6-/- mice were also analysed.  
Deletion of CCR6 delayed tumour onset, significantly reduced the extent of initial hyperplastic 
outgrowth, and decreased tumour incidence in PyMT transgenic mice. CCR6 was then shown to 
promote the recruitment of pro-tumourigenic macrophages to the tumour site, facilitating the 
onset of neoplasia. In conclusion, this study delineated for the first time a role for CCR6 in the 
development of breast cancer, and demonstrated a critical function for this receptor in 
maintaining the pro-tumourigenic cancer microenvironment.  
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Figure 4.1: CCR6 expression increases throughout progression of mammary cancer.  
Top: Representative H&E images of mammary tissue from normal gland and various stages of 
PyMT-driven tumourigenesis as indicated. Scale bar is 200µm. Bottom: Proportion of CCR6-
positive epithelial cells (CD45-negative) purified from mammary glands at respective stages of 
tumourigenesis. 18 normal samples (2 glands/sample), 7 hyperplastic samples (2 glands/sample), 
6 early carcinomas and 3 late carcinomas were analysed.	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Figure 4.2: The ligand for CCR6, CCL20, is expressed in both normal and cancerous 
mammary glands.  
Expression of CCL20, the ligand for CCR6, in normal and early neoplastic MMTV-PyMT 
Ccr6WT mammary glands, as determined by ELISA. n=4 samples per genotype.	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Figure 4.3: CCR6 deletion reduces mammary tumourigenesis.  
(A) Kaplan-Meier analysis of the palpable tumour onset in MMTV-PyMT Ccr6-/- mice (n=14) 
compared to MMTV-PyMT Ccr6WT mice (n=11). (B) Age of tumour onset in MMTV-PyMT 
Ccr6-/- mice and MMTV-PyMT Ccr6WT mice. (C) Mammary tumour incidence at the time of 
sacrifice in MMTV-PyMT Ccr6WT (n=9) and Ccr6-/- (n=14) mice.	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Figure 4.4: CCR6 deletion significantly delays tumour initiation in vivo.  
(A) Representative whole-mount images of MMTV-PyMT Ccr6WT (n=6) and Ccr6-/- (n=6) 
mammary glands from mice at 8 weeks of age. LN=lymph node. Black arrowheads indicate 
hyperplastic lesions within the gland. (B) Quantitation of area of pre-neoplastic lesions in 8 
week-old MMTV-PyMT mouse mammary glands.  
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Figure 4.5: The role of CCR6 in normal mammary development.  
(A) Representative whole-mount images of Ccr6WT (n=6) and Ccr6-/- (n=6) mammary glands 
from mice at 6 weeks of age showing development of mammary epithelium. LN=lymph node. 
(B-D) Quantitation of epithelial growth, by length of main duct (B), number of end structures 
(C) and branching (D).  
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Figure 4.6: Stimulation of CCR6 does not affect proliferation of epithelial tumour cells.  
Results of XTT proliferation assay on mammary epithelial cells purified from MMTV-PyMT 
Ccr6WT mice at the stage of early neoplasia with and without stimulation by ligand CCL20 
(100ng/ml). Foetal calf serum (FCS, 0.5%) and epidermal growth factor (EGF, 20ng/ml) were 
used as positive controls. All statistical analyses are relative to Unstimulated. Data are 
representative of 3 independent experiments, n=3 mice per experiment.    
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Figure 4.7: CCR6 deletion does not affect proliferation in the mammary gland as assessed by 
Ki67 staining.  
Analysis of Ki67-positive proliferating cells within MMTV-PyMT Ccr6WT and Ccr6-/- mice at 
the stage of early neoplasia. Shown are representative fields from 2 separate tumours per 
genotype, displaying equal distribution of cells positive for Ki67.  
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Figure 4.8: CCR6 deletion does not impact upon the mammary cell hierarchy.  
Single cell suspensions (CD45-negative) from mammary glands with early neoplasia from 
MMTV-PyMT Ccr6WT and Ccr6-/- mice were analysed by flow cytometry for the expression of 
CD24 and CD29. (A) Representative flow cytometry contour plots of gating strategy for CD24 
and CD29 for both genotypes. (B-C) Analysis of proportions of the basal cell (B) and luminal 
cell (C) lineages. Data are representative of 3 independent experiments, n=6 mice per genotype 
per experiment.   
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Figure 4.9: The CCR6 receptor does not influence self-renewal of cancer stem-like cells.  
(A) Mammosphere-forming efficiency of cells isolated from MMTV-PyMT Ccr6WT and Ccr6-/- 
mammary glands. Data are representative of 3 independent experiments, n=6 mice per genotype 
per experiment. (B) Mammosphere-forming efficiency of MMTV-PyMT Ccr6WT cells stimulated 
with varying concentrations of CCL20. Data are representative of 3 independent experiments, 
n=3 individual mice per experiment.   
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Figure 4.10: CCR6 in donor epithelium does not promote mammary tumour propagation.  
Representative whole-mount images and quantification of the neoplastic outgrowth area in 
Ccr6WT recipient glands of MMTV-PyMT Ccr6WT and MMTV-PyMT Ccr6-/- mammary tumour 
tissue transplants, n=4 recipient mice per group. LN=lymph node. Black arrowheads indicate 
donor transplant outgrowth within the glands.  
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Figure 4.11: Analysis of tumour-associated macrophage phenotype in MMTV-PyMT 
mammary tumours.  
MMTV-PyMT Ccr6WT mammary tumour cells were analysed by flow cytometry for tumour-
associated macrophage (TAM) phenotype. Analysis of M1 and M2 macrophages within the total 
macrophage population (CD45+CD11c-CD11b+F4/80+) was based on IL-4R expression and 
CD206 expression as indicated, where M1 macrophages were classed as IL-4R or CD206-
negative and M2 were IL-4R or CD206-positive. Dotted lines=FMO negative controls. M1 and 
M2 cell proportions (bottom) are presented as percentage of the total macrophage population. 
Representative results from 3 independent experiments. 
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Figure 4.12: CCR6 expression in macrophage populations in MMTV-PyMT tumours.  
(A) Representative flow cytometry plots of CCR6 expression within the total, M1 and M2 
macrophage populations as based on IL-4R and CD206. All cells were gated for CD45+CD11c-
CD11b+F4/80+ as in Figure 4.11. (B) Comparison of proportions of CCR6-positive cells and 
levels of CCR6 within putative M1 and M2 macrophage populations, based on IL-4R (left) and 
CD206 (right) expression. MFI=mean fluorescence intensity. Data are representative of 3 
independent experiments. 
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Figure 4.13: CCR6 deletion reduces the numbers and proportions of tumour-associated 
macrophages in mouse mammary cancer.  
Numbers and proportions of tumour-associated macrophages in mammary tumours from 
MMTV-PyMT Ccr6WT and Ccr6-/- mice as determined by flow cytometry. All cells were gated 
for CD45+CD11c-CD11b+F4/80+ as in Figure 4.11. Data are representative of 3 independent 
experiments, n=5-7 mice per genotype per experiment. 
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Figure 4.14: CCR6 mediates the recruitment of pro-tumourigenic macrophages to the 
mammary tumour microenvironment.  
Proportions of putative M1 and M2 macrophage subtypes within the TAM population in 
mammary tumours from MMTV-PyMT Ccr6-/- mice relative to Ccr6WT as determined by flow 
cytometry. All cells were gated for CD45+CD11c-CD11b+F4/80+ (as in Figure 4.11), and M1/M2 
status determined based on IL-4R (left) and CD206 (right). Dotted lines=FMO negative controls. 
Data are representative of 4 independent experiments, n=3 mice per genotype per experiment.  
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Figure 4.15: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating dendritic 
cells.  
MMTV-PyMT Ccr6WT dendritic cells (CD45+CD11b+MHCII+CD11c+) were assessed for CCR6 
expression (right), and numbers and proportions of dendritic cells compared between MMTV-
PyMT Ccr6WT and Ccr6-/- (bottom). Dotted line=FMO negative control. n=5-7 mice per 
genotype. 
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Figure 4.16: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating B cells.  
MMTV-PyMT Ccr6WT B cells (CD45+CD11c-CD11b-F4/80-Gr-1-MHCII+B220+) were assessed 
for CCR6 expression (right), and numbers and proportions of B cells compared between 
MMTV-PyMT Ccr6WT and Ccr6-/- (bottom). Dotted line=FMO negative control. n=5-7 mice per 
genotype. 
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Figure 4.17: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating T cells.  
MMTV-PyMT Ccr6WT T cells (CD45+CD3+) were assessed for CCR6 expression (middle), and 
numbers and proportions of T cells compared between MMTV-PyMT Ccr6WT and Ccr6-/- (right). 
Dotted lines=FMO negative controls. n=5-7 mice per genotype. 
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Figure 4.18: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating helper T 
cells.  
MMTV-PyMT Ccr6WT Th cells (CD45+CD3+CD8-FoxP3-CD4+) were assessed for CCR6 
expression (right), and numbers and proportions of Th cells compared between MMTV-PyMT 
Ccr6WT and Ccr6-/- (bottom). Dotted lines=FMO negative controls. n=5-7 mice per genotype. 
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Figure 4.19: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating cytotoxic T 
cells.  
MMTV-PyMT Ccr6WT Tc cells (CD45+CD3+CD4-CD8+) were assessed for CCR6 expression 
(right), and numbers and proportions of Tc cells compared between MMTV-PyMT Ccr6WT and 
Ccr6-/- (bottom). Dotted line=FMO negative control. n=5-7 mice per genotype. 
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Figure 4.20: CCR6 expression and effect of CCR6 deletion on tumour-infiltrating regulatory 
T cells.  
MMTV-PyMT Ccr6WT Treg cells (CD45+CD3+CD4+FoxP3+) were assessed for CCR6 
expression (right), and numbers and proportions of Treg cells compared between MMTV-PyMT 
Ccr6WT and Ccr6-/- (bottom). Dotted line=FMO negative control. n=5-7 mice per genotype. 
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Figure 4.21: Experimental setup of the macrophage reconstitution assay.  
(A) Schematic of macrophage reconstitution assay to determine contribution of macrophages to 
mammary tumourigenesis in the context of CCR6 deletion. TAM=tumour-associated 
macrophage. (B) FACS plot showing the sorted macrophage population used for reconstitution. 
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Figure 4.22: CCR6-mediated pro-tumourigenic macrophages promote mammary cancer 
progression.  
Tumour-free survival curves over the course of the macrophage reconstitution assay. 
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Figure 4.23: CCR6-mediated pro-tumourigenic macrophages promote mammary cancer 
growth.  
Tumour weight of control tumours generated in Ccr6WT recipients and in Ccr6-/- recipients ± 
tumour-associated macrophages at the time of sacrifice. n=6-8 tumours per group.   
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Figure 4.24: Assessment of tumour-associated macrophages in macrophage reconstitution 
recipients.  
Macrophage numbers in experimental groups at end-point, as assessed by flow cytometry. All 
cells were gated for CD45+CD11c-CD11b+F4/80+ as in Figure 4.11 n=3-4 samples per group.    
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5.1. Introduction 
This project investigated the roles played by the chemokine receptors CCR6 and CCR7 in the 
progression of mammary tumourigenesis, using novel bigenic mouse models that combine 
expression of the PyMT oncogene under the control of the MMTV promoter, with chemokine 
receptor deletion. It was evident that deletion of either receptor resulted in a decrease in 
mammary neoplastic development, as shown by an extended tumour latency and a decrease in 
tumour incidence. However, further studies demonstrated that CCR7 and CCR6 have distinct 
roles in mammary gland neoplasia.  
Loss of CCR7 does not decrease initial hyper-proliferative activity within the mammary gland, 
however tumour growth is significantly inhibited from this point onwards. CCR6 deletion, 
adversely, results in a very early stage decrease in mammary hyperplasia, and so the effects of 
CCR6 are present before tumourigenesis has progressed to advanced stages. One possible 
explanation for this is that CCR7 may play a more prominent role in mammary homeostasis at 
early stages of cancer development rather than as an oncogenic driver. Indeed, when normal 
mammary glands were examined, the deletion of CCR7 significantly slowed pubertal ductal 
growth within the epithelial tree and reduced the normal adult mammary stem cell pool. CCR6 
has no such effect on the normal mammary gland. Potentially, as normal stem cells transition 
into “cancer” stem cells, driving tumourigenesis, the oncogenic properties of CCR7 become 
more significant, promoting tumour development from the stage of early neoplasia onwards.  
The CCR6 receptor in the transformed mammary gland has a different function to that of CCR7. 
Despite being expressed on cancer cells, it has no significant role in cell proliferation, or 
maintenance of the mammary cellular hierarchy. Instead, its primary function appears to be to 
recruit tumour-promoting macrophages to the microenvironment, as the loss of CCR6 
specifically depletes the levels of alternatively-activated M2 macrophages. 
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As both CCR7 and CCR6 have been found to have important and distinct roles in mammary 
tumour progression, they are worth exploring both individually and in combination to potentially 
develop targeted therapeutics to treat breast cancer in its early stages. 
5.2. The role of CCR7 in breast cancer progression 
The contribution of CSCs to tumour initiation is a major issue in tumour biology, yet one of the 
least understood processes [176]. In this study, it was shown that ablating CCR7 in mammary 
cancer using a bigenic MMTV-PyMT Ccr7-/- mouse model significantly depleted the breast 
CSC-enriched pool. Using the surface marker profiles CD24+CD29hi [60] and 
CD49f+DLL1+DNER+ [71] it was shown that the underlying mechanism involves a decrease in 
the ability of stem-like cells and early progenitor cells to self-renew and initiate neoplasia. 
Significantly, exogenously targeting CCR7 with a peptide antagonist led to a decrease in 
tumourigenesis.  
CCR7 has been extensively studied for its role in adaptive immunity and secondary lymphoid 
organogenesis, and CCR7-null mice display disrupted architecture of the thymus and lymph 
node, as well as a reduced ability to mount a primary immune response [215]. The role of CCR7 
in mediating anti-tumour immunity is also slowly emerging [216]. In this context, the fact that 
abrogation of CCR7 severely affected mammary tumourigenesis provides definitive evidence of 
CCR7 as a pro-tumourigenic driver. Furthermore, numerous transplantation approaches used in 
this study underscore an immune system-independent role of this chemokine receptor in 
maintaining stem-like cell pools in breast cancer.  
Interestingly, hyperplastic outgrowth, widely believed to be a precursor of mammary tumours 
[183], was found in 100% of MMTV-PyMT Ccr7WT and Ccr7-/- glands examined. However, the 
majority of MMTV-PyMT Ccr7-/- glands were unable to sustain this initial proliferative burst of 
tumour cells and progress to the next stage in tumour development. Therefore, the delay in 
mammary tumourigenesis appears to be due to CCR7 maintaining specialised hierarchical sub-
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populations of cancer stem and progenitor-like cells that are thought to be crucial for tumour 
initiation and advanced tumourigenesis [173].  
The fact that both CCL19 and CCL21 stimulated mammosphere growth from both human and 
mouse tumour cells strongly suggests that CCR7 plays a global role in sustaining properties of 
stemness in mammary epithelium. The specificity of CCR7 in this process was validated by 
testing a panel of chemokine receptor ligands, where only CCL19 and CCL21 showed an ability 
to significantly increase MFE.  
Stimulation of CXCR4, the chemokine receptor that is consistently found to be up-regulated 
together with CCR7 in a number of cancers [125], did potentiate sphere formation but to a lesser 
extent (Figure 3.19). Recently, Clarke and colleagues demonstrated that stimulation of CXCR4 
also increased MFE preferentially in malignant breast cancer cell lines compared to normal 
breast cell lines [149]. It is interesting to speculate that as CCR7 is less important for 
homeostasis than CXCR4, as has been inferred from animal models [217], CCR7 may represent 
a more attractive target for future CSC-targeting therapies.  
As stimulation of CCR7 had no effect on proliferation of the bulk population of cells when 
seeded into adherent culture, compared to a highly significant effect in non-adherent culture, it is 
likely that CCR7 predominantly mediates specific cellular properties of stemness. Moreover, it 
was previously reported by the McColl group that CCR7 activation on breast cancer cells 
inhibits anoikis [130], a characteristic of breast and other CSCs [75, 218]. Therefore, it is 
plausible that CCR7 supports CSC survival without attachment to the extracellular matrix, a 
hypothesis that may form the basis for future studies.  
CCR7 appeared to play a quantitative rather than a qualitative role in normal mammary stem 
cells compared with CSCs. When CCR7 was deleted, a mild effect was observed on the normal 
mammary gland. In contrast, a major effect was seen in mammary tumourigenesis. Interestingly, 
whereas the morphological effect on normal mammary gland development was not extensive, 
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CCR7 deletion discreetly affected normal mammary gland stem-like cells. Therefore, it is 
possible that CCR7 has a role in regulating the properties of stemness within the mammary 
epithelial cell population, an effect that appears more prominent during cancer progression. As 
highlighted in a recent study by Cheresh and colleagues [219], dysregulation of normal stem 
cells may contribute to breast cancer progression and stemness, and CCR7 may emerge as a 
novel mediator of this transition.  
Translation of these findings from the mouse model to human disease is of particular 
significance, considering that there is currently no clear consensus on the markers that define 
functional mammary stem cells in both mice and humans. Thus these results show that CCR7 not 
only has a role in mouse mammary tissue but is also expressed, is functional and is highly 
responsive in the stem-like populations within human breast cancer tissue. Intriguingly, 
circulating tumour cells, an indicator of metastatic spread and poor outcome in breast and other 
cancers, have been recently equated to CSCs [40]. In the last decade numerous studies also 
suggested a role for CCR7 in malignant dissemination of mammary tumours to distant sites [124, 
125, 130]. Taken together, these results suggest a novel causative link between CCR7 activity on 
stem-like populations and metastatic breast cancer.  
To seek proof-of-principle on the utility of pharmacologically targeting CCR7, the receptor 
antagonist CCL19(8-83) [188] was tested. It was found that pharmacological inhibition of CCR7 
through direct mammary fat pad injection of CCL19(8-83) afforded a significant reduction in early 
stage primary mammary tumourigenesis. As the relative contribution of the malignant lesions to 
the weight of the whole mammary fat pad was very small at this early stage the reduction in total 
weight between antagonist and vehicle-treated glands was not statistically significant. However, 
the cellularity, a characteristic that directly reflects the extent of epithelial malignant outgrowth 
and is used in clinical pathology to evaluate the response to chemotherapy in breast cancer, was 
strongly impacted by treatment with the CCR7 antagonist.  
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More importantly, directly targeting CCR7 using the antagonist significantly depleted the stem-
like cell pools in both early and late-stage mammary neoplasia as was shown using the 
transplantation approach. These findings strongly suggest that the CCR7 receptor axis is a 
potential point of intervention in stem cell-targeting therapies. Furthermore, the results of this 
study provide a rationale for the use of antagonists of the CCR7 pathway as adjuvants to 
conventional cytotoxic drugs unable to eliminate quiescent CSCs [173].  
Thus, the characterisation of CCR7 in primary breast tumourigenesis in vitro and in vivo, and in 
mouse and human tissue, strongly suggests a role for this molecule in breast cancer development 
and progression. These insights raise the possibility of pharmacologically targeting CCR7 for the 
development of new therapies in breast cancer.  
5.3. The role of CCR6 in breast cancer progression 
The results of this study show that the deletion of the chemokine receptor CCR6 caused a delay 
in tumour onset and decreased mammary tumour incidence in vivo in the MMTV-PyMT 
transgenic mouse model. It was determined that the underlying basis of the CCR6 oncogenic 
function is the increase in numbers of infiltrating pro-tumourigenic macrophages.  
Multiple functional roles have been suggested for members of the chemokine family and their 
receptors in breast cancer pathophysiology [89], however little data using animal models is 
available to support these observations. The expression of CCR6 has been reported to correlate 
with higher stage and grade of human breast cancer, and has been proposed as a prognostic tool 
for determining relapse-free survival in breast cancer patients [163]. However, a causative link in 
vivo has yet to be demonstrated. The well-characterised MMTV-PyMT transgenic mouse model 
of breast cancer was employed in this study, and it was found that CCR6 facilitates an earlier 
tumour onset and an increased incidence of mammary tumours. Of note, CCR6 affects mammary 
tumourigenesis from as early as the hyperplastic, or hyper-proliferative, stage. This initial phase 
of tumour development remains largely uncharacterised, despite being the most treatment-
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effective stage of cancer progression. Therefore, a better understanding of tumour initiation is 
crucial in order to develop therapies that target the tumourigenic process at the early stages of 
breast cancer.  
When CCR6 was deleted in the MMTV-PyMT mouse, tumour latency was significantly 
extended, and these mice developed fewer mammary tumours than their Ccr6WT counterparts. 
However, CCR6 deletion did not affect tumourigenic properties of the epithelium as was found 
with the chemokine receptor CCR7 [171]. Stimulation with CCL20 did not result in an increased 
proliferation rate of purified mammary epithelial cells from hyperplastic glands or tumourous 
lesions in contrast to previous studies with primary human breast peritumoural cells [168]. 
Furthermore, the deletion of CCR6 did not lead to decreased numbers of Ki67-positive 
proliferating cells within intact tumour-bearing mammary glands, pointing to an epithelial-
independent function of this receptor in breast cancer.  
It was also observed that the loss of CCR6 did not alter the numbers and functional properties of 
mammary cancer stem-like cells. Transplantation experiments in particular demonstrated that the 
presence of CCR6 in donor epithelium was not required for tumour propagation in recipient 
mammary glands.  
Further investigation demonstrated that CCR6 functions via organisation of the immune system 
during the early stage of mammary carcinogenesis. It was shown that the levels of tumour-
associated macrophages (TAMs) are reduced by almost three-fold when CCR6 is deleted. 
TAMs, which have been previously identified in MMTV-PyMT tumours [220], are widely 
reported to support the development of cancer [190, 221] and in the tumour microenvironment 
they are generally thought to polarise towards an alternatively-activated M2 pro-tumour 
phenotype relative to the classic M1 anti-tumour phenotype [112]. Whilst the TAMs in MMTV-
PyMT tumours are polarised towards an M2-like subtype, these results show that the presence of 
CCR6 maintains M2 TAMs as the predominant phenotype. Therefore, it is plausible to suggest 
Chapter 5: Discussion 
 
	  
	   	   	   	   	    
137	  
that CCR6 in breast cancer functions to recruit pro-tumourigenic macrophages to the tumour 
immuniche [115], to support growth of transformed epithelial cells and cancer stem cells, as 
TAMs in the MMTV-PyMT model have also been shown to also maintain stem-like cells [117].  
CCR6 is not expressed on peripheral blood monocytes, and is thought to only be acquired upon 
their differentiation into macrophages, induced by the tumour microenvironment [194]. In 
accordance with this, it was found that a high proportion of macrophages within PyMT-driven 
mammary tumours express CCR6, which has not been previously demonstrated in breast cancer. 
Also of potential importance is the fact that up to 90% of pro-tumourigenic M2-like TAMs 
expressed CCR6. These findings parallel results from a recent study which showed that CCR6-
null mice bearing the adenomatosis polyposis coli (APC)min transgene (a well-characterised 
model for gastro-intestinal tumourigenesis) developed fewer intestinal adenomas and polyps, and 
that the effect of CCR6 was also linked to a significant reduction in F4/80+ macrophages [200]. 
Interestingly, Liu et al also recently demonstrated that the ligand CCL20 is secreted from both 
macrophages and tumour cells in another mouse model of colorectal cancer, potentially 
suggesting common regulatory mechanisms and a universal role for CCR6 in tumours of various 
etiology [222].  
MMTV-PyMT cancer cell transplant experiments showed that tumour growth in a CCR6-null 
microenvironment was significantly inhibited compared to wild-type microenvironment 
conditions, directly demonstrating that the mammary stroma is dependent upon CCR6 for 
adequate tumour initiation and growth support. The reconstitution of this CCR6-negative 
microenvironment with MMTV-PyMT Ccr6WT TAMs restored the tumour-promoting properties 
of mammary stroma, indicating that breast cancer can be therapeutically targeted through 
manipulation of the CCR6-CCL20 axis to control tumour-infiltrating macrophages.  
CCR6 deletion has also impeded recruitment of dendritic cells into PyMT-driven mammary 
tumours. Recruitment of dendritic cells into various solid tumours has been well-documented 
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[223], and their role in tumour progression is mainly centred around tumour antigen presentation 
to lymphocyte subsets leading to anti-tumour immune responses [224, 225]. Furthermore, there 
is some evidence supporting direct tumouricidal activity of dendritic cells [224]. As previous 
studies have reported an intrinsic requirement for CCR6 in migration and fundamental functions 
of dendritic cells [165, 212], this finding of the reduced infiltration of dendritic cells in 
mammary tumours may not be a facet of cancer development in MMTV-PyMT Ccr6-/- mice, but 
is an inherent property of dendritic cell migration at a slower rate after CCR6 deletion.  
In conclusion, results of this study show that CCR6 plays a significant role in tumour initiation 
and at the early stage of breast cancer development in vivo by mediating recruitment of pro-
tumourigenic macrophages to the tumour site, and thus facilitating further progression to 
advanced stages of mammary neoplasia. Results presented here therefore suggest CCR6 as a 
potential target for therapeutic intervention in early breast cancer.  
5.4. Implications of this study 
This is the first in vivo evidence for the important roles of CCR6 and CCR7 in promotion of 
breast cancer. This work builds on previous observations based on in vitro models and 
xenotransplantation studies, and creates a strong baseline for further research in this area. The 
area of cancer immunology is largely uncharacterised and investigation into mechanisms 
underlying the functional role of these and other receptors in breast cancer should be the next 
step forward.  
This work contributes significantly to the knowledge about the roles of the chemokine receptor 
family in breast cancer. Importantly, the work with CCR7 reveals that chemokine receptors may 
have an important function in regulation of breast cancer stem cells, an area that is still largely in 
its infancy. 
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5.5.  Clinical predictions and future work 
The studies with the CCL19(8-83) antagonist in the PyMT mouse model suggest that CCR7 may 
be an interesting candidate for further pre-clinical evaluations into targeting of evasive cancer 
stem cells. In addition to CCL19(8-83), studies have been undertaken using the truncated ligand 
CCL21(8-110). As with CCL19(8-83), injection of this peptide antagonist in PyMT-expressing 
mammary glands also resulted in a significant decrease in tumour weight and size compared to 
vehicle controls (data not shown). Another approach may be to investigate the potential of cancer 
stem cell vaccines in the context of CCR7. Wicha’s group has undertaken preliminary studies 
into the use of CSC vaccines, by pulsing dendritic cells with CSC lysates (based on expression of 
aldehyde dehydrogenase) to generate B cell-mediated immunity against CSCs in mouse models 
of melanoma and squamous cell carcinoma. Application of the dendritic cell vaccine reduced 
development of primary tumours and metastasis, and interestingly, this was associated with a 
significant decrease in expression of CCR7 and its ligand CCL21 [226]. Therefore, inhibition of 
CCR7 may potentially be used in combination with conventional chemotherapeutics in a multi-
pronged approach to eliminate both rapidly-dividing bulk tumour cells and quiescent stem-like 
cells. 
The role of the tumour microenvironment in controlling cancer progression is highly dynamic, 
and the chemokine receptor family is emerging as a key regulator of this process. In addition to 
these studies with CCR6, Pollard and colleagues have recently demonstrated that CCR1 and 
CCR2 signalling in mammary tumour-infiltrating macrophages promotes metastatic seeding of 
breast cancer cells in the lungs [227]. Most likely, various chemokine receptors are involved in 
every aspect of breast pathogenesis, and function not only on the cancer cells, but also on 
stromal and circulating cells. Identifying these receptors and their specific roles is a major 
challenge for medical research, but due to the physiological nature of GPCRs – being expressed 
on the cell surface – developing drugs that target them is somewhat more straightforward. This 
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brings up the possibility of generating carefully tailored therapeutics for individual patients 
based on their chemokine receptor profile.  
As TAMs have recently been shown to maintain the CSC niche within MMTV-PyMT tumours 
[117], it would be worth investigating the result of blocking CCR7 and CCR6 together 
pharmacologically to treat mammary cancer, as hypothetically, loss of two components that are 
separately driving the epithelial hierarchy and the recruitment of major tumour-promoting cells 
within the cancer niche could result in an even greater reduction than that that is seen by deletion 
of the single receptors. A follow-up study in this area would be of specific clinical relevance.  
However, investigation into biochemical mechanisms behind the actions of CCR7 and CCR6 is 
necessary before any clinical work could be carried out, as the genes that are turned on or 
switched off by these chemokine receptor pathways in these scenarios have not yet been 
elucidated. In models used in this study, no redundancy seems to exist between different 
chemokine receptors, however crosstalk between chemokine receptor pathways and others (such 
as Wnt and Notch) would need to be thoroughly examined.  
In terms of breast cancer stem cell regulation, chemokine receptors are only one aspect of an 
extremely complicated regulatory system. Other aspects of the immune system, most importantly 
presence or absence of various immune cell subsets, may also contribute to the maintenance of 
this important population. With various genetically-modified mouse models now at the disposal 
of researchers, and using a similar strategy to that applied in this study, it will be possible to 
examine in more detail the aspects of tumour immunology which until now have remained 
somewhat elusive.  
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5.6.  Conclusion 
The chemokine receptors CCR6 and CCR7 play distinct but important roles in mammary cancer 
development. As the loss of these receptors largely blocks tumourigenesis, antagonists towards 
CCR6 and CCR7 should be explored further as potential therapeutics, to target both the tumour 
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Abstract Cancer stem cells are believed to be a subset of
heterogeneous tumour cells responsible for tumour initiation,
growth, local invasion, and metastasis. In breast cancer, nu-
merous factors have been implicated in regulation of cancer
stem cells, but there is still a paucity of information regarding
precise molecular and cellular mechanisms guiding their
pathobiology. Components of both the adaptive and the innate
immune system have been shown to play a crucial role in
supporting breast cancer growth and spread, and recently
some immune mediators, both molecules and cells, have been
reported to influence breast cancer stem cell biology. This
review summarises a small, pioneering body of evidence for
the potentially important function of the “immuniche” in
maintaining and supporting breast cancer stem cells.
Keywords Breast cancer . Cancer stem cells . Immune
system . Chemokine . Cytokine . Immunotherapy
Abbreviations
ALDH1 Aldehyde dehydrogenase 1
BCSC Breast cancer stem cell
CAF Cancer-associated fibroblast
CCL C-C chemokine ligand
CCR C-C chemokine receptor
CSC Cancer stem cell
CXCL C-X-C chemokine ligand





MMTV Mouse mammary tumour virus
MSC Mesenchymal stem cell
PyMT Polyoma middle T antigen
RANK Receptor activator of NFκB
RANKL Receptor activator of NFκB ligand
TAM Tumour-associated macrophage
TGF-β Transforming growth factor β
Introduction
The evolution of the cancer stem cell (CSC) theory [1] has
provided a new paradigm for how we view cancer initiation,
progression and metastasis. A large body of evidence has been
accumulated to support this theory following the first identi-
fication of stem-like cells in acute myeloid leukaemia by John
Dick and colleagues [2]. This theory states that within a
hierarchically organised yet heterogenous tumour mass, there
resides a small subset of cells with specific characteristics
generally attributed to adult and embryonic stem cells such
as quiescence and pluripotency among others, which are
responsible for initiation and maintenance of the tumour and
subsequent re-seeding to a secondary location [3, 4].
Targeting these quiescent cancer stem cells for therapeutic
intervention has come to the forefront of medical research [3],
and many of their regulatory mechanisms have been discov-
ered. Themajor molecular pathways implicated in CSC patho-
biology include Notch, Hedgehog, Wnt and TGF-β signalling
systems [5–8]. For a recent detailed review see [9]. Important-
ly, the hypothesis that CSCs exist in a specific stem cell
“niche” has recently been supported by a small body of
evidence. The CSC niche includes nerves, mesenchyme, and
extracellular matrix, as well as stromal and adipose cells [10].
Breast cancer stem cells (BCSCs) have been putatively
identified based on the expression of specific surface markers
CD44+CD24-/lo (human) and CD24+CD29hiCD49fhi (mouse)
[11–13] or methods such as the side population technique (a
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Hoechst dye-effluxing cell subset [14]) or ALDEFLUOR
assay (based on enzymatic activity of aldehyde dehydroge-
nase 1, ALDH1 [15]). The ability to sort stem cells based on
these markers and to assay their function through use of non-
adherent mammosphere assays, in which sphere-forming ef-
ficiency can be a measure of self-renewal capability [16], has
provided the basis for recent important discoveries in this area.
The immune system plays an important role in cancer
progression. Through a series of mutagenesis events, cancer
cells may acquire the ability to evade the immune system and
overcome anti-tumour host defences. This allows tumour cells
to escape T cell-mediated cytotoxicity in primary lesions and
potentially extravasate into circulation where they are capable
of metastasising [17]. The immune system can be a double-
edged sword during cancer progression, as immune cells have
been proposed to promote cancer development through secre-
tion of inflammatory cytokines, chemokines, autoantibodies,
proteases and induction of angiogenesis [18, 19]. Tumours are
known to also dampen the anti-tumour response by activation
of suppressive immune cell subsets, such as regulatory T cells
and myeloid-derived suppressor cells which are readily re-
cruited and infiltrate the tumour mass [20–22]. Immune mod-
ulatory cytokines, chemokines and other molecules are also
secreted and/or expressed by immune and cancer cells alike,
stimulating cancer cell motility, survival and proliferation
[23]. In breast and other cancers, the overall role that the
immune system and immune modulators have in facilitating
or preventing malignant progression has been summarised
elsewhere [24, 25] and is outside the scope of this article.
Recently, literature has begun to emerge that specifically
implicates molecules and cells of the immune system in the
biology of cancer stem cells. Below, we discuss how certain
immune-associated cells and molecules may regulate breast
cancer stem cells and maintain the BCSC immunological
niche, which we have termed the “immuniche”, outlined in
Fig. 1. We will also examine how BCSCs may be phenotyp-
ically selected for by immune cells and discuss recently pro-
posed cell-based immunotherapies to target BCSCs.
Promotion of Breast Cancer Stem Cells by Immune
Modulators
Chemokines and Chemokine Receptors
Chemokines and chemokine receptors have been widely
shown to regulate immune cell homeostasis, inflammation
and/or responses to infection [26]. In the last two decades,
chemokines and their receptors have been implicated in the
pathogenesis of various malignancies including colon, lung,
pancreatic, skin and many other cancers (for an excellent
overview of the multifaceted functions of the chemokine
family in cancer see [23]). In breast cancer development, this
receptor/ligand family is reported to affect multiple stages of
progression, including initial cellular transformation, local
invasion, angiogenesis and metastasis [27–30].
Seminal work on the involvement of chemokine receptors
in BCSCs has come from Max Wicha’s group which have
studied the role of CXCR1. CXCR1 is closely related to
CXCR2, with which it shares multiple ligands including che-
mokine interleukin-8 (IL-8, also known as CXCL8). Both
receptors have been heavily implicated in the elimination of
pathogens but also shown to contribute significantly to
disease-associated processes, including tissue injury, fibrosis,
angiogenesis and tumourigenesis [31]. It was found that
CXCR1-positive cells were present in the CD44+CD24− pop-
ulation in breast cancer cell lines, and were also almost exclu-
sively contained in the ALDEFLUOR-positive population.
Stimulation of CXCR1 with IL-8 increased primary and sec-
ondary mammosphere-forming efficiency (MFE). In addition,
CXCR1+ALDEFLUOR+ cells were able to form heterogenous
tumours upon transplantation [32, 33], providing functional
support for the role of CXCR1 in BCSC regulation. Treatment
of breast cancer cell lines with a CXCR1 inhibitor or an anti-
CXCR1 antibody resulted in a 5-fold reduction in
ALDEFLUOR+ cells and inhibition of the CXCR1 interaction
with its ligands in sphere culture caused a massive decrease in
primary and secondary MFE. Interestingly, when normal hu-
man mammary epithel ial cel ls were cultured as
mammospheres, IL-8 again increased the primary and second-
ary MFE, further implicating CXCR1 as a regulator of
stemness in both cancer and normal breast development [33].
The CXCR2 chemokine receptor was previously shown to
mediate breast cancer chemoresistance [34], an implied prop-
erty of BCSCs. Co-expression of CXCR1 and CXCR2 by
cancer cells is reported to promote cancer growth [35], and as
mentioned above, both are receptors for IL-8 which is
expressed by BCSCs [36]. As well as IL-8, CXCR2 interacts
with chemokines CXCL3, CXCL5, and CXCL7. Wicha and
colleagues also examined the result of neutralising CXCR2 but
did not observe a difference in the BCSC population [33].
Contrary to this, other reports showed that siRNA targeting of
CXCR2 and CXCL3 decreased the viability of CD44+CD24−
basal-like breast cancer cell lines through a decrease in STAT3
activity [37], and sequestering CXCL7 blocked expression of
other immune modulators from putative BCSCs [38]. In addi-
tion, CXCL5 stimulation of breast cancer cell lines increased
the ALDEFLUOR+ population [38]. As CXCR2 antagonists
are already in the clinic for other conditions such as pulmonary
disease [39], inhibiting this receptor may prove a promising
BCSC-targeting therapy, however the role of CXCR2 in
BCSCs still remains to be validated in cancer models in vivo.
Whilst the chemokine receptor CCR7 is upregulated during
breast cancer metastasis and has been associated with poor
prognosis for breast cancer patients [30], its function in mam-
mary tumourigenesis is still largely uncharacterised. We have
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recently shown that CCR7 is expressed on BCSCs from both
mice and humans (manuscript submitted for publication).
Deletion of CCR7 reduced the BCSC content and self-renew-
al activity in an MMTV-PyMT mouse model of breast cancer,
providing a mechanistic basis for the observed delay in tu-
mour onset and severely reduced tumour burden. We have
also demonstrated that pharmacological inhibition of CCR7
in vivo leads to impairment of primary tumour growth via
BCSC-related mechanisms, supporting the hypothesis that the
CCR7 receptor pathway is a point of intervention in stem cell-
targeting therapies.
The CCR7 and CXCR4 receptors are often concurrently
upregulated in cancer [30, 40] and we have shown previously
that CXCR4 together with CCR7 promotes cancer cell metas-
tasis through inhibition of anoikis, the process of detachment-
mediated cell death [41]. Interestingly, whilst CXCR4 has
been heavily implicated in various malignancies, its involve-
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Fig. 1 Maintenance of breast cancer stem cells by immune cells and
immune modulators within the immuniche. Breast cancer stem cells
(BCSCs) express a variety of immune modulatory receptors on their
surface, which correlates with biomarker expression, survival, EMT,
and mammosphere-forming ability. Chemokine receptors on the BCSC
surface are activated by chemokines secreted by mesenchymal stem cells
(MSCs) and cancer-associated fibroblasts (CAFs), promoting properties
of stemness. Autocrine and MSC-secreted IL-6 stimulates multiple func-
tions in the BCSC, and stimulation by other cytokines such as RANKL
and TGF-β result in EMT, an implied characteristic of BCSCs. Tumour-
associated macrophages (TAMs) promote BCSC survival both indirectly
and directly, and infiltrating T cell subsets in the immuniche provide a
catalyst for immune selection of the BCSC
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Recently however, CXCR4 was reported to contribute to the
maintenance of the BCSC population through transactivation
of the aryl hydrocarbon receptor [42] and was also expressed
in CD44+CD24− breast cancer cell lines, which correlated
with their invasiveness [43]. Furthermore, CXCR4 was de-
tected on the surface of mammosphere cells, and CXCR4
antagonists decreased MFE and the proportion of putative
CD44+CD24−BCSCs [44]. The CXCR4 antagonist plerixafor
(AMD3100) has shown some promise in preclinical trials [45,
46] and could also provide an option for targeting stem cells.
For example, in tamoxifen-resistant breast cancer cells,
Dubrovska et al. showed that AMD3100 inhibited the
BCSC-enriched side population [42]. This study, together
with our own observations, highlights the potential use of
chemokine receptor pathway antagonists as adjuvants to con-
ventional cytotoxic drugs, which alone cannot eradicate the
quiescent cancer stem cell populations.
In a recent study, Asiedu et al. comprehensively
characterised the chemokine and chemokine receptor profiles
in breast cancer cell lines with high CD44+CD24− cell content,
with the view to identify potential BCSC regulators among this
class of immune modulators. They reported increased expres-
sion of CCR7, but unexpectedly down-regulation of CXCR4.
In addition, CD44+CD24− breast cancer cells had increased
expression of CXCR7, CCL13, CCL11, CCL12, CCL2,
CCL5, CCL6, CCL7 and CCL8, and down-regulated CCR3,
CXCL1 and CCL20 [47]. Notably, CXCR7 also binds the
ligand for CXCR4, CXCL12, and scavenges CXCL12 to pro-
mote cancer cell metastasis [48]. Increased expression of
CXCR7 in the CSC population and its impact upon CXCR4
activity remains to be functionally assessed. Of the chemokines
upregulated, only CCL2 and CCL5 have been conclusively
shown to have a role in breast cancer [49, 50].
CCL2 has been proposed to affect properties of stemness in
breast cancer cells. In addition to secretion from BCSCs,
treating mammosphere culture with exogenous CCL2 in-
creased stem cell function via Notch-1 signalling and resulted
in more spheres with a higher number of slow-cycling stem
cells, as was measured by retention of PKH67 dye [51].
Whilst there are clear indications of a potential function for
CCL2 from both BCSCs and the immuniche, more specific
in vivo evidence is needed to confirm its role in BCSC
regulation. Of note, CCL2 is also involved in recruitment of
monocytes, memory T cells, regulatory T cells and dendritic
cells to inflammatory sites [52], and to breast tumours [22]
through its receptors CCR2 and/or CCR4, which may aid
BCSCs in controlling the immune system.
Interleukin-6
Interleukin-6 (IL-6) regulates a number of immune functions
and stimulates many inflammatory and auto-immune process-
es. As yet, it is one of the most studied cytokines in BCSC
biology with significant evidence accumulated to support its
multi-faceted role in this specialised subset of tumour cells.
Thus, NFκB-mediated upregulation of IL-6 was reported for
mammosphere cells when compared to the bulk cell popula-
tion [53, 54], and trastuzumab-resistant CSCs also expressed
high levels of IL-6 [36]. Stem-like cells were found to express
higher levels of IL-6 than differentiated cells and the addition
of IL-6 to differentiated cell culture could force cells to rapidly
de-differentiate. When an anti-IL-6 antibody was added, this
de-differentiation was blocked [55]. As de-differentiation was
recently proposed as an important mechanism in the genera-
tion of BCSCs [56], this novel finding may provide new
options in specifically targeting the BCSC axis.
Similarly, blocking the interaction of IL-6 with its receptor
(IL-6R) in mammosphere cultures also inhibited cell propaga-
tion through down-regulation of Notch-3 [53, 54], and blocking
IL-6 activity via siRNA or neutralising antibody decreased
viability of CD44+CD24− putative BCSCs [36, 37]. Further-
more, it was found that IL-6 is able to increase stem cell activity,
via Notch-3 mediated up-regulation of Jagged-1, and STAT-3.
It was proposed that IL-6 induces an autocrine loop and stem
cell-linked aggressiveness in breast cancer cells [54, 57]. The
fact that in the presence of high levels of IL-6, drugs such as
trastuzumab fail to eliminate cancer stem cells in culture and
xenograft models [36] makes the IL-6 axis a firm candidate for
stem cell directed therapeutic intervention.
Circulating tumour cells are believed to possess properties of
stemness such as anoikis resistance and a more mesenchymal
phenotype. High levels of IL-6 have been reported to promote
the epithelial-to-mesenchymal transition (EMT) in breast can-
cer cells, leading to a conversion to the BCSC phenotype [58].
Thus, addition of IL-6 to adherent human breast cancer cells
was found to increase the proportion of CD44+ putative
BCSCs, which had greater ability to form mammospheres as
well as increased in vivo tumourigenic potential over CD44−
cells. The acquisition of CD44 also coincided with a change in
cell morphology from cobblestone to spindle-like, increased
invasiveness, and the induction of a gene expression profile
consistent with EMT, including decreased E-cadherin, and
increased vimentin and twist [36, 59, 60].
RANK and RANKL
Receptor activator of NFκB ligand (RANKL) is a member of
the Tumour Necrosis Factor cytokine family. It is expressed
by T cells and stromal cells, and is thought to be involved in
dendritic cell maturation [61, 62]. Activation of its receptor
RANK in breast cancer cells through administration of
RANKL inhibited cell differentiation, induced EMT, and pro-
moted expression of stem cell surface markers and stemness
genes (such as SOX2, NANOG and OCT4). Furthermore, the
RANK-RANKL interaction was found to increase self-
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renewing capacity and augment tumour development both in
transplant models and spontaneously [63–65].
More direct evidence for the role of RANK and RANKL in
BCSCs was obtained using the medroxyprogesterone acetate
(MPA) mouse model of mammary cancer. Schramek et al.
found that MPA-induced tumour formation triggered an in-
duction of RANKL, with a corresponding expansion of
Lin−CD24+CD49fhi BCSCs in Rank+/+ mice, but not in
MMTV-Rank−/− mice. While both Rank+/+ and MMTV-
Rank−/− breast cancer cells were able to form primary spheres,
secondary spheres could only be propagated when RANK
was present [66], demonstrating the role of RANK and
RANKL in BCSC self-renewal.
Cancer and normal mammary stem cells have been proposed
to follow similar regulatory routes [67, 68]. Interestingly, RANK
and RANKL also have important roles in the regulation of
normal mammary stem cells, in adulthood and in alveologenesis
during pregnancy. Thus, in response to progesterone signalling,
RANKL is expressed in the mature luminal cell subset and
RANK is up-regulated in the mammary stem and basal progen-
itor cell compartment. The interaction of RANKL on luminal
cells and RANK on stem/basal cells potentially creates a para-
crine loop, in which RANKL acts as a key hormone mediator
for mammary stem cells in mice [69, 70].
These findings warrant further investigation in potentially
important functions of both RANK and RANKL in regulation
of human BCSCs. A small number of other factors have been
shown to play a role in promotion of the BCSC phenotype,
however the evidence for their role may be circumstantial. The
only other well-documented player in regulation of BCSCs is
TGF-β, the role of which has been comprehensively reviewed
elsewhere [71].
The “Immuniche”: The Role of the Immune System
in the BCSC Niche
Breast cancer stem cells are thought to reside within a stem
cell niche composed of nerves, mesenchyme and extracellular
matrix [10]. To some extent, each of these components sup-
ports the turnover and survival of this sub-population. More
recently, certain immune cells and stromal cells secreting
cytokines, chemokines, and other immune modulators, have
been identified as playing a specific role in the BCSC niche, to
form an “immuniche” that provides stem cells with necessary
growth signals and factors to maintain their stemness proper-
ties, avoid immuno-surveillance and propagate tumours.
Stroma-Derived Cells and the Immuniche
Mesenchymal stem cells (MSCs) are heavily involved in sup-
port of both active and innate immune cells [72, 73]. They have
been shown previously to have a role in breast cancer
progression and metastasis through secretion of, or migration
in response to chemokines CCL5 and CCL2 [74, 75]. It was
recently found that the co-culture of human breast cancer cells
with bone marrow-derived MSCs also led to an increase in
ALDEFLUOR+ and CD44+CD24− putative BCSCs. This co-
culture induced the expression of CXCL1, CXCL5, CXCL6
and CXCL7, as well as IL-6 and IL-8, from both theMSCs and
BCSCs [38]. Therefore MSCs in the immuniche are potentially
an important source of secreted specific immune modulators
that are required to maintain stem cell activity by BCSCs.
Cancer-associated fibroblasts (CAFs), another notable
component of the immuniche, have been well documented
for their function in breast cancer promotion via secretion of a
milieu of cytokines and chemokines [76–78]. Whilst direct
evidence for the role of CAFs in BCSC regulation is yet to be
established, some recent findings suggest that CAFs may be
important for maintaining optimal conditions in the BCSC
immuniche, as it was shown that breast cancer cells co-
cultured under mammosphere conditions with CAFs that se-
crete CXCL12 and/or CCL2 have higher MFE and propor-
tions of CD44+CD24− putative BCSCs. Furthermore,
neutralising CCL2 secreted from CAFs with antibody
completely inhibits MFE of the breast cancer cells, therefore
disrupting the BCSC immuniche [44, 51].
Immune Cells and the Immuniche
Macrophages are innate immune cells that are often recruited to
the tumour microenvironment. As tumour cells may be
recognised as self, these tumour-associated macrophages
(TAMs), rather than aid the anti-tumour response, promote
breast cancer cell growth and metastasis by the secretion of
immune modulators [79, 80]. Their role in the CSC immuniche
is largely uncharacterised, but limited evidence has come to
light that implicates TAMs in regulation of BCSCs.
In the study of breast cancer metastasis to the bone, TAMs
were generated by stimulating human monocytes with cyto-
kines and conditioned media and co-injected into tibial bones
of mice with magnetically isolated CD44+CD24− cells from
the 231BoM breast cancer cell line which is highly metastatic
to the bone. This co-injection significantly augmented tumour
growth compared to injection of CD44+CD24− cells alone,
strongly supporting the idea that TAMsmay play an important
role in BCSC maintenance. Using an antibody array and
immunofluorescent microscopy, it was further found that
platelet-derived growth factor (PDGF) was specifically re-
leased from TAMs upon co-culture and interaction with
CD44+CD24− cells. The authors showed that TAMs had a
dual role in the immuniche, additionally stimulating stromal
cells such as fibroblasts and MSCs to secrete FGF and other
growth factors, that act directly on BCSCs [81].
TAMs were found to produce large amounts of the growth
factor milk fat globule (MFG)-E8, and colon and lung CSCs
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were found to specifically induce MFG-E8 expression from
macrophages to support their survival when inoculated into
syngeneic mice. MFG-E8 secreted from TAMs suppressed
caspase-3 activation, inhibiting apoptosis in the lung and
colon cancer stem cell populations. This was then tested in
putative BCSCs, with similar results [82]. Considering the fact
that the presence of TAMs in the BCSC immuniche has a
number of direct and indirect functions, these immune cells
may be targeted by anti-BCSC therapies.
T cells can participate in breast cancer promotion when they
are recruited to the tumour microenvironment [18, 20, 22].
Breast cancers of higher histological grade and with highly
aggressive steroid receptor-negative status have high levels of
CD8+ cytotoxic T cell infiltration and pro-inflammatory cyto-
kines associated with a CD4+ helper Tcell response [83–85]. In
addition, FOXP3+ regulatory T cells, which have been impli-
cated in breast cancer aggressiveness, are recruited to the tu-
mour microenvironment by CCL22 [22, 86]. There is little
evidence available to date on the direct role of different T cell
subsets on BCSCs, however emerging data suggest that T cells
may also be active players in the BCSC immuniche.
Thus, it has been reported that high grade estrogen receptor-
negative and highly aggressive triple-negative breast cancers
had increased levels of cytotoxic, helper and regulatory T cell
tumour infiltrations. This was also correlated with increased
CD44+CD24−ALDH1+ tumour cell content and expression of
EMT-associated markers vimentin, osteonectin and smooth
muscle actin [85]. Additionally, it has been suggested that
EMT induction to generate BCSCs may be dependent on
cytotoxic T cells [87]. However, this increase in BCSC content
upon tumour infiltration by Tcells may also be due to stem cell
specific immune selection, discussed in more detail below.
Although the role of active immune cells in regulation of
BCSCs is currently not well defined, some recent advances in
delineating a function for specific T cell subsets within the
BCSC immuniche should encourage more research in this
area. Moreover, given the large part that T cells can play in
breast cancer development, it is thought that this field will
soon expand significantly.
Immune Selection and Tolerance of Breast Cancer Stem
Cells
One of the hallmarks of cancer is the evasion of immune
clearance [17] and the ability of rapidly-dividing bulk cancer
cells to do this has been well characterised [88]. Immune
evasion by quiescent cancer stem cells, including breast
CSCs, is an interesting paradigm that remains to be elucidated.
Currently, the exact origin of BCSCs is yet to be uncovered. It
is thought that a bona fide cancer stem cell, with acquired
stem-like properties, evolves from the tumour cell-of-origin
through survival of the fittest [56]. The presence of immune
cells within the immuniche may aid cancer cells in acquiring a
more stem-like and immune-resistant phenotype through a
process termed “immune selection” (Fig. 1).
Immune selection may play a part in resistance to immune-
mediated therapy of cancer stem cells. Bulk cancer cells can
develop resistance to conventional cytotoxic drugs due to up-
regulation of drug transporters [17], and it is thought that CSCs
may have more robust mechanisms of drug efflux. The same
may be true for immunotherapies, where CSCs avoid killing by
cytotoxic cells. For example, it was found that treatment with
trastuzumab depleted HER2-expressing breast cancer cells
through a natural killer (NK) cell-mediated mechanism. How-
ever, cells that survived this NK immune selection had in-
creased CD44hiCD24lo surface marker expression and were
able to grow more robustly as mammospheres compared with
naïve cells. After six cycles of treatment, the CD44hiCD24lo cell
content was significantly increased, indicating that proportions
of BCSCs increased over time through immune selection [89].
Tumour cells are also able to avoid recognition by primed
immune cells through immuno-editing, a process in which
tumour cells lose or modify tumour antigens. Findings by
Knutson et al. showed that immuno-editing may occur
through the process of EMT, a route that may also result in
the acquisition of a BCSC phenotype. The authors have
suggested that immuno-editing is not an incremental loss of
tumour antigens but rather an active process in which cells use
EMT to de-differentiate into cells of a stem-like state [90].
Immune selection and immuno-editing may result in tu-
mour cells that are recognised as self by immune cells, thus
leading to tolerance and evasion of the immune system. Exact
mechanisms underlying these phenomena are not yet known,
however glycoprotein CD200 (OX2) has been reported to be
an important player in BCSC immune evasion. OX2 is com-
monly expressed in myeloid cells and has been studied as a
therapeutic target for its role in tolerance. In tumourigenic and
invasive breast cancer cells, it was found that a high percent of
OX2+ cells were CD44+CD24− [91].
In summary, it is plausible that the infiltration of immune
cells into mammary tumours may stimulate more mature
breast cancer cells to de-differentiate into stem-like cells
through EMT, coinciding with the activation of molecules that
promote tolerance of CSCs by the immune system. This in
turn may lead to CSC immune evasion and the development
of more aggressive tumours. This hypothesis warrants specif-
ically designed future studies, which should examine the
interplay between immune infiltrates and BCSC populations
in animal models and primary human tumour samples.
Cell-Based Immunotherapy and Breast Cancer StemCells
Numerous cancer-targeted immunotherapies are currently be-
ing explored and considerable progress has been made in the
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development of cell-based novel therapeutics, also known as
“activation” immunotherapy, for the treatment of breast cancer
(for a recent review, see [92]). Whilst the use of cell-based
immunotherapy to treat multiple malignancies has progressed
to the advanced stages of preclinical development, the concept
of CSC-directed immunotherapy is still in its infancy. Bearing
in mind that CSCs are largely resistant to conventional thera-
peutics, the generation of new cell-based approaches aimed at
specifically eliminating this evasive cancer cell subset may
provide a potential cure for as yet incurable cancers.
Recently, Wang et al. developed an irradiated whole cell
vaccine from CD24+CD29+ mammosphere cells, originally
from HER2/neu transgenic mice with breast cancer. Once mice
were immunised with the vaccine, both cytotoxic and helper T
cells were isolated from draining lymph nodes, separated, and
activated by cytokines in vitro. When the primed T cells were
adoptively transferred into mice with established lung metasta-
sis, there was near complete eradication of lung tumours [93],
demonstrating the applicability of this cell-based approach.
Another group found that in drug-resistant breast cancer
cell lines which have a high proportion of cells expressing
BCSC markers, the balance of stem cell-associated molecules
Notch and its antagonist Numb shifted towards Numb. In
culture, Numb-1 peptides were able to activate Numb1+CD8+
immune cells, and when these Numb1+CD8+ cells were incu-
bated with breast cancer cells, the proportion of
CD44hiCD24-/lo cells was reduced. This implies that cells with
BCSC markers could be eliminated by Numb-1-peptide com-
plex specific cytotoxic T cells to induce cell-mediated cyto-
toxic immunity [94]. Adoptive transfer experiments may
show whether this approach is a viable in vivo option.
Pulsed dendritic cell vaccines may also hold potential as
BCSC vaccines. At the time of writing this review, no litera-
ture was available on this topic. However, it is feasible that a
similar approach as described in melanoma could be applied
to breast cancer. Recently, Ning et al. showed that pulsing
dendritic cells with ALDH1+/hi melanoma cells to obtain a
CSC vaccine, and subsequent immunisation of mice followed
by challenge with bulk tumour cells, induced both humoral
and cell-mediated protective immunity. Treatment of mice
with this vaccine led to reduced tumour growth and metastasis
in murine xenograft models of melanoma [95].
The latest study by Knutson and colleagues proposed a
multi-peptide vaccination in combination with antibody ther-
apy to simultaneously target various cell subsets within the
tumour and the immuniche including TAMs and BCSCs.
However, these results do not directly assess the impact of
this therapeutic approach on the BCSC populations [96].
These approaches are only just evolving and there remains
the need to verify and validate their feasibility in more diverse
disease models, particularly in mouse models of breast cancer
and human preclinical studies. Whilst vaccines specifically
targeting BCSCs are a promising avenue for more effective
future treatments, a great deal of work is still required as there
are no currently available data for their use in primary settings.
Also, the possibility of immune selection of cells able to
acquire stem-like characteristics remains a cause for concern.
Conclusions
There is considerable evidence that the maintenance and activity
of breast cancer stem cells is dependent to a large extent on
immune modulators expressed not only by BCSCs themselves
but also by stromal and immune cells within the immuniche. The
presence of cancer-associated fibroblasts, mesenchymal stem
cells, macrophages and T cells may be necessary for BCSC
self-renewal andmaintenance of the stem cell phenotype through
secreted factors. Furthermore, the impact of T cells and other
immune cellsmust be carefully balanced to prevent tolerance and
immune selection of BCSCs which are able to survive the
onslaught of conventional therapies. In the near future, the de-
velopment of novel agents and approaches targeting the compo-
nents of the immuniche may provide more effective cancer stem
cell-directed therapies for breast cancer patients.
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The chemokine receptor CCR7 promotes mammary
tumorigenesis through amplification of stem-like cells
ST Boyle1, WV Ingman2,3, V Poltavets1, JW Faulkner1, RJ Whitfield4,5, SR McColl1,6 and M Kochetkova1
The chemokine receptor CCR7 is widely implicated in breast cancer pathobiology. Although recent reports correlated high CCR7
levels with more advanced tumor grade and poor prognosis, limited in vivo data are available regarding its specific function in
mammary gland neoplasia and the underlying mechanisms involved. To address these questions we generated a bigenic mouse
model of breast cancer combined with CCR7 deletion, which revealed that CCR7 ablation results in a considerable delay in tumor
onset as well as significantly reduced tumor burden. Importantly, CCR7 was found to exert its function by regulating mammary
cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through
deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary
tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. These data characterize the
oncogenic properties of CCR7 in mammary epithelial neoplasia and point to a new route for therapeutic intervention to target
evasive cancer stem cells.
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INTRODUCTION
Despite concerted efforts and significant advances, breast cancer-
related mortality is still a leading cause of death in women
worldwide.1 Clearly novel therapies are urgently needed. The
'cancer stem cell' theory specifies that a small subset of cells in a
heterogeneous tumor (termed 'cancer stem cells' (CSCs)) possess
stem cell-like properties of self-renewal and differentiation. CSCs
are suggested to sustain and propagate tumors, and are
inherently therapy-resistant (for the latest reviews see2 and3).
CSCs may originate from adult stem cells, but can also arise
from more committed lineage progenitor cells if they acquire
stem cell-like features owing to genetic or epigenetic changes.4
Multiple intrinsic and extrinsic factors are reported to have a role
in CSC maintenance, regulation and support of stem-like
characteristics. Most prominent are the Notch,5 Hedgehog,6
Wnt7 and TGFβ8 signaling systems. Several cytokines and
chemokines have also been recently suggested as maintaining
and promoting the CSC phenotype in a number of solid
malignancies, including mammary tumors (reviewed in9); how-
ever, definitive in vivo data has been sparse.
Chemokine receptors and their cognate chemokine ligands
have become widely accepted as important mediators of
cancer growth and progression in many human neoplasms,
being involved in tissue transformation, invasion, angiogenesis
and resistance to chemotherapy.10 Among these, the chemokine
receptor CCR7 has been implicated in metastatic spread of
multiple malignancies.11 In breast carcinogenesis, it has been
attributed a number of potential functions, including promo-
tion of cell motility, migration and adhesion, regulation
of matrix metalloproteinases leading to basement membrane
degradation,12 and cell survival through inhibition of anoikis.13
Data obtained using cell lines has implicated CCR7 in breast
cancer spread to the lymph nodes,14 and in human breast cancer
its role was inferred from retrospective studies on archived tumor
tissues.15 High expression levels of CCR7 were also correlated with
higher grade and occurrence of secondary tumors, and poor
prognosis.16,17
Whereas all these studies point to a role for CCR7 in malignancy,
a direct function for CCR7 in cancer has not yet been established.
Furthermore, its role in breast cancer in particular is unclear. We
show here the development of a novel bigenic mouse model
combining deletion of CCR7 with the polyoma middle-T
transgene, which is under control of the mouse mammary tumor
virus promoter (MMTV-PyMT), to study tumor development in vivo.
Using this model we show that CCR7 deletion has a striking
preventative effect on PyMT-driven mammary tumors, supporting
the notion that CCR7 has a major determining role in breast
oncogenesis. Moreover, our data reveal that the tumor-promoting
effect of CCR7 is mediated through stem-like cells in both primary
mouse and human breast tumors. These results provide new
insights into the role of CCR7 in breast cancer stem-like cells and
have important implications for the development of future
therapeutics in breast cancer.
RESULTS
CCR7 deletion arrests mammary tumorigenesis in the PyMT
transgenic breast cancer mouse model
The MMTV-PyMT transgenic breast cancer mouse model has been
extensively used in recent years to study various aspects of
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mammary neoplasia. Expression of the PyMT protein promotes the
rapid epithelial transformation of mammary cells via the corruption
of various pathways including those of Src, ras and PI3 kinase.
This model also results in spontaneous metastasis and has been
found to closely mimic the development of human breast
cancer.18–20 Representative images are shown in Supplementary
Figure 1a, in which α-smooth muscle actin is used to stain
myoepithelial cells.
To directly assess the role of CCR7 in the multistage process of
mammary tumorigenesis in vivo, we generated bigenic MMTV-
PyMT Ccr7−/− knockout mice (further referred to as CCR7 KO+) and
traced the development of mammary tumors relative to MMTV-
PyMT Ccr7WT mice (further referred to as WT+).
Deletion of CCR7 significantly delayed PyMT-driven primary
mammary tumorigenesis (representative pictures Figure 1a).
Tumor-free survival was significantly extended (Figure 1b) and
total tumor burden was markedly reduced in CCR7 KO+ mice
(Figure 1c) when compared with the WT+ animals. The lungs of
WT+ and CCR7 KO+ females were also examined for metastatic
lesions at the time of killing. CCR7 KO+ mice developed
significantly fewer and smaller metastases than WT+ mice
(Figures 1d–f), although the number of metastases varied largely
between mice of the same genotype.
As these experiments indicated a role for CCR7 in mammary
gland function, we next examined normal, pre-cancerous and
cancer-bearing mouse mammary glands for CCR7 expression and
signaling. CCR7 was shown to be expressed on all mouse
mammary epithelial cells tested, regardless of the tumor stage
(Supplementary Figure 1b), and the removal of CCR7 did not affect
the expression levels of its ligands CCL19 and CCL21 within the
mouse mammary fat pad (Supplementary Figure 2a). CCR7 was
also found to be functional in PyMT-driven mammary tumors, as
tumor cells mobilized intracellular calcium, a hallmark of
chemokine receptor activity, in response to stimulation with
CCL21 (Supplementary Figure 2b). These data showed that CCR7
was expressed and was functional within normal and transformed
mammary epithelium.
Interestingly, despite the large impact of CCR7 on overall
mammary tumorigenesis, initial PyMT-driven hyperplastic growth
in 8- or 11-week-old WT+ and CCR7 KO+ mice was not affected
(Supplementary Figure 3a), with similar tissue architecture in
glands from both genotypes (Supplementary Figure 3b). This
indicated that the CCR7 KO+ mammary glands underwent the
initial oncogenic transformation leading to epithelial proliferation,
but further tumorigenic transition was largely blocked by CCR7
deletion.
CCR7 promotes tumorigenesis by amplifying breast cancer
stem-like cells
To investigate the underlying mechanisms responsible for the
tumorigenic effects seen, we examined the role of CCR7 in
mammary gland development and on stem-like cells. We found
that in non-PyMT wild-type (WT) pubertal mice, the epithelial tree
was longer with a better developed ductal structure than that in
Ccr7−/− (CCR7 KO) mice (Figures 2a and b), indicating that ablation
of CCR7 had a mild inhibitory effect on pubertal growth of the
mammary gland epithelium. CCR7 was robustly expressed in
normal mammary epithelium (Figure 2c), making this receptor
also potentially relevant to normal mammary development.
However, the development of mammary epithelium in the CCR7
KO mice caught up with that of the WT mice by the age of
8 weeks, and at 12 weeks mammary glands from the two
genotypes were indistinguishable (Figure 2d), demonstrating that
CCR7 deletion mainly delays early mammary gland development.
Because normal development and breast cancer are believed to
be linked by common regulatory mechanisms, we hypothesized
that the observed promotion of PyMT-driven tumorigenesis and
mammary development was due to CCR7 regulating stem/
progenitor cell pools in mammary epithelium. Thus, we next
assayed the stem-like cell content in mice using the lineage-
negative (Lin−) CD24+CD29hi cell surface marker profile,4 which
was previously functionally characterized in the MMTV-PyMT
model.21,22 CCR7 was expressed in all cell lineages in both the
normal and PyMT-expressing mammary glands regardless
of CD24 and CD29 status. Notably, however, higher levels of
CCR7 (490%) were observed in Lin−CD24+CD29hi normal and
cancer mouse mammary stem cell-enriched populations
(Figure 3a, Supplementary Figure 4a and b). Importantly, CCR7
was also expressed on human CD44+CD24− putative mammary
stem cells23 from both normal and breast tumor tissue (Figure 3b,
Supplementary Figure 4c).
Further analysis demonstrated a significantly lower content of
Lin−CD24+CD29hi cells in non-PyMT CCR7 KO mice relative to WT
(Figure 3c left panel). In PyMT-expressing mice at the stage of
early neoplasia, when no morphological differences were found in
WT+ and CCR7 KO+ glands (Supplementary Figure 3) and the
stem/progenitor cell populations may, therefore, best reflect the
tumor-initiating cell content, the difference in the stem cell-
enriched population between WT+ and CCR7 KO+ mice was even
more pronounced with the deletion of CCR7 leading to a twofold
reduction in stem-like cells (Figure 3c right panel).
Recently Pece et al. have suggested a new and potentially more
efficient set of markers, in which the notch ligands delta-like
ligand 1 (DLL1) and delta and notch-like epidermal growth factor-
related receptor (DNER) are used in combination with CD49f
(Lin−CD49f+DLL1+DNER+) to delineate putative stem cells in
human mammary tumors.24 We found that the stem-like cells
from both human and mouse mammary glands defined by this
profile also expressed high levels of CCR7 (Supplementary Figure
4d and e). Moreover, the Lin−CD49f+DLL1+DNER+ cell pools were
significantly smaller in both normal and PyMT-expressing CCR7 KO
murine mammary glands (Supplementary Figures 5a and b),
providing further support for the findings described above.
It is generally accepted that non-adherent passaged mammo-
sphere cultures are enriched in cells with stem-like characteristics,
and secondary/tertiary mammosphere-forming efficiency (MFE) is
representative of cells’ potential to exhibit stem cell traits.25–27
Stem-like activity, as measured by MFE, was then analyzed in the
mammary epithelium in the presence or absence of CCR7. Primary
and secondary sphere formation from normal (Figure 3d) or PyMT-
expressing (Figure 3e) mammary cells was substantially reduced
after CCR7 ablation and, importantly, stimulation of WT and WT+
cells with CCR7 ligands CCL19 and CCL21 significantly potentiated
mammosphere growth (Figures 3d and e).
This CCR7 stimulatory function was seen exclusively on
mammosphere growth, as stimulation with CCL19 and CCL21
had no detectable effect on the proliferation of bulk mammary
tumor cells in adherent culture, a condition that supports a more
differentiated phenotype (Supplementary Figure 5c). The addition
of CCR7 ligands to sphere cultures derived from CCR7 KO+
mammary cells also had no effect on MFE (Supplementary Figure 5d),
demonstrating a CCR7 receptor-mediated mechanism. The
specificity of CCR7 was further shown by testing a panel of
ligands for other tumor-associated chemokine receptors CCR6,16
CXCR328 and CXCR5.29 No effects were observed on MFE
(Supplementary Figure 5e).
To extend these findings to human breast cancer we next
examined the activity of CCR7 in human primary tumor cells from
resected breast cancer tissue. The addition of CCL19 and CCL21
resulted in an increase in primary and secondary MFE of human
breast cancer cells by two- to threefold (Figure 3f), consistent with
results obtained in the mouse model.
To specifically link the deletion of CCR7 to depleted tumor-
initiating cells, a limiting dilution transplantation approach was
used24 to estimate tumor-initiating cell (TIC) frequency. Secondary
CCR7 promotes breast cancer via stem-like cells
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mammosphere-derived cells from WT+ and CCR7 KO+ mice with
early neoplasia were used in this assay to address the potential of
cells in mammosphere cultures to exhibit stem cell traits of self-
renewal and tumor initiation in vivo, in the context of CCR7-
dependency. Cells were injected into contralateral inguinal fat
pads of non-PyMT WT recipients. Analysis of grafted fat pads after
6 weeks showed that WT+ sphere cells produced much more
robust growth at all dilutions (Figure 4a and Supplementary Figure 6).
Most importantly, the frequency of stem-like cells capable of
tumor initiation within WT+ sphere culture (1/189) was over
threefold higher than in CCR7 KO+ (1/913) (Figure 4b), providing
strong evidence for the critical role of CCR7 in the regulation and
maintenance of stem-like cells and tumor-initiating cells in the
mammary gland.
CCR7 is required for the propagation of mammary tumors
To obtain in vivo evidence for the role of CCR7 in tumor
propagation, we took advantage of the PyMT mouse model, which
allows tumor formation upon transplantation.20 Expression of the
PyMT oncogene results in multifocal tumors and hence can
Figure 1. CCR7 deletion arrests mammary tumorigenesis in the PyMT transgenic breast cancer mouse model. (a–c) CCR7 ablation delays
tumor onset and reduces tumor burden in the MMTV-PyMT-driven mouse model of breast cancer. (a) Representative images of MMTV-PyMT
Ccr7WT (WT+) and MMTV-PyMT Ccr7−/− (CCR7 KO+) mice at 22-weeks-old, showing grossly visible tumors (demarcated by red arrows and
dotted lines). (b) Kaplan–Meier analysis of tumor-free survival for WT+ (n= 18) and CCR7 KO+ (n= 17) mice. (c) Number of tumors in WT+ and
CCR7 KO+ mice at the time of killing. (d–f) CCR7 KO+ mice developed less lung metastases than their WT+ counterparts. (d) Total cumulative
area of lung metastatic lesions in WT+ (n= 8) and CCR7 KO+ (n= 8) mice. (e) Distribution data of lung metastases in WT+ and CCR7 KO+ mice.
(f) Representative images of H&E-stained lung sections from WT+ (left) and CCR7 KO+ (right) mice with metastatic lesions (black arrowheads).
Red arrowhead indicates inset magnified image. *Po0.05, **Po0.01, ***Po0.001.
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Figure 2. The effect of CCR7 on normal mammary development. (a and b) Development of the mammary ductal tree was evaluated in Ccr7WT
(WT) and Ccr7−/− (CCR7 KO) C57Bl/6 mice at 6 weeks of age. (a) Representative whole mount images of mammary glands, with apparent
reduction in the size of ductal trees in CCR7 KO (right, n= 6) compared with WT (left, n= 7). LN= lymph node. (b) Quantitation of the length
of the main epithelial duct (left), total number of mammary epithelial terminal structures (center), and branching within mammary epithelium
determined by quantifying branch points per mm along three individual ducts (right). *Po0.05, **Po0.01, ***Po0.001. (c) CCR7 expression
(magenta) in normal mouse mammary terminal end buds of pubertal mice. Nuclei are counterstained with DAPI (gray). (d) Representative
whole mount images of mammary glands taken from adult WT (left, n= 6) and CCR7 KO (right, n= 6) mice at 12 weeks of age with no
apparent differences in the size and architecture of the mammary tree.
Figure 3. CCR7 activity amplifies stem-like cells in both mouse and human mammary glands. (a–c) Normal mammary glands and mammary
tumors were analyzed by flow cytometry for stem-like cell content. (a) Proportion of cells positive for CCR7 in Lin− stem cell-enriched
populations in normal mouse mammary epithelium (left) and PyMT-expressing glands (right), as denoted by surface marker expression CD24+
CD29hi. Shaded histograms= fluorescence-minus-one negative gates. (b) Proportion of cells positive for CCR7 in putative stem-like cell
populations in normal human mammary epithelium (left) and breast cancer (right), as denoted by surface marker expression CD44+CD24−.
Shaded histograms, fluorescence-minus-one negative gates. (c) CCR7 deletion decreases the proportion of mouse Lin− stem cell-enriched
populations in normal (left) and PyMT-expressing (right) mammary glands as indicated. (d–f) The effect of CCR7 deletion/activation on
primary and secondary mammosphere formation was assessed. Shown are mammosphere-forming efficiencies of cells derived from normal
mouse mammary glands (d), PyMT-expressing mouse mammary glands (e), and human patient-derived breast tumors (f). WT mouse
cells and primary human cells were stimulated with CCL21 and CCL19 as indicated. (a–f) Mouse data are representative of at least three
independent experiments, n= 6–10 mice per group. Human results are representative of two normal and four independent tumor samples.
*Po0.05, **Po0.01, ***Po0.001.
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generate diverse CSC pools owing to various underlying muta-
tions within the same gland at the late stages of tumorigenesis.
Therefore, we reasoned that if taken at the early stage of pre-
neoplastic tumor development, the population of CSCs should be
more homogeneous. Consequently, small 1mm3 fragments of pre-
neoplastic mammary tissue from 8-week-old PyMT transgenic
WT+ and CCR7 KO+ mice were simultaneously transplanted into
contralateral inguinal mammary fat pads of non-PyMT WT
CCR7 promotes breast cancer via stem-like cells
ST Boyle et al
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recipients. Representative histological sections from both WT+
and CCR7 KO+ 8-week-old mice, corresponding to donor tissue,
are shown in Figure 5a, confirming that the glands used for
transplantation were at the equivalent stage of tumorigenesis.
Analysis of tumorigenic outgrowth from transplanted tissue
showed that the deletion of CCR7 almost completely blocked
secondary tumor development. Only one out of six transplants
from the CCR7 KO+ donors was able to give rise to a neoplastic
lesion, whereas five out of six fragments from the WT+ donors
produced secondary outgrowths in WT recipients (Figures 5b and c),
demonstrating a key role of CCR7 in tumor propagation.
Pharmacological antagonism of CCR7 in vivo depletes the
stem-like cell population and inhibits mammary tumorigenesis
A CCR7 antagonist, CCL19(8–83),
30 was used to explore the
potential of targeting CCR7 for CSC-directed therapeutic interven-
tion. Initially, the ability of CCL19(8–83) to block the stimulatory
activity of CCR7 ligands on mammosphere-forming capacity was
tested ex vivo and found to specifically abrogate the effect of
CCL21 (Figure 6a) and CCL19 (data not shown) on mammosphere
growth, providing a rationale for in vivo studies.
The effect of CCR7 blockade by CCL19(8–83) on tumor initiation
was then examined in the context of the PyMT transgenic mouse
model. CCL19(8–83) was injected for eight consecutive weeks into
inguinal mammary glands of animals from the age of 4-weeks-old.
Glands were then excised and examined for the extent of
tumorigenesis and stem-like cell content and function. Macro-
scopic analysis demonstrated that CCL19(8–83)-injected glands had
smaller lesions than their control counterparts (representative
image Figure 6b). The total weight of fat pads was not statistically
different; however, the cellularity (total cell count and cells per mg
of tissue) was significantly reduced by the antagonist (Figure 6c,
Supplementary Figures 7a and b).
Treatment with CCL19(8–83) also resulted in a significant
decrease in the proportion of stem-like cells (Lin−CD24+CD29hi
Figure 6d left panel, and Lin−CD49f+DLL1+DNER+ Supplementary
Figure 7c) and the function of stem and early progenitor cells
(Figure 6d right panel), without affecting the level of CCR7
receptor expression (Supplementary Figure 7d). PyMT transgenic
mice on both FVB and C57Bl/6 (not shown) backgrounds were
tested, with similar results.
To determine whether treatment with CCL19(8–83) has an
inhibitory effect on established and/or advanced later stage
tumors, 1mm3 size fragments of MMTV-PyMT WT+ tumors from
16-week-old mice, corresponding to the invasive ductal carcinoma
stage of human breast cancer (Supplementary Figure 1a), were
transplanted into inguinal glands of WT recipients followed by
eight weekly injections of CCL19(8–83) or vehicle control (Figure 6e
left panel). Although no significant differences were seen between
CCL19(8–83)- or vehicle-treated tumors in size or cellularity
(Supplementary Figure 7e) as was observed in primary tumors,
the proportions of stem-like cells determined by both
Figure 4. CCR7 increases in vivo tumor-initiating capacity of sphere cells. (a) Representative images of intact and respective whole-mounted
contralateral mammary glands engrafted with 2500 WT+ or CCR7 KO+ sphere-derived cells. Black arrowheads indicate areas of outgrowth
from engrafted cells. LN= lymph node. (b) Results of limiting dilution assay indicating frequency of tumor-initiating cells (TIC) in WT+ and
CCR7 KO+ sphere cultures. Fractions indicate the number of fat pads with lesion(s) per total number of recipient fat pads.
CCR7 promotes breast cancer via stem-like cells
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conventional (Lin−CD24+CD29hi Figure 6e center panel) or novel
(Lin−CD49f+DLL1+DNER+ Supplementary Figure 7f) marker sets, as
well as mammosphere growth (Figure 6e right panel), were
significantly reduced in antagonist-treated glands, demonstrating
that the CCR7 axis can be blocked in vivo to target stem-like cells
in mammary tumors.
DISCUSSION
The contribution of CSCs to tumor initiation is a major issue in
tumor biology, yet one of the least understood processes.3 We
show here that ablating CCR7 using a bigenic MMTV-PyMT Ccr7−/−
model significantly depleted the breast CSC-enriched pool. Using
the surface marker profiles CD24+CD29hi 4 and CD49f+DLL1+
DNER+ 24 we showed that the underlying mechanism involves
a decrease in the ability of stem-like cells and early progenitor cells
to self-renew and initiate neoplasia. Significantly, exogenously
targeting CCR7 with a peptide antagonist led to a decrease in
tumorigenesis.
CCR7 has been extensively studied for its role in adaptive
immunity and secondary lymphoid organogenesis, and CCR7-null
mice display disrupted architecture of the thymus and lymph
node, as well as a reduced ability to mount a primary immune
response.31 The role of CCR7 in mediating anti-tumor immunity is
also slowly emerging.32 In this context, the fact that abrogation of
CCR7 severely affected mammary tumorigenesis provides defini-
tive evidence of CCR7 as a pro-tumorigenic driver. Furthermore,
numerous transplantation approaches used in this study under-
score an immune system-independent role of this chemokine
receptor in maintaining stem-like cell pools in breast cancer.
Interestingly, hyperplastic outgrowth, widely believed to be a
precursor of mammary tumors,20 was found in 100% of WT and
Figure 5. CCR7 is required for the propagation of mammary tumors. (a) Representative H&E-stained sections of pre-neoplastic mice at the
WT+ and CCR7 KO+ donor age of 8 weeks. Bottom: magnified images of boxed area. (b) Representative whole-mount images of WT-recipient
glands after transplantation of pre-neoplastic mammary tissue from WT+ (top) and CCR7 KO+ (bottom) donor mice at 8 weeks of age. Black
arrowheads indicate areas of outgrowth from donor tissue. Fractions indicate the number of fat pads with lesion(s) per total number of
recipient fat pads. LN= lymph node. (c) Cumulative area of transplant outgrowth in recipient mammary glands. n= 6 mice per group.
*Po0.05.
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Figure 6. Pharmacological antagonism of CCR7 in vivo depletes the stem-like cell population and inhibits mammary tumorigenesis. (a) MFE of
Lin− mammary cells from WT+ mice (n= 9), untreated or treated with CCL21 and/or the CCR7 antagonist CCL19(8–83). *Po0.05. (b–d)
Treatment of mice with CCL19(8–83) reduces tumorigenesis in MMTV-PyMT WT+ mice. (b) Representative image of intact mammary glands
treated with vehicle or CCL19(8–83) as indicated. (c) Cellularity of contralateral vehicle- or CCL19(8–83)-treated glands. (d) Proportions of Lin
−
CD24+CD29hi cells (left) and MFE (right) of cells from vehicle- or CCL19(8–83)-treated glands. (e) Treatment of mice with CCL19(8–83) reduces the
stem cell-enriched population in a transplant model. Experimental strategy (left), proportion of Lin−CD24+CD29hi cells (center) and MFE (right)
of cells from transplanted tumors with or without CCL19(8–83) treatment. (b–e) Data are representative of two independent experiments, n= 4–
6 mice per experiment. *Po0.05, ***Po0.001.
CCR7 promotes breast cancer via stem-like cells
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CCR7-null PyMT-carrying glands examined. However, the majority
of CCR7 KO+ glands were unable to sustain this initial proliferative
burst of tumor cells and progress to the next stage in tumor
development. Therefore, the delay in mammary tumorigenesis
appears to be due to CCR7 maintaining specialized hierarchical
sub-populations of cancer stem and progenitor-like cells that are
thought to be crucial for tumor initiation and advanced
tumorigenesis.2
The fact that both CCL19 and CCL21 stimulated mammosphere
growth from both human and mouse tumor cells strongly
suggests that CCR7 has a global role in sustaining properties of
stemness in mammary epithelium. The specificity of CCR7 in this
process was validated by testing a panel of chemokine receptor
ligands, where only CCL19 and CCL21 showed an ability to
significantly increase MFE.
Stimulation of CXCR4, the chemokine receptor that is consis-
tently found to be upregulated together with CCR7 in a number of
cancers,17 did potentiate sphere formation but to a lesser extent
(Supplementary Figure 5e). Recently, Clarke and colleagues
demonstrated that stimulation of CXCR4 also increased MFE
preferentially in malignant breast cancer cell lines compared with
normal breast cell lines.26 It is interesting to speculate that as CCR7
is less important for homeostasis than CXCR4, as has been inferred
from animal models,33 CCR7 may represent a more attractive
target for future CSC-targeting therapies.
As stimulation of CCR7 had no effect on proliferation of the bulk
population of cells when seeded into adherent culture, compared
with a highly significant effect in non-adherent culture, it is likely
that CCR7 predominantly mediates specific cellular properties of
stemness. Moreover, we have previously reported that CCR7
activation on breast cancer cells inhibits anoikis,13 a characteristic
of breast and other CSCs.25,34 Therefore, it is plausible that CCR7
supports CSC survival without attachment to the extracellular
matrix, a hypothesis that may form the basis for future studies.
CCR7 appeared to have a quantitative rather than a qualitative
role in normal mammary stem cells compared with CSCs. When
CCR7 was deleted we saw a mild effect on the normal mammary
gland. In contrast, a major effect was seen in mammary
tumorigenesis. Interestingly, whereas the morphological effect
on normal mammary gland development was not extensive, CCR7
deletion discreetly affected normal mammary gland stem-like
cells. Therefore, it is possible that CCR7 has a role in regulating the
properties of stemness within the mammary epithelial cell
population, an effect that appears more prominent during cancer
progression. As highlighted in a recent study by Cheresh and
colleagues,35 dysregulation of normal stem cells may contribute to
breast cancer progression and stemness, and CCR7 may emerge
as a novel mediator of this transition.
Translation of our findings from the mouse model to human
disease is of particular significance, considering that there is
currently no clear consensus on the markers that define functional
mammary stem cells in both mice and humans. Thus, we show
here that CCR7 not only has a role in mouse mammary tissue but
is also expressed, is functional and is highly responsive in the
stem-like populations within human breast cancer tissue.
Intriguingly, circulating tumor cells, an indicator of metastatic
spread and poor outcome in breast and other cancers, have been
recently equated to CSCs.36 In the last decade numerous studies
also suggested a role for CCR7 in malignant dissemination of
mammary tumors to distant sites.13,15,17 Taken together, these
results suggest a novel causative link between CCR7 activity on
stem-like populations and metastatic breast cancer.
To seek proof-of-principle on the utility of pharmacologically
targeting CCR7 we tested the receptor antagonist CCL19(8–83).
30
We found that pharmacological inhibition of CCR7 through direct
mammary fat pad injection of CCL19(8–83) afforded a significant
reduction in early-stage primary mammary tumorigenesis. As the
relative contribution of the malignant lesions to the weight of the
whole mammary fat pad was very small at this early stage the
reduction in total weight between antagonist and vehicle-treated
glands was not statistically significant. However, the cellularity, a
characteristic that directly reflects the extent of epithelial
malignant outgrowth and is used in clinical pathology to evaluate
the response to chemotherapy in breast cancer, was strongly
impacted by treatment with the CCR7 antagonist.
More importantly, directly targeting CCR7 using the antagonist
significantly depleted the stem-like cell pools in both early and
late-stage mammary neoplasia as was shown using the transplan-
tation approach. These findings strongly suggest that the CCR7
receptor axis is a potential point of intervention in stem cell-
targeting therapies. Furthermore, the results of this study provide
a rationale for the use of antagonists of the CCR7 pathway as
adjuvants to conventional cytotoxic drugs unable to eliminate
quiescent CSCs.2
In conclusion, the characterization of CCR7 in primary breast
tumorigenesis in vitro and in vivo, and in mouse and human tissue,
strongly suggests a role for this molecule in breast cancer
development and progression. These insights raise the possibility
of pharmacologically targeting CCR7 for the development of new
therapies in breast cancer.
MATERIALS AND METHODS
Mice
Mice were maintained in pathogen-free conditions in the University of
Adelaide’s Laboratory Animal Services facility. Ccr7−/− mice were
purchased from Jackson Laboratory. FVB MMTV-PyMT (+) mice were
backcrossed for 14 generations to C57Bl/6 background, and C57Bl/6
background was confirmed by microsatellite analysis. PyMT-carrying males
were then crossed with Ccr7−/− females, and the offspring were interbred
to produce MMTV-PyMT Ccr7WT and MMTV-PyMT Ccr7−/− mice.
The University of Adelaide institutional animal ethics committee approved
all experimentation. For the assessment of CCR7 expression and
CCL19(8–83) function both C57Bl/6 and FVB backgrounds were tested to
eliminate any strain bias. For experiments involving knockout mice, only
C57Bl/6 mice were tested. Nomenclature used for genotypes is as follows:
Ccr7WT =WT, Ccr7−/−=CCR7 KO, MMTV-PyMT Ccr7WT =WT+, MMTV-PyMT
Ccr7−/−=CCR7 KO+.
Human mammary tissue
Ethical approval was granted by the Royal Adelaide Hospital Ethics
Committee and all patients gave written, informed consent prior to
surgery. Pathology reports for tumors used are available on request.
Normal breast tissue samples were obtained from the Queen Elizabeth
Hospital, Adelaide.
Whole mount staining
Mammary glands were fixed in Carnoy’s and were stained overnight in
Carmine Alum before dehydration and mounting. Image 'stitching' and
analysis was performed using Image J.
Histology
Lungs of MMTV-PyMT WT+ or CCR7 KO+ mice were perfused and
dissected, then cryoembedded in optimal cutting temperature (OCT)
reagent and serially sectioned at 9μm. Formalin-fixed paraffin-embedded
mammary glands/tumors were sectioned at 5μm. All slides were stained
using haemotoxylin and eosin, dehydrated and mounted. Slides were
scanned using the NanoZoomer Digital Pathology System (Hamamatsu
Photonics, Shizuoka, Japan) and lung sections were manually quantitated
using the NanoZoomer Digital Pathology Virtual Slide Viewer software for
number of metastases and area at the largest point.
Immunofluorescent microscopy
Antigen retrieval of formalin-fixed paraffin-embedded mouse mammary
sections was performed by boiling slides in 0.1 M sodium citrate buffer
(pH 6.0). Slides were stained with rabbit anti-CCR7 (Epitomics, Burlingame,
CA, USA) overnight at 4 °C, and primary antibody was detected with Alexa
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Fluor 488-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA, USA)
for 30min. Slides were counterstained with DAPI (4',6-diamidino-
2-phenylindole), mounted and analyzed using the Leica TCS SP5 Confocal
Microscope System.
Processing mouse mammary tissue to single cell suspension
Mouse mammary glands/tumors were dissected, with removal of the
lymph node if possible. Tissue was manually dissociated and then digested
in 10% collagenase/hyaluronidase (Stem Cell Technologies, Vancouver, BC,
Canada) in Dulbecco's Modified Eagle's medium (DMEM) for 3-4 h with
gentle tilting. Single cells were extracted as previously described37 and
filtered through a 70 μm nylon mesh. To remove contaminating infiltrating
cells of hematopoietic origin, Biotin Binder Dynabeads (Invitrogen) in
combination with a biotinylated anti-mouse lineage antibody panel
(BioLegend, San Diego, CA, USA) were used as suggested by the
manufacturer.
Processing human mammary tissue to single cell suspension
Surgical specimens were minced and digested in 10% collagenase/
hyaluronidase (Stem Cell Technologies) in DMEM supplemented with
20mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid),
penicillin–streptomycin and 0.25 μg/ml fungazone. Organoids were
then extensively washed with DMEM, and red blood cells were lysed by
isotonic lysis buffer (150mM NH4Cl in 17mM Tris-HCl, pH 7.2). Single cell
suspensions were obtained by digesting organoids with trypsin for
10min at room temperature, with subsequent filtration through a 70 μm
nylon mesh.
Flow cytometry
Cells were fixed in 4% formaldehyde and immunostained for 45min on ice
in phosphate-buffered saline/0.5% bovine serum albumin (PBS/0.5% BSA).
Antibodies used were: Alexa Fluor 647-conjugated anti-mouse CCR7,
phycoerythrin (PE)-conjugated anti-mouse/anti-human CD24, fluorescein
isothiocyanate (FITC)/PECy5-conjugated anti-human CD49f, FITC-
conjugated anti-human CD44 (all from BD, North Ryde, NSW, Australia),
FITC-conjugated anti-mouse CD29, PE-conjugated anti-mouse/anti-human
DLL1 (all from BioLegend), and biotinylated anti-mouse/anti-human
DNER (R&D Systems, Minneapolis, MN, USA). Samples containing
biotinylated antibodies were resuspended in PerCP/Cy5.5 or Alexa
Fluor 488-conjugated streptavidin in PBS/0.5% BSA for 30min on ice.
Fluorescence-minus-one samples or conjugated isotypes were used as
negative controls. Flow cytometry was carried out using FACSCanto
equipment (BD). Data analysis was performed using FlowJo software (Tree
Star Inc., Ashland, OR, USA).
Mammosphere assay
Cells were seeded in mammosphere medium (1:1 mixture of DMEM and
Ham’s F12 medium (Gibco, Life Technologies, Mulgrave, VIC, Australia)
supplemented with 1× B27 (Invitrogen), 20ng/ml epidermal growth factor,
20 ng/ml basic fibroblast growth factor, 4 μg/ml heparin (Sigma-Aldrich, St
Louis, MO, USA), penicillin–streptomycin, and 0.25 μg/ml fungazone) at
4× 104 cells/ml to an ultra-low attachment tray (Corning Inc., Corning,
NY, USA). Where indicated, CCL21, CCL19 and CCL19(8–83) were added
at concentrations of 10 ng/ml, 200 ng/ml and 100 ng/ml, respectively.
Media was replenished every second day. After 7–10 days, mammospheres
were counted and passaged.
Limiting dilution assay
Mammosphere colonies derived from 8-week-old pre-neoplastic MMTV-
PyMT WT+ and CCR7 KO+ mice were dissociated using trypsin and
triturated through a 19G needle. Following filtration, cells were injected in
20% Matrigel (BD):80% DMEM into the fourth inguinal mammary glands of
anaesthetized WT-recipient mice (8-weeks-old) at limiting dilutions as
previously described.24 Mice were killed after 6 weeks and glands whole-
mounted. Tumor-initiating cell-frequency and statistical calculations were
performed using L-Calc software (Stem Cell Technologies).
Tissue transplants
Mammary gland fragments of 1mm3 size from donor MMTV-PyMT mice
were transplanted into contralateral sides of anaesthetized congenic
non-PyMT WT-recipient mice (8-weeks-old) within the fourth inguinal
mammary glands. Mice were monitored for adverse reactions to surgery
and subsequent tumor growth.
In vivo treatment with CCR7 antagonist
Mice were injected under anesthetic into an inguinal mammary fat pad,
with 1 μg CCL19(8–83) truncated ligand in 50 μl saline vehicle, as indicated.
As a control, mice were injected in the contralateral inguinal mammary fat
pad with vehicle alone as previously reported.38,39
Statistical analysis
Unless otherwise indicated, analyses were carried out using GraphPad
Prism and data is shown as mean± s.e.m. Significant statistical difference
was estimated using student’s t-tests, or χ2-tests for distribution analysis.
Tumor-free survival curves were graphed using the Kaplan–Meier method
and distributions were compared by the log-rank statistic (Mantel–Cox
test). All measurements were done in triplicate. P-values were used to
denote statistical significance. Levels of significance were *P⩽ 0.05,
**P⩽ 0.01 and ***P⩽ 0.001.
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SUPPORTING INFORMATION 
Supplementary Experimental Procedures 
Immunohistochemistry (IHC) 
Immunohistochemical analysis was performed using standard procedures. Briefly, 
antigen retrieval of FFPE mouse mammary sections was carried out by boiling slides in 0.1M 
sodium citrate buffer (pH 6.0) under pressure. Slides were immersed in 3% hydrogen peroxide in 
PBS for 20 minutes with gentle agitation to inhibit endogenous peroxidase activity and blocked 
for 30 minutes in 10% normal serum in PBS to prevent non-specific antibody binding. Slides 
were then incubated overnight at 4°C with mouse anti-α-smooth muscle actin (α-SMA, Dako). 
Specific antibody binding was detected using the EnVision Dual Link System (Vector 
Labs) followed by incubation with diaminobenzidine (DAB) substrate (Dako). Sections were 
counterstained with haemotoxylin, dehydrated and mounted. 
	  
Calcium (Ca+) Signaling Analysis 
Intracellular calcium mobilization assay was performed on cells isolated from tumors 
dissected from C57Bl/6 MMTV-PyMT mice at 20 weeks of age as described (1). Ligands added 
were CCL21 (100ng/ml) and lysophosphatidic acid (LPA) (50ng/ml). 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Wells were coated in CCL21 and CCL19 capture antibody (R&D) and receptors blocked 
using PBS/3%BSA for 1 hour at 37°C. After determining WT and CCR7 KO mammary gland 
weight, fat pad samples were homogenized in PBS buffer (10% glycerol, 1x protease inhibitor) 
and aliquotted to coated wells for 90 minutes at 37°C. Detection antibody (R&D) was added for 
1 hour then streptavidin-HRP added for 30 minutes.  
Proliferation Assay 
Isolated lineage-negative mouse mammary cells were plated in adherent culture 
(DMEM:F12/10% FCS, supplemented with 20ng/ml EGF, 5µg/ml insulin, 0.5µg/ml 
hydrocortisone, penicillin-streptomycin, and 0.25µg/ml fungazone) in 96-well plates and the 
following day were serum-starved for 4 hours. The cell proliferation assay was carried out 24 
hours later using the XTT Cell Proliferation Kit (ATCC) according to manufacturer’s 
instructions, using 100ng/ml CCL19 and CCL21. FCS was used at a concentration of 5%. 
Supplementary References 
1. Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promotes 
metastasis by preventing anoikis in cancer cells. Cell death and differentiation. 2009; 16(5):664-
73. Epub 2009/01/13 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1 (Related to Figure 1)  
(a) Serial sections of mouse mammary tissue from normal mice and at different tumourigenic 
stages stained with haemotoxylin and eosin (H&E) and for α-smooth muscle actin (α-SMA) as 
indicated. (b) Mammary cells were gated to exclude debris, dead cells and doublets (top) and 
proportions of CCR7-positive cells in mammary epithelial cell preparations from corresponding 
stages in (a) were analyzed by flow cytometry(bottom). Shaded histograms= fluorescence-
minus-one negative gate. wo= weeks old. 
Supplementary Figure 2 (Related to Figure 1)  
(a) Expression of CCR7 ligands (CCL21 and CCL19) in WT and CCR7 KO mammary fat pads 
with excised inguinal lymph nodes was assessed by ELISA. n=6 glands per genotype. (b) 
Calcium mobilization analysis of PyMT-expressing WT+ mouse mammary cells in response to 
lysophosphatidic acid (LPA) (positive control) and the CCR7 ligand, CCL21. Arrowheads 
indicate a point of stimulus addition. 
Supplementary Figure 3  
Ablation of CCR7 has no effect on early mammary tumourigenesis in MMTV-PyMT mice. (a) 
Top: Representative images of inguinal mammary glands of WT+ (left) and CCR7 KO+ (right) 
mice harvested at 8 and 11 weeks of age as indicated. Arrowheads indicate areas of epithelial 
hyperplasia. LN= lymph node. Bottom: Quantitation of area of hyperplasia in WT+ and CCR7 
KO+ at 8 weeks old. n=6 glands per genotype. (b) Serial sections of mouse mammary tissue 
from WT+ and CCR7 KO+ mice at 8 weeks old stained with haemotoxylin and eosin (H&E) and 
for α-smooth muscle actin (α-SMA) as indicated. 
Supplementary Figure 4 (Related to Figure 3)  
All cells were pre-gated to exclude debris, dead cells and doublets. (a-b) Flow cytometry gating 
strategy for delineating the stem cell-enriched population (CD24+CD29hi) and non-stem cell 
populations (CD24+CD29lo cells and stromal cells) and proportion of CCR7 positive cells within 
these populations, in normal mice (a) and from MMTV-PyMT mice (b). (c) Flow cytometry 
gating strategy for delineating the stem cell-enriched population (CD44+CD24-) and non-stem 
cell population (CD44-CD24+) in human mammary epithelium, and proportion of CCR7 positive 
cells within these populations as indicated. (d-e) Flow cytometry gating strategy for delineating 
mouse (d) and human (e) stem cell-enriched populations based on alternative 
CD49f+DLL1+DNER+ surface marker expression, together with representative plots 
demonstrating proportion of CCR7 positive cells within these populations. “FMO” and shaded 
histograms= fluorescence minus one negative gates. 
Supplementary Figure 5 (Related to Figure 3)  
(a-b) CCR7 deletion decreases proportion of the stem cell-enriched population in normal (a) and 
PyMT-expressing mice (b) designated by a putative marker profile of Lin-
CD49f+DLL1+DNER+. Data are representative of at least three independent experiments, n=6 
mice per genotype. (c) CCR7 stimulation does not have any effect on proliferation of WT+ 
mammary cells in adherent culture. Shown are results of XTT proliferation assay with and 
without addition of CCR7 ligands. FCS was used as a positive control. (d) The stimulatory effect 
of CCL19 and CCL21 on MFE of MMTV-PyMT cells is dependent on CCR7. The primary MFE 
of CCR7 KO+ (n=4 mice) mouse mammary cells was not affected by the addition of these 
chemokines. (e) Effect of stimulation of primary WT+ (n=6 mice) mammosphere culture with 
chemokine ligands for receptors CCR6, CXCR3, CXCR4 and CXCR5 respectively. 
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Supplementary Figure 6 (Related to Figure 4)  
Representative images of WT recipient glands engrafted with WT+ or CCR7 KO+ 
mammosphere-derived cells as indicated. Shown are contralateral glands in which both WT+ and 
CCR7 KO+ cells produced outgrowths (black arrowheads), to demonstrate differences in size 
between lesions. At the lowest dilution, only WT+ cells produced any outgrowth. LN= lymph 
node.  
Supplementary Figure 7 (Related to Figure 6)   
(a) Total mammary epithelial cell count in MMTV-PyMT mice following injection with vehicle 
or CCL19(8-83) antagonist for 8 weeks in contralateral inguinal mammary fat pads. (b) Weight of 
mammary glands. (c) Comparison of stem cell-enriched population in MMTV-PyMT glands 
delineated by alternative marker set Lin-CD49f+DLL1+DNER+. (d) Treatment of mammary 
glands with vehicle control (left) or CCL19(8-83) (right) does not alter CCR7 expression levels in 
the Lin-CD24+CD29hi  population. Shaded histograms = fluorescence minus one negative gates. 
(e) Treatment with CCL19(8-83) does not change cellularity of transplanted tumor tissue despite 
affecting the stem cell-like pool. (f) Comparison of the stem cell-enriched population in 
transplanted glands treated with CCL19(8-83) or vehicle, as delineated by alternative marker set 
Lin-CD49f+DLL1+DNER+. 
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The chemokine receptor CCR6 facilitates the
onset of mammary neoplasia in the MMTV-PyMT
mouse model via recruitment of tumor-promoting
macrophages
Sarah T. Boyle1, Jessica W. Faulkner1, Shaun R. McColl1,2 and Marina Kochetkova1*
Abstract
Background: The expression of the chemokine receptor CCR6 has been previously correlated with higher grades
and stages of breast cancer and decreased relapse-free survival. Also, its cognate chemokine ligand CCL20 has been
reported to induce proliferation of cultured human breast epithelial cells.
Methods: To establish if CCR6 plays a functional role in mammary tumorigenesis, a bigenic MMTV-PyMT CCR6-null
mouse was generated and mammary tumor development was assessed. Levels of tumor-infiltrating immune cells
within tumor-bearing mammary glands from MMTV-PyMT Ccr6WT and Ccr6−/− mice were also analyzed.
Results: Deletion of CCR6 delayed tumor onset, significantly reduced the extent of initial hyperplastic outgrowth,
and decreased tumor incidence in PyMT transgenic mice. CCR6 was then shown to promote the recruitment of
pro-tumorigenic macrophages to the tumor site, facilitating the onset of neoplasia.
Conclusions: This study delineated for the first time a role for CCR6 in the development of breast cancer, and
demonstrated a critical function for this receptor in maintaining the pro-tumorigenic cancer microenvironment.
Keywords: Breast Cancer, Mammary Gland, Chemokine Receptor, CCR6, Transgenic Mouse Model, Immune System,
Macrophages
Introduction
Breast cancer is one of the leading causes of cancer-
related death in women world-wide. Evasion of the
immune system is a hallmark of cancer, and aids tumor
cells to survive, intravasate, and potentially form distal
metastases [1]. As such, the tumor microenvironment
has a profound effect on the development and progres-
sion of malignancies, and it has been suggested that
levels of infiltrating immune cells correlate with stage
and aggressiveness of human breast cancer [2]. In particu-
lar, tumor-associated macrophages (TAMs) have been
found to play an important part in facilitating breast
tumor development [3] through polarization from a
classically-activated “M1” anti-tumor resident cell within
adult mammary tissue to an alternatively-activated “M2”
pro-tumor phenotype [4]. This “switch” results in shifts in
cell metabolism, a decrease in pro-inflammatory chemo-
kine/cytokine production, poor antigen-presentation abil-
ity, and suppression of T cell responses. In addition, M2
TAMs promote angiogenesis, cell proliferation and tissue
remodeling (reviewed in [5]).
Chemokines and their cognate receptors are involved
in the development, migration and activation of many
different types of immune cells, both adaptive and
innate. Small molecular-weight proteins, chemokines
bind to their cognate seven-transmembrane domain
G-protein coupled receptors (GPCRs), activating a
multitude of signaling pathways, which mediate many
different homeostatic and inflammatory functions. Im-
portantly, a large body of literature in the last decade
has linked the action of chemokines and chemokine
receptors to cancer progression and metastasis [6].
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The CC-chemokine receptor CCR6 is expressed on
dendritic cells [7, 8], regulatory T cells and various T
helper lymphocyte subsets [9, 10], and mediates their
migration and function via stimulation with its ligand
CCL20 (also known as macrophage inflammatory pro-
tein (MIP)-3α [11]). CCR6 is also expressed on natural
killer cells, B lymphocytes, neutrophils [12] and macro-
phages [10, 13]. Despite the significant role of TAMs in
breast cancer, the expression and function of CCR6
within the macrophage population has not been shown
within the mammary gland.
Interestingly, together with CCL20, CCR6 expression
has been correlated with stage and prognosis in a variety
of cancers including hepatocellular carcinoma [14, 15],
colorectal carcinoma [16–18], glioma [19], and non-
small cell lung cancer [20], and a function for CCR6 in
regulation of cancer progression has been putatively
demonstrated using cell lines and xenograft models [16,
18, 21, 22]. In breast cancer, higher CCR6 expression
levels were linked with tumor stage and grade [23], and
incidence of metastasis to the pleura [24]. Stimulation of
ex vivo mammary peritumoral cells with CCL20 was
found to increase their proliferation rate, invasiveness
and migration [25]. CCL20 is also upregulated in human
triple negative breast cancer cell lines [26]. Moreover, it
was recently proposed that the presence of CCR6 may
act as a prognostic factor for breast cancer patient
survival [23]. However, no causative or functional link
between the CCR6-CCL20 axis and progression of
breast cancer has been documented to date.
In this study we have utilized a well-characterized
transgenic model for breast cancer, in which the poly-
oma middle-T oncogene is activated under control of
the mouse mammary tumor virus promoter (MMTV-
PyMT) [27]. This transgenic model has been shown to
closely mimic the stages of human breast disease from
initial hyperplasia, through to ductal carcinoma in situ
and invasive ductal carcinoma [28]. Crossing this trans-
genic mouse with a CCR6-null mouse to generate a
bigenic MMTV-PyMT Ccr6−/− animal model has allowed
us to directly assess the role of CCR6 in mammary
tumorigenesis in vivo. The results demonstrated that
CCR6 promotes breast cancer initiation and progression
through maintenance of pro-tumorigenic TAMs within
tumor-bearing mammary glands, warranting further
investigation of CCR6 as a possible therapeutic target.
Results
CCR6 expression increases throughout cancer
development and results in a higher number of
mammary tumors
To first determine whether CCR6 may play a role in the
regulation of mammary neoplasia, we investigated ex-
pression of the receptor in CD45-negative normal mouse
mammary cells, and cells from various tumor stages
(representative H&E pictures in Fig. 1a). CCR6 was
expressed on a low proportion of normal mammary
cells, but this proportion was greatly amplified in
accordance with increasingly higher grades of MMTV-
PyMT cancer including initial hyperplasia, early carcin-
oma and late carcinoma as indicated (Fig. 1a). This is
consistent with human breast cancer [23] and other
mouse models of cancer [17]. Additionally, in both non-
PyMT Ccr6WT and MMTV-PyMT Ccr6WT mammary
tissues the ligand for CCR6, CCL20, was highly expressed
at concentrations over 50 ng/mg tissue (Fig. 1b). These
data raise the possibility of a role for CCR6 in breast can-
cer development.
To next establish the role of CCR6 deletion on mam-
mary tumorigenesis, we compared the rate and total
extent of PyMT-driven neoplasia between MMTV-
PyMT Ccr6WT and Ccr6−/− mice. Tumor onset was
significantly delayed in MMTV-PyMT Ccr6−/− mice
(Fig. 1c), with some mice not developing palpable
tumors until 150 days old (21 weeks) compared to a
maximum onset age of 130 days old (18 weeks) for
MMTV-PyMT Ccr6WT counterparts (Fig. 1d).
In order to assess the impact of CCR6 on the later
stages of cancerogenesis, MMTV-PyMT Ccr6WTand
Ccr6−/− mice were sacrificed at 22–24 weeks of age and
the total number of mammary tumors per mouse was
determined. We found that MMTV-PyMT Ccr6−/− mice
had significantly decreased tumor incidence compared
to MMTV-PyMT Ccr6WT animals (Fig. 1e). Together,
these results implicate CCR6 as being an important
player in breast oncogenesis.
CCR6 deletion significantly delays tumor initiation in vivo
We then sought to examine whether CCR6 influenced
early hyperplasia of mammary glands during tumor
initiation as well as late stage tumorigenesis. Glands
from 8-week-old MMTV-PyMT Ccr6−/− and Ccr6WT
mice were extracted and whole mounted for quantita-
tion of hyperplastic/early-neoplastic lesions (represen-
tative images from both genotypes shown in Fig. 2a).
We found that the deletion of CCR6 significantly
reduced the initial hyperplastic outgrowth within the
gland (Fig. 2b), a common indicator of future breast
cancer development. As the total area of PyMT-
driven hyperplastic outgrowth per gland was reduced
by threefold in CCR6-null animals, we concluded that
the effect of CCR6 on mammary tumorigenesis is
manifested very early on in cancer development.
The difference seen in early tumor initiation between
MMTV-PyMT Ccr6WT and Ccr6−/− mice can potentially
result from a difference in normal mammary develop-
ment, which may then have translated into decreased
hyperplasia. We therefore extracted pubertal mammary
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glands from non-PyMT 6-week-old Ccr6WT and Ccr6−/−
mice. Representative glands are shown in Additional
file 1: Figure S1a. When ductal epithelial growth was
quantitated, we observed no statistically significant
difference in ductal length, number of terminal end
structures or branching between Ccr6WT and Ccr6−/−
mice (Additional file 1: Figure S1b-d), and hence the
overall effect of CCR6 deletion on normal mammary
Fig. 1 CCR6 expression increases throughout cancer development and results in a higher number of mammary tumors. a Top: Representative
H&E images of mammary tissue from normal gland and various stages of PyMT-driven tumorigenesis as indicated. Scale bar is 200 μm. Bottom:
Proportion of CCR6-positive epithelial cells (CD45-negative) purified from mammary glands at respective stages of tumorigenesis. 18 normal
samples (2 glands/sample), 7 hyperplastic samples (2 glands/sample), 6 early carcinomas and 3 late carcinomas were analyzed. b ELISA for CCL20,
the ligand for CCR6, in normal (left) and early neoplastic MMTV-PyMT Ccr6WT (right) mammary glands. n = 4 samples per genotype. c Kaplan-Meier
analysis of the palpable tumor onset in MMTV-PyMT Ccr6−/− mice (n = 14) vs MMTV-PyMT Ccr6WT mice (n = 11). d Age of tumor onset in
MMTV-PyMT Ccr6−/− mice and MMTV-PyMT Ccr6WT mice. e Mammary tumor incidence in MMTV-PyMT Ccr6WT (n = 9) and
Ccr6−/− (n = 14) mice
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gland biology appears to be minimal and is unlikely
to account for differences in PyMT-driven tumor
development between the two genotypes. Further-
more, the levels of CCL20 were not statistically differ-
ent between non-PyMT Ccr6WT and MMTV-PyMT
Ccr6WT mammary tissues (Fig. 1b), demonstrating
that the expression of CCL20 is not affected by the
process of tumorigenesis. Taken together, these data
show that early stage tumorigenesis is mediated by a
CCR6-dependent mechanism, without affecting nor-
mal mammary morphogenesis.
CCR6 promotes mammary gland neoplasia independently
of cancer epithelial cells or stem-like cells
To investigate the mechanism underlying CCR6-driven
mammary tumorigenesis, we studied the epithelial cell
population to determine if CCR6 was having a direct
effect on cell proliferation. Cells at the stage of early
neoplasia from MMTV-PyMT Ccr6WT mammary glands
were assayed for proliferation upon stimulation with
CCL20. No differences in cell proliferation were observed
(Fig. 3a). Furthermore, Ki67 staining of sectioned hyper-
plastic mammary glands from MMTV-PyMT Ccr6WT and
Ccr6−/− mice showed that epithelial cells in knock-out
mice are still able to adequately proliferate and staining of
Ki67 is equal to that in the Ccr6WT (Fig. 3b). This suggests
that the role of CCR6 in breast cancer is independent of
epithelial cells.
We next determined whether CCR6 may exert its
effect by skewing distinct cell populations within the
bulk epithelium, as we have reported previously for the
chemokine receptor CCR7 [29]. The current prevailing
paradigm has mammary epithelial and breast cancer
cells hierarchically organized with a self-renewing, quies-
cent, multipotent progenitor (or stem-like cell) popula-
tion giving rise to basal and luminal progenitors which
in turn differentiate into specific lineages making up the
mammary gland and heterogenous breast tumors [30].
Recently, a number of immune mediators including
chemokine receptors have been implicated in mainten-
ance of the cancer stem-like cells within mammary
tumors (reviewed in [31]). We therefore tested the
Fig. 2 CCR6 deletion significantly delays tumor initiation in vivo. a Representative whole mount images of MMTV-PyMT Ccr6WT (n = 6) and Ccr6−/−
(n = 6) mice at 8 weeks of age. LN = lymph node. Black arrowheads indicate hyperplastic lesions within the glands. b Quantitation of area
of pre-neoplastic lesions in 8 week-old MMTV-PyMT mice
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Fig. 3 CCR6 promotes mammary gland neoplasia independently of cancer epithelial cells. a Proliferation assay of mammary epithelial cells
purified from MMTV-PyMT Ccr6WT mice at the stage of early neoplasia with and without stimulation by recombinant CCL20 (100 ng/ml).
Fetal calf serum (0.5 %) and EGF (20 ng/ml) were used as positive controls. Data are representative of 3 independent experiments, n = 3
mice per experiment. b Analysis of Ki67-positive proliferating cells within MMTV-PyMT Ccr6WT and Ccr6−/− mice at the stage of early
neoplasia. Shown are representative fields from 2 separate tumors per genotype, displaying equal distribution of cells positive for Ki67
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potential link between the tumor-promoting function of
CCR6 and breast cancer stem-like cell pools.
Freshly isolated MMTV-PyMT Ccr6WT and Ccr6−/−
mammary cells from pre-neoplastic mice at 8–9 weeks-
old were assayed by flow cytometry for expression of cell
surface markers CD24 and CD29 [32] (representative
plots shown in Fig. 4a), which were previously used to
define stem cells in the MMTV-PyMT [33, 34] and
other breast cancer mouse models [35, 36]. We found
that the deletion of CCR6 did not alter the proportions
Fig. 4 CCR6 promotes mammary gland neoplasia independently of cancer stem-like cells a-b Single cell suspensions (CD45-negative) from
mammary glands with early neoplasia from MMTV-PyMT Ccr6WT and Ccr6−/− mice were analyzed by flow cytometry for the expression of
CD24 and CD29 to quantitate the proportions of basal and luminal cell lineages. c Mammosphere-forming efficiency of cells isolated from
MMTV-PyMT Ccr6WT and Ccr6−/− mammary glands. a-c Data are representative of 3 independent experiments, n = 6 mice per genotype
per experiment. d Mammosphere-forming efficiency of MMTV-PyMT Ccr6WT cells stimulated with varying concentrations of CCL20. Data
are representative of 3 independent experiments, n = 3 individual mice per experiment. e Representative whole mount images and quantitation of
the neoplastic outgrowth area in Ccr6WT recipients of MMTV-PyMT Ccr6WT and MMTV-PyMT Ccr6−/− mammary tumor tissue transplants; n = 4 recipient
mice per group, LN = lymph node. Black arrowheads indicate donor transplant outgrowth within the glands
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of the stem cell-enriched basal population (CD24+CD29hi)
nor the luminal population (CD24+CD29lo) (Fig. 4b) in
hyperplastic mammary glands.
We also investigated the effect of CCR6 ablation on
functional stem-like mammary cancer cell pools using
the mammosphere assay, which is used to select for
colonies of early stem-like progenitors [37]. Pre-
neoplastic MMTV-PyMT Ccr6WT and Ccr6−/− mammary
cells were seeded into non-adherent mammosphere
culture and allowed to grow for 7 days. The deletion of
CCR6 did not alter mammosphere-forming efficiency
(Fig. 4c), and when sphere cultures were stimulated with
varying concentrations of CCL20, no change in their
ability to form mammospheres (Fig. 4d) was observed,
supporting results obtained using flow cytometric analysis.
Having found no difference in the proportion or func-
tion of stem cell-like pools within early tumorigenic
lesions, we next tested a bona fide property of cancer
stem cells – their ability to propagate tumors upon
transplantation. MMTV-PyMT Ccr6WT and Ccr6−/−
donor mammary tissue was transferred into recipient fat
pads of syngeneic non-PyMT Ccr6WT mice. Using this
approach, we found no significant difference between
MMTV-PyMT Ccr6WT and Ccr6−/− tissue in the ability
to form outgrowths when transplanted into Ccr6WT
recipients (Fig. 4e), indicating that the deletion of CCR6
did not reduce the tumor-propagating capability of
mammary epithelium.
Altogether, these results demonstrate that the role of
CCR6 in breast cancer is independent of breast epithelial
and progenitor cells, raising the possibility that its mech-
anism of action involves the tumor microenvironment.
CCR6 mediates the recruitment of pro-tumorigenic
macrophages to the mammary tumor microenvironment
To test whether the reduced mammary tumorigenesis
caused by the deletion of CCR6 was due to an effect of
the CCR6-CCL20 axis on the tumor microenvironment
we next investigated by flow cytometry the levels and
identity of tumor-infiltrating leukocytes in mammary
tumors at the stage of early carcinoma (see Fig. 1a).
Tumor-associated macrophages have been extensively
implicated in tumor promotion both in the mammary
gland and elsewhere, due to their role in angiogenesis,
cell proliferation and tissue remodeling [5]. To initially
examine the polarization of TAMs in the MMTV-PyMT
mice, macrophages were assessed for expression of
prototypic markers interleukin-4-receptor (IL4-R) and
mannose receptor (CD206), which have been used
previously in flow cytometric analysis to distinguish
alternatively-activated M2 macrophages from classically-
activated M1 [38–42]. We estimated using these markers
that a high proportion of TAMs were of an M2-like
phenotype (Additional file 1: Figure S2a), as has been
suggested previously for MMTV-PyMT mammary tumors
[43]. Interestingly, CCR6 was found to be highly expressed
within the TAM population as it was detected on greater
than 60 % of total macrophages (Additional file 1: Figure
S2b). Most importantly, CCR6 was expressed at higher
levels and on a significantly higher proportion of putative
M2 macrophages (up to 90 %) than M1 (Fig. 5a and
Additional file 1: Figure S2b), using both IL4-R and
CD206 to delineate the populations. This strong correl-
ation potentially implicates CCR6 in the regulation of
pro-tumorigenic macrophages within the mammary
gland microenvironment.
We then assessed the levels of macrophages in mam-
mary tumors from MMTV-PyMT Ccr6WT and Ccr6−/−
mice, and found that the proportion and overall num-
bers of TAMs were significantly reduced in MMTV-
PyMT Ccr6−/− mammary tumors relative to Ccr6WT
(Fig. 5b). Furthermore, the deletion of CCR6 resulted in
a shift towards an M1 macrophage phenotype, defined
by both IL4-R and CD206 prototypic markers (Fig. 5c).
The deletion of CCR6 also resulted in reduced traffick-
ing of dendritic cells to the tumor site, consistent with
previous studies, which demonstrated a reduced overall
migratory ability of dendritic cells in CCR6-null mice
[44, 45]. Although, overall numbers of tumor-infiltrating
dendritic cells were much lower than the corresponding
macrophage population. Notably, the majority of tumor-
infiltrating dendritic cells were CCR6-positive, consistent
with previous findings [12] (Additional file 1: Figure S3).
We have also assessed CCR6 expression on B cells and
specific T cell subsets (helper T cells (Th), cytotoxic T
cells (Tc), and regulatory T cells (Treg)) within mam-
mary tumors. In agreement with earlier reports for vari-
ous biological settings [12, 46], all tested infiltrating
leukocyte subsets expressed CCR6 at varying levels.
When CCR6 was ablated, only the Tc cell subset showed
a slight increase in the MMTV-PyMT Ccr6−/− as a
proportion of CD45+ tumor-infiltrating cells, however
no significant differences were found in total cell num-
bers between the two genotypes (Additional file 1:
Figures S4 and S5).
Our findings thus suggest that CCR6 promotes mam-
mary tumorigenesis through an epithelium-independent
mechanism involving tumor-infiltrating macrophages.
CCR6-mediated pro-tumorigenic macrophages promote
breast cancer in vivo
We then sought to provide definitive evidence for the
macrophage-mediating function of CCR6 in mammary
tumor promotion using an in vivo macrophage reconsti-
tution assay. Reconstitution assays, sometimes referred to
as “add-back” assays, are frequently used to underscore a
role for various cellular subsets in multiple pathological
settings, and macrophage reconstitution has been used
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previously in mammary gland studies [47]. A schematic of
the experimental setup is shown in Fig. 6a. MMTV-PyMT
mammary tumor cells from Ccr6WT donor mice were
purified and transplanted into the inguinal mammary fat
pads of non-PyMT Ccr6WT and Ccr6−/− recipients at
5 weeks of age. Two days post-transplantation, TAMs
(CD45+F4/80+) were sorted from excised and dissociated
MMTV-PyMT Ccr6WT tumors (Fig. 6b) and orthotopi-
cally injected into a group of Ccr6−/− recipients as speci-
fied in Fig. 6a. All other recipients received sham
Fig. 5 CCR6 mediates the recruitment of pro-tumorigenic macrophages to the mammary tumor microenvironment. a Comparison of proportions
of CCR6-positive cells and levels of CCR6 within putative M1 and M2 macrophage populations, based on IL4-R (left) and CD206 (right) expression.
MFI = mean fluorescence intensity. Representative results from 3 independent experiments. b Proportion of TAMs in mammary tumors from
MMTV-PyMT Ccr6WT and Ccr6−/− mice as determined by flow cytometry. Data are representative of 3 independent experiments, n = 5-7 mice per
genotype per experiment. c Proportions of putative M1 and M2 macrophage subtypes within the TAM population in mammary tumors
from MMTV-PyMT Ccr6−/− mice relative to Ccr6WT, as determined by flow cytometry. Dotted line = FMO control. Data are representative of
4 independent experiments, n = 3 mice per genotype per experiment
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injections with vehicle only, followed by assessment of
mammary tumor growth 6 weeks later.
In agreement with the results from spontaneous tumori-
genesis studies, we have found that tumors grew signifi-
cantly slower in the Ccr6−/− hosts compared to Ccr6WT,
indicating that CCR6 is required in the mammary stroma
for robust tumor development. However, when the re-
duced macrophage phenotype was restored in Ccr6−/−
mice through orthotopical injections, the tumor latency
was significantly shortened, approaching that of the
Ccr6WT mice (Fig. 6c).
It was further found that the supplementation of Ccr6−/−
mice with TAMs restored the efficiency of tumor growth
(measured by weight of tumor-bearing mammary glands)
within these mice to that seen in the Ccr6WT, whilst
Ccr6−/− mice that received sham injections displayed
reduced tumorigenesis (Fig. 6d) as seen in the spon-
taneous model (see Fig. 1).
Enumeration of macrophages within grafted tumors
in Ccr6WT and Ccr6−/− mice (Fig. 6e) paralleled the
results seen in spontaneous mammary tumors (see
Fig. 5b). Whilst there was an upward trend towards
increased TAMs in the Ccr6−/− mice that received
TAM injections, the difference was not statistically signifi-
cant (Fig. 6e). This, combined with the decreased tumor
growth in the CCR6-null mice, indicated that the support
Fig. 6 CCR6-mediated pro-tumorigenic macrophages promote breast cancer in vivo. a Schematic of macrophage reconstitution assay to
determine contribution of macrophages to mammary tumorigenesis in the context of CCR6 deletion. TAM = tumor-associated macrophage.
b FACS plot showing the sorted macrophage population used for reconstitution. c Tumor-free survival curves over the course of the experiment. d Tumor
weight of control tumors generated in Ccr6WT recipients and in Ccr6−/− recipients ± TAMs. n = 6-8 tumors per group. e Macrophage numbers in
experimental groups at end-point, as assessed by flow cytometry. n = 3-4 samples per group
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of macrophages is essential at the early stages of tumor
growth.
We have thus established an essential role for CCR6 in
the tumor microenvironment, providing a causative link
between this receptor, infiltrating macrophages and mam-
mary tumor development. Hence, therapeutic opportun-
ities may be explored to control breast cancer progression,
via manipulation of the CCR6-CCL20 axis to control
tumor-promoting macrophages.
Discussion
We show here that the deletion of the chemokine recep-
tor CCR6 caused a delay in tumor onset and decreased
mammary tumor incidence in vivo in the MMTV-PyMT
transgenic mouse model. We have determined that the
underlying basis of the CCR6 oncogenic function is the
increase in numbers of infiltrating pro-tumorigenic
macrophages.
Multiple functional roles have been suggested for
members of the chemokine family and their receptors in
breast cancer pathophysiology [6], however little data
using animal models is available to support these obser-
vations. The expression of CCR6 has been reported to
correlate with higher stage and grade of human breast
cancer, and has been proposed as a prognostic tool for de-
termining relapse-free survival in breast cancer patients
[23]. However, a causative link in vivo has yet to be demon-
strated. We have employed the well-characterized MMTV-
PyMT transgenic mouse model of breast cancer, and have
found that CCR6 facilitates an earlier tumor onset and an
increased incidence of mammary tumors. Of note, CCR6
affects mammary tumorigenesis from as early as the hyper-
plastic, or hyper-proliferative, stage. This initial phase of
tumor development remains largely uncharacterized,
despite being the most treatment-effective stage of cancer
progression. Therefore, a better understanding of tumor
initiation is crucial in order to develop therapies that target
the tumorigenic process at the early stages of breast cancer.
When CCR6 was deleted in the MMTV-PyMT mouse,
tumor latency was significantly extended, and these mice
developed fewer mammary tumors than their Ccr6WT
counterparts. However, CCR6 deletion did not affect
tumorigenic properties of the epithelium as we have
found with the chemokine receptor CCR7 [29]. Stimula-
tion with CCL20 did not result in an increased prolifera-
tion rate of purified mammary epithelial cells from
hyperplastic glands or tumorous lesions in contrast to
previous studies with primary human breast peritumoral
cells [25]. Furthermore, the deletion of CCR6 did not
lead to decreased numbers of Ki67-positive proliferating
cells within intact tumor-bearing mammary glands,
pointing to an epithelial-independent function of this
receptor in breast cancer.
We have also observed that the loss of CCR6 did not
alter the numbers and functional properties of mammary
cancer stem-like cells. Transplantation experiments in
particular demonstrated that the presence of CCR6 in
donor epithelium was not required for tumor propaga-
tion in recipient mammary glands.
Further investigation demonstrated that CCR6 func-
tions via organization of the immune system during the
early stage of mammary carcinogenesis. We have shown
that the levels of TAMs are reduced by almost threefold
when CCR6 is deleted. TAMs, which have been previ-
ously identified in MMTV-PyMT tumors [48], are
widely reported to support the development of cancer
[3, 49] and in the tumor microenvironment they are
generally thought to polarize towards an alternatively-
activated M2 pro-tumor phenotype relative to the classic
M1 anti-tumor phenotype [4]. Whilst the TAMs in
MMTV-PyMT tumors are polarized towards an M2-like
subtype, we have shown that the presence of CCR6
maintains M2 TAMs as the predominant phenotype.
Therefore, it is plausible to suggest that CCR6 in breast
cancer functions to recruit pro-tumorigenic macro-
phages to the tumor immuniche [31], to support growth
of transformed epithelial cells and cancer stem cells, as
TAMs in the MMTV-PyMT model have also been
shown to also maintain stem-like cells [50].
CCR6 is not expressed on peripheral blood monocytes,
and is thought to only be acquired upon their differenti-
ation into macrophages, induced by the tumor micro-
environment [12]. In accordance with this, we found
that a high proportion of macrophages within PyMT-
driven mammary tumors express CCR6, which has not
been previously demonstrated in breast cancer. Also of
potential importance is the fact that up to 90 % of pro-
tumorigenic M2-like TAMs expressed CCR6. Our find-
ings parallel results from a recent study which showed
that CCR6-null mice bearing the adenomatosis polyposis
coli (APC)min transgene (a well-characterized model for
gastrointestinal tumorigenesis) developed fewer intes-
tinal adenomas and polyps, and that the effect of CCR6
was also linked to a significant reduction in F4/80+
macrophages [17]. Interestingly, Liu et al. also recently
demonstrated that the ligand CCL20 is secreted from
both macrophages and tumor cells in another mouse
model of colorectal cancer, potentially suggesting com-
mon regulatory mechanisms and a universal role for
CCR6 in tumors of various etiology [51].
MMTV-PyMT cancer cell transplant experiments
showed that tumor growth in a CCR6-null micro-
environment was significantly inhibited compared to
wild-type microenvironment conditions, directly dem-
onstrating that the mammary stroma is dependent
upon CCR6 for adequate tumor initiation and growth
support. The reconstitution of this CCR6-negative
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microenvironment with MMTV-PyMT Ccr6WT TAMs
restored the tumor-promoting properties of mammary
stroma, indicating that breast cancer can be therapeutic-
ally targeted through manipulation of the CCR6-CCL20
axis to control tumor-infiltrating macrophages.
CCR6 deletion has also impeded recruitment of den-
dritic cells into PyMT-driven mammary tumors. Recruit-
ment of dendritic cells into various solid tumors has
been well-documented (reviewed in [52]), and their role
in tumor progression is mainly centered around tumor
antigen presentation to lymphocyte subsets leading to
anti-tumor immune responses [53, 54]. Furthermore,
there is some evidence supporting direct tumoricidal
activity of dendritic cells [53]. As previous studies have
reported an intrinsic requirement for CCR6 in migration
and fundamental functions of dendritic cells [44, 45],
our finding of the reduced infiltration of dendritic cells
in mammary tumors may not be a facet of cancer devel-
opment in MMTV-PyMT Ccr6−/− mice, but is an inher-
ent property of dendritic cell migration at a slower rate
after CCR6 deletion.
Conclusions
In conclusion, we show here that CCR6 plays a signifi-
cant role in the initiation and at the early stage of breast
cancer development in vivo by mediating recruitment of
pro-tumorigenic macrophages to the tumor site, and
thus facilitating further progression to advanced stages
of mammary neoplasia. Results presented in this study
therefore suggest CCR6 as a potential target for thera-
peutic intervention in early breast cancer.
Methods
Mice
Mice were maintained in pathogen-free conditions in the
University of Adelaide’s Laboratory Animal Services facil-
ity. Ccr6−/− mice have been described previously [44].
Ccr6−/− females were crossed with C57BL/6 MMTV-
PyMT males and the heterozygous offspring were
interbred to produce MMTV-PyMT Ccr6WT (wild-type
for CCR6) and bigenic MMTV-PyMT Ccr6−/− mice on
the C57Bl/6 background. The University of Adelaide
institutional animal ethics committee approved all animal
experimental protocols.
Histology
Mouse mammary tissues were extracted, fixed in forma-
lin and embedded in paraffin before sectioning at 5 μm.
Haemotoxylin and eosin staining was carried out accord-
ing to standard protocols. For immunohistochemical
analysis of Ki67, slides were immersed in 0.5 % hydrogen
peroxide in methanol for 10 minutes to inhibit endogen-
ous peroxidase activity, followed by antigen retrieval by
boiling slides in 0.1 M sodium citrate buffer under
pressure. Slides were blocked for 20 minutes in 5 % nor-
mal rabbit serum in TBS/0.1 % Tween to prevent non-
specific antibody binding, and then incubated overnight
at 4 °C with mouse anti-Ki67 antibody (Vector Labs)
according to the manufacturer’s instructions. Specific
antibody binding was detected using the EnVision Dual
Link System (Vector Labs), followed by incubation with
diaminobenzidine (DAB) substrate (Dako). Sections
were counterstained with haemotoxylin, dehydrated
and mounted.
Enzyme-linked immunosorbent assay
Wells were coated with anti-CCL20 capture antibody
(R&D Systems) at 2 μg/ml overnight followed by a block-
ing step in PBS/3%BSA. Homogenized mammary tissue
lysates (in PBS containing 10 % glycerol and 1x protease
inhibitor) were added for 1.5 hours at 37 °C. Biotinylated
anti-CCL20 detection antibody (R&D Systems) was added
at 50 ng/ml for 1 hour at 37 °C followed by incubation
with streptavidin-HRP (Rockland) for 30 minutes at room
temperature. Wells were washed with PBS/0.05 % Tween
after each incubation.
Whole mount staining
Mammary glands were mounted on slides, fixed in Car-
noy’s (30 % glacial acetic acid, 30 % absolute ethanol, 10 %
chloroform), stained overnight in Carmine Alum (Stem
Cell Technologies), then dehydrated and mounted using
Permount (ThermoFisher Scientific). Image “stitching”
and analysis were performed using Image J software.
Processing mouse mammary tissue to single cell
suspension
Mouse mammary gland/tumor tissue was minced and
then digested in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) containing 1 mg/mL collagenase III,
100U/mL hyaluronidase (both from Worthington), 2 %
fetal calf serum (FCS) and penicillin-streptomycin for 3–4
hours with gentle tilting. Organoids were further digested
for 15 minutes with 6U/mL dispase (Gibco) in PBS and
20U/mL DNase I (Merck), and red blood cells were lysed
by isotonic lysis buffer (150 mM NH4Cl in 17 mM
Tris–HCl, pH 7.2). Single cells were obtained by filtration
through a 70 μm nylon mesh.
Proliferation assay
Isolated mouse mammary cells were plated in adherent
culture (1:1 mixture of DMEM and Ham’s F12 medium
(Gibco) with 10 % FCS, supplemented with 20 ng/ml
EGF, 5 μg/ml insulin, 0.5 μg/ml hydrocortisone,
penicillin-streptomycin, and 0.25 μg/ml fungazone) in a
96-well plate. The following day the medium was
replaced by DMEM with no additives, and after 2 hours
of starvation cells were stimulated with FCS (0.5 %) ±
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CCL20 (a gift from the late Professor Ian Clark-Lewis) at
a concentration of 100 ng/ml. Stimulation with EGF at
20 ng/ml was used as a positive control. The cell prolif-
eration assay was carried out 24 hours later using the
XTT Cell Proliferation Kit (ATCC) according to manu-
facturer’s instructions.
Flow cytometry
Single cell suspensions from processed mammary glands
were incubated for 30 minutes on ice in PBS/0.5%BSA
with anti-mouse primary antibodies to cell surface
markers as indicated. Antibodies used were as follows: PE-
conjugated anti-CCR6 (R&D), AlexaFluor647-conjugated
anti-CCR6, PerCP/Cy5.5-conjugated anti-CD11c, PerCP/
Cy5.5-conjugated anti-CD206, FITC-conjugated anti-CD29
(all from BioLegend), BV421-conjugated anti-B220, PE/
Cy7-conjugated anti-CD11b, PE-conjugated anti-CD24,
FITC-conjugated anti-CD4, APC-conjugated anti-CD45,
biotinylated anti-CD45.2, FITC-conjugated anti-CD45.2,
BV510-conjugated anti-CD8a, PE-conjugated anti-IL4-R
(all from BD Biosciences), PE/Cy7-conjugated anti-CD3e,
FITC-conjugated anti-F4/80 (both from eBioscience), and
biotinylated anti-F4/80 (Life Technologies). When required,
cells were also permeabilized using the FoxP3 Staining Kit,
and incubated with PerCP/Cy5.5-conjugated anti-FoxP3
(both from eBioscience).
Samples containing biotinylated antibodies were further
stained with BV510-conjugated streptavidin (BD Biosci-
ences) in PBS/0.5 % BSA for 30 minutes. Fluorescence-
minus-one (FMO) samples or cells stained with conjugated
isotype control antibodies only were used as negative
controls. After staining cells were fixed in 1 % paraformal-
dehyde and flow cytometry carried out using FACSCanto
or LSRII equipment (BD). Data analysis was performed
using FlowJo software (Tree Star Inc.). All flow cyto-
metry data presented has been gated to exclude dead
cells and debris using FSC-A/SSC-A, and to exclude
doublets using FSC-A/FSC-H plots.
Mammosphere assay
Freshly isolated mammary cells were seeded into
ultra-low attachment plates (Corning Inc.) at a con-
centration of 4x104/ml, in a 1:1 mixture of DMEM
and Ham’s F12 medium supplemented with 1xB27
(Invitrogen), 20 ng/ml FGF, 20 ng/ml EGF, 4 μg/ml
heparin (Sigma Aldrich), penicillin-streptomycin and
0.25 μg/ml fungazone. Mammosphere cultures were
incubated at 37 °C for 7 days ± CCL20 at varying
concentrations before manual enumeration under a
light microscope.
Mammary Fat Pad transplants
Mammary gland fragments of 1 mm3 size from donor
MMTV-PyMT mice (18 weeks-old) were transplanted
into contralateral sides of anaesthetized congenic non-
PyMT recipient mice as indicated (8 weeks-old) within
the inguinal mammary glands, and were monitored for
adverse reactions to surgery. After 7 weeks, recipient glands
were extracted and whole mounted for quantification.
Macrophage reconstitution assay
Mammary tumor cell suspensions were prepared from
MMTV-PyMT Ccr6WT mice at 15 weeks-old as de-
scribed above and injected into the fourth inguinal
mammary fat pads of anaesthetized 5 week-old Ccr6WT
and Ccr6−/− recipients in 80:20 % DMEM:Matrigel (BD),
at 100,000 cells/gland.
Two days later, tumor-associated macrophages were
sorted from MMTV-PyMT Ccr6WT excised and dissoci-
ated mammary tumors based on CD45+F4/80+ expression.
50,000 TAMs per gland were injected in DMEM orthoto-
pically into the inguinal glands of Ccr6−/− tumor cell
recipients. Control groups of Ccr6−/− and Ccr6WT tumor
cell recipients were sham-injected with vehicle only.
Tumor development was monitored for 6 weeks, then
mice were sacrificed and tumors extracted for analysis.
Statistical analysis
Analyses were carried out using GraphPad Prism and data
is presented as mean ± SEM unless otherwise indicated.
Significant statistical difference was estimated using
student’s t-tests, ANOVA for multiple comparisons, or
chi-square tests for distribution analysis. Tumor-free
survival curves for spontaneous tumors were graphed
using the Kaplan-Meier method and compared by the
log-rank statistic (Mantel-Cox test). Tumor-free survival
curves for the reconstitution assay were compared using
2-way ANOVA with Tukey’s multiple comparison test.
P-values were used to denote statistical significance. Levels
of significance were *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
Additional file
Additional file 1: Figures S1-S5. Accompanies the manuscript.
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Figure S1: The role of CCR6 in normal mammary development  
(a) Representative whole mount images of Ccr6WT (n=6) and Ccr6-/- (n=6) mice at 6 weeks of age showing 
development of mammary epithelium. LN=lymph node. (b-d) Quantitation of epithelial growth, by length of 
main duct (b), number of end structures (c) and branching (d).   
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Figure S2: Analysis of infiltrating macrophages in MMTV-PyMT mammary tumors  
(a) Analysis of M1 anti-tumor and M2 pro-tumor macrophages within the total macrophage population 
(CD45+CD11c-CD11b+F4/80+), based on IL4-R expression and CD206 expression as indicated, where M1 
macrophages are classed as IL4-R or CD206-negative and M2 are IL4-R or CD206-positive. Dotted 
line=FMO control. M1 and M2 cell proportions (bottom) are presented as percentage of the total macrophage 
population. (b) Representative flow cytometry plots of CCR6 expression within the total, M1 and M2 
macrophage populations as based on IL4-R and CD206 (gated as in (a)). (a-b) Representative results from 3 
independent experiments.  
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Figure S3: Infiltrating dendritic cells in MMTV-PyMT Ccr6WT and Ccr6-/- mammary tumors as 
determined by flow cytometry 
All cells were gated for CD45+. MMTV-PyMT Ccr6WT dendritic cells were assessed for CCR6 expression 
(right), and proportions and numbers of dendritic cells compared between MMTV-PyMT Ccr6WT and Ccr6-/- 
(bottom). Dotted line=FMO control. n= 5-7 mice per genotype. 
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Figure S4: Infiltrating B and T immune cells in MMTV-PyMT Ccr6WT and Ccr6-/- mammary tumors as 
determined by flow cytometry 
All cells were gated for CD45+. (a) MMTV-PyMT Ccr6WT B cells were assessed for CCR6 expression (right), 
and proportions and numbers of B cells compared between MMTV-PyMT Ccr6WT and Ccr6-/- (bottom). (b) 
MMTV-PyMT Ccr6WT T cells were assessed for CCR6 expression (middle), and proportions and numbers of 
T cells compared between MMTV-PyMT Ccr6WT and Ccr6-/- (right). Dotted lines=FMO controls. n= 5-7 








Figure S5: Infiltrating T cell subsets in MMTV-PyMT Ccr6WT and Ccr6-/- mammary tumors as 
determined by flow cytometry 
All cells were gated for CD45+. (a) MMTV-PyMT Ccr6WT helper T cells (Th) were assessed for CCR6 
expression (right), and proportions and numbers of Th cells compared between MMTV-PyMT Ccr6WT and 
Ccr6-/- (bottom). (b) MMTV-PyMT Ccr6WT cytotoxic T cells (Tc) and regulatory T cells (Treg) were assessed 
for CCR6 expression (right), and proportions and numbers of Tc/Treg cells compared between MMTV-PyMT 
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